Development of responsive polymers for drug delivery applications by Benzeval, Ian
 Page i 
 
Development of Responsive 
Polymers for Drug Delivery 
Applications 
 
submitted by Ian David Benzeval 
 
 
A thesis submitted for the degree of Doctor of Philosophy 
 
University of Bath 
Department of Chemical Engineering 
 
January 2009 
 
COPYRIGHT 
Attention is drawn to the fact that copyright of this thesis rests with its author. A copy of 
this thesis has been supplied on condition that anyone who consults it is understood to 
recognise that its copyright rests with the author and they must not copy it or use material 
from it except as permitted by law or with the consent of the author. 
 
This thesis may be made available for consultation within the University Library and may 
be photocopied or lent to other libraries for the purposes of consultation. 
 
 
 
Ian David Benzeval 
 Page i 
Abstract 
In this thesis, glucose responsive hydrogels based on cross-linked dextran molecules were 
studied to determine the diffusion rate of an insulin analogue. Investigations of the 
interaction between concanavalin A and dextran, both in free solution and in the form of 
glucose responsive hydrogels were conducted. 
The free solution results have shown that there is an increase of association constant 
between concanavalin A and dextran when the molecular mass of the dextran is increased. 
Free solution viscometric tests have shown that increasing the molecular mass or the 
concentration of the dextran increases the viscosity. 
The hydrogels have been shown to form for dextrans of molecular mass 43kD or greater. 
Smaller molecular mass dextrans were found to coalesce into small beads which appeared 
to prevent hydrogel formation with these materials. 
Experiments conducted with hydrogel membranes in a diffusion cell have shown that the 
batch to batch reproducibility of hydrogel transport properties is low. This is partly due to 
the weak mechanical nature of the hydrogel and partly due to the heterogeneous nature of 
the precursor dextrans. However, clear evidence of glucose enhanced transport was 
obtained and these results were compared with predictions obtained from a theoretical 
model of gel permeability that accounts for competitive displacement of affinity cross links. 
Oscillatory rheological tests of gelation mixtures which showed an increase in complex 
viscosity at the gel point with increasing molecular mass of dextran were in agreement with 
empirical observations that gels formed from the highest molecular mass dextrans were 
more physically robust and easier to handle. 
Swelling rate experiments have shown that the rate of hydration of a hydrogel in the 
presence of glucose is decreased due to the osmotic pressure of the glucose. 
This work has shown that the multivalent nature of concanavalin A may not be a necessary 
pre-requisite for this type of hydrogel due to spatial constraints decreasing the number of 
potential affinity bonds per tetramer. In-house production of more tightly defined dextrans 
(molecular mass and branching ratio) might be expected to reduce heterogeneity and 
improve the reproducibility of this type of hydrogel membrane. 
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y(t)   Displacement from baseline (m) 
z   Complex number 
γ*   Complex shear strain 
γ0   Peak shear strain 
   Shear strain rate (s-1) 
δ   Phase Angle (o) 
δG   Thickness of hydrogel (m) 
η   Viscosity (Pas) 
θ   Argument of complex number 
v
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λ     LDE factor (s-1) 
ξ   Mesh size (m) 
Π Osmotic pressure (Pa) 
σ*   Complex shear stress (Pa) 
σ0   Peak shear stress (Pa) 
   Shear stress rate (Pas
-1
) 
τm   Time constant = η/G (s) 
χ2   Size of error (chi2) 
χ1   Flory polymer-solvent interaction parameter 
ω   Frequency of oscillation (Hz) 
ωn   Natural frequency (s-1) 
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Introduction 
Drug delivery is traditionally performed as single point introductions of the desired 
compound, be this through injection or ingestion. Many of these drugs are now being 
formulated so that they are released slowly into the body over a period of time, rather than 
the sudden increase followed by a long tail-off period associated with single point 
introductions. The concept of responsive polymers and hydrogels is that they can actually 
respond in real time to the needs of the patient without any user or doctor input required, 
much in the same way as the human body does naturally. 
 
The main focus of this work is to investigate hydrogels incorporating concanavalin A and 
dextran which potentially could be used to supply insulin to a patient with Type I Diabetes 
Mellitus. The rate of supply of insulin is greatly dependent upon the patient’s situation; 
exercise undertaken, food eaten and sleep patterns are all influential, hence a need to move 
away from single point introductions which cannot mimic the natural response of the 
pancreas. 
 
Current approaches to insulin delivery all depend upon monitoring of glucose levels by the 
patient, or estimating the glucose levels based on the behaviour of the patient in order to 
supply the correct dose. This is far from ideal. 
 
Section One of this report contains a literature review, in which the disease Diabetes 
Mellitus is studied and the possible treatment types investigated. The materials used in the 
experimental work are then assessed for their viability and finally the approach to 
producing and analysing hydrogels is considered. Section Two details the materials and 
methods used to create the hydrogels. 
 
The main thesis is split into two parts. Firstly, sections Three and Four detail the 
investigation of the dextran / concanavalin A interaction in a free situation. Secondly, 
sections Five, Six and Seven detail the investigation of the hydrogels.  
 
Sections Eight and Nine evaluate the results obtained and detail possible future work. 
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Aims and Objectives 
The aim of this work was to investigate the use of hydrogels for responsive drug delivery, 
with the primary consideration being for the delivery of insulin to patients with type I 
diabetes. Hydrogels have been produced by Zhang et al. from dextran and concanavalin A 
to respond to the presence of glucose in solution [1]. The first phase of the work in this 
thesis was to investigate how the molecular mass of the dextran molecule used in the 
hydrogel affected the interaction with concanavalin A. This was done using two specialised 
techniques. Firstly, isothermal titration calorimetry was used to investigate the 
thermodynamics of the interaction. Secondly, surface plasmon resonance was used to 
investigate the kinetics of the interaction. 
 
The second phase of this work involved investigating the behaviour of the hydrogels 
themselves. This was done using oscillatory rheology to study the strength of the 
hydrogels; diffusion cell experiments were performed to investigate the rate of diffusion of 
protein through a hydrogel and finally the hydrogel mixture was allowed to set within UV-
spectrophotometer cuvettes and the rate of swelling of the hydrogels tested. 
 
During the course of all work, where possible experiments were conducted at physiological 
conditions to ensure the relevance of the data obtained to those expected from a patient. 
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Section 1. Literature Review 
This work’s primary focus is to investigate responsive hydrogels aimed at providing insulin 
release systems for sufferers of type I diabetes. A basic understanding of the disease is 
required, though the effects of insulin on the body are too numerous to be thoroughly 
studied here. Once the relevant aspects of the illness have been considered current 
treatments will be reviewed. Approaches to design and production of responsive hydrogels 
will be the last aspect reviewed. 
Section 1.1. Diabetes Mellitus and the Role of Insulin 
Section 1.1.1. Diabetes Mellitus 
Diabetes (full name diabetes mellitus) is the third leading cause of death in the United 
States (only cancer and heart disease cause more)[2] and is estimated to affect 200 million 
people worldwide [3]. Diabetes is concerned with the body’s ability to produce and / or use 
insulin and comes in two forms. Type I diabetes, or juvenile onset diabetes, is caused by the 
pancreas (β cells) ceasing to produce insulin. The destruction of the β cells within the 
pancreas is thought to be an autoimmune response, but the reasons behind it are not fully 
understood. Statistical evidence has been found to suggest that environmental factors have 
an effect, though more evidence is required [4]. Type II diabetes, or maturity onset 
diabetes, is believed to be caused by a problem with the insulin receptors on cells as tests 
have shown that the level of insulin in the body is not low [2, 3, 5, 6]. The work undertaken 
here is to investigate responsive polymers for treatment of type I diabetes and type II will 
not be considered further. 
 
In a healthy human body, glucose levels are held at a concentration of 3.5-5.5mM with 
increases due to digestion being rapidly controlled. In diabetic patients, the aim is to 
maintain the level at 4-8mM [5, 7]. Concentrations outside of this range for a long period 
can be harmful, particularly in the brain for which glucose is the primary fuel. When the 
level of glucose in the blood gets too low (hypoglycaemia) the brain will become starved of 
glucose and the patient can become comatose. In the long term, hypoglycaemia and 
hyperglycaemia (levels of glucose too high) can cause a range of problems. The symptoms 
are mainly caused by the effect of the fluctuating glucose level on the blood vessels. 
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Damage to the retina (retinopathy – developed by 30% of patients [3]), to the glomerulus in 
the kidneys (nephropathy – 20-30% incidence for type I sufferers [3]) and damage to the 
nerves in the extremities (peripheral neuropathy - incidence widely affected by period of 
time with the disease and ability to manage glycaemic levels) and the circulatory system 
nerves (autonomic neuropathy) are all caused by damage to the microvascular  blood 
vessels. Damage to the macrovascular blood vessels can lead to coronary heart disease and 
atherosclerosis (heart disease being the most common cause of death in type II sufferers 
and is also prevalent in type I sufferers [3]) [2, 3, 5, 6, 8].  
 
Section 1.1.2. Insulin 
Under normal physiological conditions there are several hormones which regulate glucose 
homeostasis. Insulin, produced in the β islets of the pancreas, is a polypeptide hormone of 
approximately 5800 Daltons. It facilitates the reduction in blood-glucose levels by 
activating the production of glycogen, though it also stimulates, amongst other functions, 
lipid and protein synthesis. Increasing the level of glucose in the body is facilitated by 
several hormones; glucagon, adrenaline, cortisol and growth hormone. [3] 
 
Glucose not used directly by the body for metabolic purposes is stored as glycogen, 
primarily in the skeletal muscle and the liver. It consists of long chains of α(1-4) linked 
glucose molecules with α(1-6) branches every 8 to 12 glucose residues (see Section 1.4 for 
details) [9]. 
 
Insulin does not directly interact with glucose; it binds to surface receptors and stimulates 
glucose transport, glycogen synthesis, lipid synthesis, protein synthesis, potassium ion 
entry to cells and sodium ion retention in renal tubes. It also inhibits gluconeogenesis 
(glucose production from C3 non-hexose precursors), glycogenolysis (the breakdown of 
glycogen), lipolysis and proteolysis (the breakdown of fats and proteins respectively). [3] 
Ultimately, insulin is the only known control mechanism used by the body to reduce 
glucose concentration.  
 
When there is an excess of glucose in the body, the production of proinsulin is triggered. 
This is a protein consisting of a chain of amino acids that can be considered as three 
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sections, A, B and C (see Figure 1-1 below). Proinsulin forms a structure in which sections 
A and B can bind together via two disulphide links. The C chain is then proteolytically 
excised from A and B, which remain bound together as the functional version of insulin [2]. 
 
Figure 1-1 Diagram of proinsulin molecule. 
Once the disulphide bridges are formed, the C chain (in brown) is proteolytically 
cleaved from the A and B chains (in blue) to leave the functional insulin molecule 
(Taken from [2], p.193). 
 
Section 1.1.3. Treatment 
For people with type 1 diabetes the approach to regulate glucose levels that most patients 
currently use is regular injection of insulin, though there are other options under 
investigation. In order for any treatment to work there must be either measurement or 
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estimation of the glucose concentration in the body so that the correct dose can be 
administered. They must also overcome the problem of insulin having a short biological 
half-life: only 3-4 minutes in the circulatory system [10]. 
Section 1.1.3.1. Methods for Treating Diabetes 
There are many ways of treating diabetes, with individual patients having to find what is 
best suited to their condition and their desired lifestyle. As the disease progresses it is often 
necessary to alter the treatment to reflect changes in the condition. 
 
The best way to avoid complications arising from diabetes is to maintain the correct level 
of glucose in the blood and brain. Keeping a regular and sensible diet is a major step, 
particularly the reduction of simple sugars (sugar in tea etc) which are very rapidly 
absorbed and thus can cause sudden changes in the blood-glucose levels. Exercise is 
another way of helping control the blood-glucose levels by metabolising the glucose for 
energy. Hypoglycaemia may be a problem though and the first few days of each exercise 
should be monitored to see how the individual patient responds. [3, 5, 8] 
 
For the majority of type I sufferers, dietary control is not enough to completely control 
glycaemic levels. There is therefore a need to control the blood-glucose levels, primarily 
through the injection of insulin. There are several analogues of insulin available for 
injection, based on whether it is desired to be fast or slow acting in the body. The rate of 
absorption of the injected material is also affected by other factors. It is known that 
injections into the abdomen are absorbed faster than those into the arm, which are in turn 
more rapid than those into the thigh, though each of these is also dependant upon any 
exercise undertaken as heat generated in a moving limb can alter the absorbance rates [3, 5, 
8]. 
 
As well as subcutaneous injections, peritoneal, intranasal, gastrointestinal and pulmonary 
routes have been investigated for the administration of insulin. The peritoneal route (the 
peritoneum is the sack which contains the abdominal internal organs) is a similar method to 
peritoneal dialysis. The peritoneum can be filled with an insulin solution, its large surface 
area enables uptake to the circulatory system. Tests have shown that this approach can help 
reduce severe hypoglycaemic episodes, but delivery time is much greater than for 
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subcutaneous injections [11]. The intranasal route is an idea based on the large surface area 
available in the nose and the fact that no needles are required, unlike the subcutaneous or 
peritoneal routes [12]. The primary obstacle to overcome in the preparation of an intranasal 
delivery system is the nose’s ability to recognise and expel foreign matter. The insulin must 
be able to be absorbed rapidly enough to overcome this, whilst not providing too great a 
peak in concentrations of insulin in the blood. The gastrointestinal approach to insulin 
delivery is not easy. Insulin is broken down in the gut and so must be transported past the 
stomach before release. This can be done with pH sensitive gels (Section 1.2.2), but initial 
studies have not been successful. Inhalation studies using preprandial human insulin 
inhalation powder (HIIP), have produced results which suggest it can be as effective as 
subcutaneously injected insulin [13, 14]. 
Section 1.1.3.2. Methods for ‘Curing’ Diabetes 
Effective treatment of diabetes, though desirable, is not the whole story. Ideally it should be 
possible to remove the necessity of external insulin administration altogether. This can be 
done on a limited basis by pancreas transplantation from organ donors, but this has all the 
usual complications of rejection associated with organ transplants and there can be 
additional complications with the kidneys [3]. A number of institutions have tried 
transplants of just the β islets from various sources, but these have had limited success – the 
longest recorded duration of a patient not requiring insulin treatment was less than six years 
[3].  One of the major problems with β islet transplantation is that they make up ≤ 2% of 
the cells within the donor pancreas [15]. Work is being performed to try and improve this, 
but is still not clinically viable [15]. Gene therapy is also being investigated, primarily by 
altering hepatocytes from the patient themselves to produce and secrete insulin [3]. 
 
In between approaches to treatments for diabetes and ‘cures’ for diabetes there is the 
artificial pancreas approach. This is where a device is produced which behaves in the same 
way as the β islets, recognising the presence of glucose and proportionally releasing 
insulin, but without the risk of rejection and other complications that arise through 
transplantation of actual pancreas or β islet tissue. The primary focus of the work 
performed thus far, and the main focus of this thesis, is hydrogels. These are polymeric 
membranes which are capable of swelling, and therefore increasing porosity, when in the 
presence of a variety of stimuli [16]. This is discussed further in Section 1.2. 
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Section 1.1.3.3. Methods for Blood-Glucose Concentration Measurement or 
Estimation 
Insulin treatment must be administered carefully as under- or overdose can lead to hyper-or 
hypoglycaemia respectively, both of which have health complications (as discussed in 
Section 1.1.1). The obvious course of action is to measure the blood-glucose level so that 
the amount of insulin required can be calculated. This can, however, be inconvenient and 
can also be unpleasant for the patient as the most common approach involves a pinprick to 
a finger [8]. There is also a need to keep a detailed record and to fully understand how and 
how fast the insulin will affect the blood-glucose level, else there will be very little control 
and the long-term complications will still arise. 
 
Blood-glucose monitoring is also possible by monitoring the amount of glucose or ketones 
in the patient’s urine. There is a threshold glucose level, over which damage to the kidneys 
occurs. There is evidence that some drugs including aspirin, paracetamol, iodine and 
dopamine can cause false readings in the tests performed on the patient’s urine, so care 
must be taken [8]. 
 
Non-invasive techniques are being investigated to remove the need for a blood sample. 
Infra-red spectroscopy through the skin has been investigated, but so far the signal to noise 
ratio through the skin is too great [11]. Reverse iontophoresis has also been investigated, 
the concept being that the electrical current applied to the skin draws through salts, which 
in turn draw through water which contains glucose [11]. Accurate calibration is essential 
for this process and levels of perspiration and thickness of skin can have very noticeable 
effects on the results. 
 
Due to the inconvenient nature of testing, and the fact that a dozen tests per day is still not 
frequent enough due to the fluctuations that can occur in the body, responsive hydrogels 
that continuously deliver insulin based on glucose levels in the patient are highly attractive.  
Section 1.2. Responsive Polymers - Hydrogels 
There are many stimuli with which responsive polymers can be made to react, with each 
having specific advantages and disadvantages. The polymers that are used tend to be 
classified as hydrogels [16-20]. At a conference for hydrogel research in the 1970s, B.D. 
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Ratner suggested, "A hydrogel can be defined as a polymeric material which exhibits the 
ability to swell in water and retain a significant fraction (e.g. >20%) of water within its 
structure, but which will not dissolve in water." [21]  
 
The swelling associated with a hydrogel is normally designed such that the ‘pores’ between 
the polymer strands increase in size, thus allowing diffusion of an entrapped molecule. In 
the case of the responsive hydrogels that are reviewed here, the general concept is that 
when the relevant stimulus is present, the gel is allowed to swell, thus releasing the drug to 
be delivered. Ideally, these gels will react to release insulin, either by directly removing 
bonds holding the insulin to the hydrogel, or by increasing the permeability of insulin 
through the hydrogel. 
Section 1.2.1. Temperature Sensitive Hydrogels 
Temperature based changes in the swelling of a polymer are reasonably simple to achieve. 
However, hydrogels designed for insulin release must operate within the human body, with 
a base temperature of 37
o
C and with only very small changes acceptable. The majority of 
hydrogels that have been developed to react to temperature changes require large (~10
o
C) 
changes for any significant changes in swelling to occur, though some have been made to 
work over a temperature change of only 2
o
C [22-24]. 
Section 1.2.2. pH Sensitive Hydrogels 
Hydrogels which are responsive to pH are also relatively simple to achieve, Akala et al. 
[25] have developed pH sensitive hydrogels aimed at being stable in the acidic conditions 
of the stomach, and which then start to release the drug in the more pH neutral conditions 
of the colon. However, as with the temperature sensitive gels, the pH changes within the 
human body (outside of the gastro-intestinal tract) are tiny, based around a core value of pH 
7.4 [7]. 
 
There is the possibility of using a secondary compound to produce a localised pH change 
which would allow the required change within the hydrogel. Several different approaches 
have been attempted using glucose oxidase (GOD) within the hydrogel and glucose as the 
trigger. The overall concept is that in the presence of glucose, the glucose oxidase catalyses 
the production of gluconic acid, thus lowering the pH of the surrounding environment. It 
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has been demonstrated that GOD can be used to both increase and decrease the swelling of 
hydrogels, depending upon the backbone utilised [26-30]. In the case of an increase in 
swelling in the presence of glucose, the associated increase in porosity allows insulin to 
permeate through; where shrinkage occurs the insulin is squeezed out within the fluid 
expelled by the contracting hydrogel.  
 
Equation 1-1 
 
Kim et al. have also demonstrated that liposomes infused with GOD can respond to 
differing glucose concentrations, the pH change causing destabilisation of the outer 
membrane [10]. 
 
The primary problem with using GOD is that the by-product of the conversion of glucose to 
gluconic acid is hydrogen peroxide. The bacterium that produces GOD, Aspergillus niger, 
also produces a peroxidase to remove the hydrogen peroxide. This would need to be 
included in any implant as hydrogen peroxide is very harmful inside the human body and 
also leads to rapid inactivation of the GOD which produces it. Oxygen is also a limiting 
factor of this reaction making it possible for the presence of glucose to not be enough to 
trigger the response.  
Section 1.2.3. Antigen – Antibody 
Miyata et al. [31, 32] have proposed hydrogels which contain antibodies and immobilised 
antigens. The concept is that in the presence of free antigen, i.e. when the patient is ill, the 
antibody-antigen binding within the gel is displaced allowing the natural swelling effect to 
take place, releasing the relevant molecule. There are however no known antigen-antibody 
reactions relevant to type I diabetes. Similar approaches do exist for insulin, though, and 
are further examined in Section 1.2.4 to Section 1.2.6. 
Section 1.2.4. Glucose Sensitive Hydrogels – Phenylboronic Acid 
Phenylboronic acid (PBA) has been used to produce two types of hydrogel. Shiino et al. 
have produced a hydrogel in which the PBA binds to gluconated insulin (G-ins) [33, 34]. 
When glucose is then introduced it displaces the binding between the PBA and the glucose 
2222 OHacidgluconicOHOglucose
GOD + →++
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moiety of the G-ins, thus releasing the G-ins (Figure 1-2). However this only occurs 
satisfactorily at pH 8.4, and is thus not suitable for direct inclusion in the body (human 
physiological pH = 7.4 [7]). 
 
PBA hydrogels have also been developed such that the PBA binding is to a backbone 
within the hydrogel structure and the insulin is free within the hydrogel. When glucose is 
present it disrupts the binding between the PBA and the backbone, increasing the porosity 
of the hydrogel thus allowing the release of the insulin [35-37]. Both of these systems work 
most effectively at pH values above that desired by human physiology, though it is possible 
to reduce this by altering the amine groups present. 
 
Figure 1-2 Depiction of the binding of insulin to a charged Boronic acid group and 
its disruption by free glucose (Taken from [33]). 
Section 1.2.5. Glucose Sensitive Hydrogels – Concanavalin A 
Concanavalin A (conA) is a lectin produced by jack beans. It is known to bind some mono- 
and polysaccharides including glucose and dextran [38] (see Section 1.3 for details). 
Several groups have performed work using conA, either creating hydrogels with dextran or 
directly binding modified insulin to the lectin. 
 
Two groups, led by Obaidat [39, 40] and by Taylor and Tanna [41-45], have produced 
hydrogels using Acrylamide-allyl glucose copolymer (Obaidat) and glycogen / carbopols / 
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dextran (Taylor) to supply the binding backbone for the conA. In all cases, the binding 
between the glucose moiety and the conA is the only structure present. When glucose is 
introduced into the gel the entire structure collapses (assuming sufficient glucose). This sol-
gel response allows proteins, such as insulin, to permeate through. Both systems have been 
shown to be reversible, which is essential for diabetes patients. However, both will require 
a secondary membrane which will allow the insulin through into the body, but prevent 
conA from being released as it is required to reform the gel and because it is mitogenic (see 
Section 1.3 for details). 
 
A more direct approach was taken by Brownlee et al. [46], Makino et al. [47] and Kim et 
al. [48-51], whereby the insulin was glycosylated (G-ins) and bound directly to the conA. 
The presence of glucose therefore directly unbound the insulin which was then capable of 
permeating through the microporous capsule in which the conA mixture was held. 
 
Tang and Zhang et al. [1, 52] have developed a conA-dextran system in which the conA is 
covalently bonded to a cross-linked dextran backbone. This results in the gel not being 
reduced to a solution in the presence of glucose, but which allows swelling and therefore an 
increase in porosity. These gels have been shown to be reversible and to give varying levels 
of permeability depending upon the concentration of the glucose. 
 
Ballerstadt et al. [53] have also used conA with dextran to try to devise a glucose sensor 
based on the large viscosity differences between conA-dextran and conA-dextran-glucose 
solutions. 
Section 1.2.6. Other Responsive Polymers and their Stimuli 
Section 1.2.6.1. Glucose Oxidase 
Ito et al. have used glucose oxidase, in a similar manner to Section 1.2.2, to control the 
release of insulin [54, 55]. In their approach, the glucose oxidase (GOD) is bound to the 
surface of a membrane so that it is near the pores through the membrane. The pores 
themselves are filled with poly(acrylic acid) such that the pore is blocked by reduced 
carboxylic acid groups, all of which repel each other. When glucose is present, it is 
oxidised by the GOD, producing gluconic acid, which in turn protonates the poly(acrylic 
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acid) (see Equation 1-1). When protonated, the repulsion forces within the poly(acrylic 
acid) are no longer present, resulting in their collapse and the unblocking of the pores. It is 
suggested that this system responds more rapidly than hydrogels that use GOD, but there is 
no information as to how long the poly(acrylic acid) would survive being protonated and 
then deprotonated, as would happen continuously in a patient. There is also an issue with 
the GOD reaction with glucose as hydrogen peroxide is one of the by-products. Ito et al. 
have also used GOD bound directly to insulin via a disulphide bridge, the bridge is then 
severed when glucose is catalysed to gluconic acid by GOD [56]. 
 
Cartier et al. have also produced membranes with carboxylic acid groups acting as the 
barrier. They found that the basal transport rate was too high and no follow-up work has 
been published [57]. 
Section 1.2.6.2. Glucose Dehydrogenase 
Glucose dehydrogenase (GDH) has been used to facilitate the cleavage of covalently bound 
insulin from a backbone by supplying an electron [58]. GDH, NAD (Nicotinamide adenine 
dinucleotide), FAD (Flavin adenine dinucleotide) and insulin are all covalently bound to a 
backbone. The GDH reacts with glucose to form gluconolactone. The electron taken by the 
GDH is passed to NAD, on to FAD and on to the disulphide bridge holding the insulin to 
the backbone. The disulphide bridge breaks when the electron reaches it, releasing the 
insulin. Once the electron has been passed on the GDH, NAD and FAD are all ready to 
perform the action again. It is also possible to perform this with the GDH in solution, rather 
than bound to the backbone, but this would then result in a need to prevent its release into 
the body. 
Section 1.2.7. Mannose Binding Lectin (MBL) 
Human mannose binding lectin is a potential replacement for conA in hydrogel systems. It 
is known to bind to glucose as well as mannose and will not have the toxic problems of 
conA because it is from a human source [59-61]. MBL is also being investigated for other 
therapeutic applications which would aid its approval for in vivo use. 
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Section 1.2.8. Summary of Current Thinking on Hydrogels 
Section 1.2.1 to Section 1.2.7 shows that there have been many attempts to find hydrogels 
that can be used in the treatment of type 1 diabetes. All have specific advantages and 
disadvantages associated with them. These are summarised in Table 1-1. 
Table 1-1 Summary of advantages and disadvantages of the methods being 
investigated for treatment of type I diabetes. 
Process Advantages Disadvantages Ref. 
pH sensitive, GOD 
Correct pH range can 
be targeted 
H2O2 is a by-product, 
requires oxygen 
[26-30] 
PBA 
Useable with normal or 
glycosylated insulin, 
reversible 
Only active at pH >8.4 [33-37] 
ConA, Sol-Gel 
Reversible, glucose is 
not rendered useless in 
reaction 
Secondary membranes 
required to prevent 
leakage, conA is 
mitogenic 
[39-45] 
ConA, G-Ins 
Direct release, swelling 
ratio not important 
Secondary membranes 
required to prevent 
leakage, conA is 
mitogenic 
[46-51] 
ConA, cross-linked 
No membrane required, 
reversible, glucose is 
not rendered useless in 
reaction 
ConA is mitogenic [52] 
GOD, PAA 
Diffusion rate 
controlled by 
membrane 
No reversibility data, 
requires oxygen, H2O2 
is a by-product 
[54, 55] 
GDH, NAD/FAD 
Direct release, swelling 
ratio not important 
Requires three 
components to work  
[58] 
MBL 
From human source, is 
not mitogenic 
No work yet performed [59-61] 
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Section 1.3. Lectins 
The hydrogels that are to be developed in this work are to be based around a lectin 
(concanavalin A (conA)) – dextran system. The reasons for using dextran are discussed in 
Section 1.4. 
 
Lectins are proteins produced by a range of organisms to bind specifically to one or more 
types of carbohydrate. They were first found in 1888 owing to their ability to agglutinate 
erythrocytes, and it was not until many years later that it was discovered that the binding 
was taking place with saccharide moieties on the surface of the erythrocytes [62-64]. ConA 
is a lectin produced by the Jack Bean (Canavalia ensiformis) and is probably the most 
investigated lectin in science [38, 65-71]. When used in a hydrogel, conA is capable of 
reversibly binding to any glucose or mannose moiety present without chemically altering 
itself or the compound to which it is bound.  
 
Under physiological conditions (pH7.4 [7]) conA exists as a tetramer, each monomer being 
a 25500 Dalton, 237 amino acid residue molecule. At lower pH it exists as a dimer and at a 
pH less than 4 it exists as a monomer [72]. The advantage of the tetrameric form is that it 
will generate a more highly cross-linked hydrogel when in the presence of dextran. The 
dextrans used have the ability to bind the terminus of every chain (non-anomeric end plus 
branches) to each monomer unit. The active form of a conA monomer contains three 
binding sites, two for metal ions, Mn
2+
 and Ca
2+
, as well as a third for the saccharide. The 
manganese ion can be replaced by other transition metal ions, but one plus the calcium ion 
are needed before the saccharide binding can occur [62, 66]. 
 
The primary problem with conA is that it is mitogenic and capable of agglutinating 
erythrocytes [62]. Given these problems, it is not feasible to implant conA directly into the 
patient. Ballerstadt et al. have shown that the amount of conA used for a sensor would not 
be hazardous, but the mass of conA in a hydrogel would be greater than that of a sensor 
[73]. Even with cross-linking to lock the conA into a gel or membranes to block its release, 
it is an unsuitable choice. The solution to this is to use a protein from a human source 
which should have no toxic effects when implanted into a patient. Human Mannose 
Binding Lectin (MBL) would make a suitable candidate though currently it is not 
 Page 14 
commercially available, it must be purified from serum [74]. Therefore, this work will be 
based on developing the concept of the hydrogel using conA such that future work on MBL 
will have a base on which to build [60].  
Section 1.4. Mono- and Polysaccharides 
In the work for this thesis it has been decided to use dextran as the backbone to the 
hydrogel. Dextran is a primarily α(1-6) glucose polymer with α(1-3) and occasional α(1-4) 
branches also present depending on the bacteria used for production [9]. Clinically, it is 
produced primarily by Leuconostoc mesenteroides, though there are other sources. In 
theory, most glucose polymers would provide the necessary binding sites (chemical 
conformation allowing), but dextran has been deemed to offer the most suitable option for 
the reasons discussed below. 
 
 
Figure 1-3 Structure of a dextran molecule with an α(1-3)- branch. 
It is also possible for dextran to have α(1-4)- branches. 
 
There are several other possible polymers: amylose (solely α(1-4)), amylopectin (α(1-4) 
with α(1-6) branches ~every 24-30 residues), cellulose (β(1-4)), glycogen (α(1-4) with 
α(1-6) every 8-12 residues), maltose (dimer of glucose) and maltotriose (a trimer of 
glucose) [9]. Amylose and amylopectin are collectively known as starch (a storage 
molecule for glucose within plants) and cellulose is the structural material in plants. None 
of these is particularly soluble in water, particularly at low (physiological) temperatures, 
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making them impractical for this application. Glycogen, the animal equivalent of starch, 
has been used to make hydrogels with conA [41], but is not as soluble as dextran. Maltose 
and maltotriose would be too short to provide good cross-linking between conA molecules. 
 
Therefore dextran was the polymer of choice because it is very soluble in water at 
physiological temperatures, can be cheaply obtained at a variety of molecular masses and 
has been approved for use in vivo. Dextran can be obtained in varying molecular masses, 
from 6000 to 2,000,000 Daltons. Much work has been done to try and identify the 
branching ratio of these products based on the bacterial strain used to grow the dextran [75-
81] and the operating conditions of the fermentation reactor [82]. Though the majority of 
the work, performed in the 1950s and 1960s, suggests that the majority of bacteria (and in 
particular the strain used to produce the dextran as used here, supplied by Sigma Aldrich) 
produce branching ratios of 5% (1 branch per 20 glucose residues) there is a suggestion in 
Kim’s work [82] that this is by no means guaranteed. 
 
Without knowing the branching ratio of the dextrans, the effective ligand density is 
unknown and so it will not be possible to accurately obtain the binding kinetics and 
equilibrium constants for the system. Therefore part of the study reported here concerns the 
determination of branching ratios for the dextran preparations used. 
  
Much work has been performed by Dam et al. [68, 83-85] which shows that, as the number 
of mannotriose moieties on a dendrimer increase, the association constant of binding to 
conA also increases. It will therefore be interesting to investigate the affect of varying 
molecular mass of the dextran to see if a similar pattern exists. 
Section 1.5. ConA / Dextran Interaction Characterisation 
The preceding sections of this literature review have suggested that the most attractive 
materials to make glucose-responsive hydrogels are dextran and conA. The conA used will 
only have concentration as a variable (i.e. site density). The dextran, however, can be 
obtained with varying molecular masses and branching densities allowing gel density and 
ligand concentration to be varied independently within the gels. 
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In order for the gel to work correctly in a human, the gel must respond at physiological 
blood-glucose levels and must swell to release the necessary amount of insulin for the level 
of glucose [3, 5, 7, 8]. Therefore it is necessary to characterise how the size of the dextran 
molecule affects the binding with the conA. 
  
The reversible binding of a molecule to a lectin is characterised primarily by the association 
constant (Ka) and the enthalpic change (∆H) of the reaction. Linked with these, there is also 
the entropic change of reaction (∆S) and the rates of association and dissociation (ka and kd 
respectively). Each of these parameters are linked, based on the thermodynamics of the 
reaction: 
Equation 1-2 
 
Equation 1-3 
Where R is the universal gas constant (8.314 Jmol
-1
K
-1
) and T is the temperature of the 
reaction (K). 
 
For a reaction to proceed spontaneously, the Gibbs free energy change (∆G) must be 
negative, thus implying that the association rate must be greater than the dissociation rate. 
 
There are several commercially available instruments which can be used to follow these 
binding interactions. Two which will be used here are the MicroCal™ isothermal titration 
calorimeter (ITC) and the Biacore® X which utilises surface plasmon resonance (SPR) to 
quantify binding where one component is immobilised to a sensor chip. 
Section 1.5.1. Isothermal Titration Calorimetry (ITC) 
The MicroCal™ ITC is capable of providing the data needed to evaluate Equation 1-3. The 
machine consists of an active cell and a reference cell. One of the two components of the 
reaction, typically the protein, is placed in the active cell at the desired concentration.  Over 
a given time period the second component is injected into the cell and the reaction 
proceeds. The cell itself is held within a Peltier element which is capable of adding or 
removing known amounts of energy depending upon the endo- or exothermic nature of the 
d
a
a
k
k
K =
STHKRTG a ∆−∆=−=∆ ln
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reaction respectively to maintain the cell at a constant temperature (hence isothermal). 
Once the series of injections is complete, a profile of the energy released for each given 
amount of injectant is produced: 
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Figure 1-4 The energy release profile of 0.1mM conA when titrated with 24.77mM 
2000kD dextran 
(Concentration is of branch ends assuming 1 branch per 20 glucose residues) 
 
The software supplied with the machine is capable of matching a curve to the data based on 
a stipulated number of binding sites and the relevant concentrations. This matched curve 
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provides values for the association constant (Ka) and the enthalpic change (∆H). From these 
two parameters the entropic change (∆S) can be inferred. 
Section 1.5.2. Surface Plasmon Resonance (SPR) 
The Biacore® X utilises surface plasmon resonance (SPR) to obtain information about the 
binding kinetics of a system. Within the machine a chip with a gold surface can be mounted 
which has dextran bound to one face (other types of chip are available). It is recommended 
that the protein, in this case conA, is covalently bound to the dextran using appropriate 
chemistry and any remaining dextran chains deactivated. The ligand is then passed over the 
surface, allowing association to take place. After an allocated time the liquid passing over 
the cell is changed from buffer with ligand to just buffer, enabling the dissociation to be 
monitored in a similar manner to the association. The resulting mass of material affects the 
surface of the gold producing the plasmons from a beam of light incident upon the opposite 
surface (see Section 4.1.1), it is then possible for the supplied software to produce values 
for the association and dissociation rates of the reaction. These should then coincide, using 
Equation 1-2, with the measured values from the ITC. 
 
Section 1.6. Hydrogel Production Methods 
Section 1.6.1. Production 
There are two published approaches to forming hydrogels which use lectins as one of the 
binding groups. Taylor and Tanna [41-44] take the sol/gel approach of mixing the lectin 
with the secondary material (dextran, glycogen etc.) and allowing the structure to 
completely disintegrate when the competing ligand (glucose) is present. However this 
results in the need for membranes to prevent leakage of the materials into the body of the 
patient. The second approach, which will be the one used in this work, is to covalently 
cross-link the two components together such that the competing ligand disruption only 
leads to an increase in swelling, rather than complete dissolution. Currently under 
investigation at the University of Bath is a third option whereby it has been demonstrated 
that low molecular mass dextran, when in solution, will irreversibly aggregate [86]. 
Therefore there is a possibility of entrapping lectins within these structures, thereby 
removing the need for chemical cross-linking and additional membranes. 
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Covalent cross-linking of the hydrogels has been demonstrated using two approaches. The 
first utilises divinyl sulphone, ethylene diamine, cyanuric chloride and triazine to create 
covalent bonds between dextran and conA and has been demonstrated by Tang et al. [52]. 
The second approach, used by Zhang [87], involves carboxymethylation of the dextran 
chains with sodium chloroacetate, the cross-linking is then achieved using 1-ethyl-(3-3-
dimethylaminopropyl) carbodiimide hydrochloride (EDC) and N-hydroxysuccinimide 
(NHS). This gives a ‘zero-length’ bond and introduces no toxic components which makes it 
the preferred approach. Both of these methods create a binding site on the dextran for an 
amine group. It is likely that some of the reversible binding sites on the conA molecules are 
disrupted by the cross-linking positions. However, careful control of the degree of cross-
linking should enable fine-tuning of the hydrogel so that it still works correctly. 
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Section 2. Materials and Methods 
This section contains details of the generic materials used throughout this project. More 
specific information for ITC, SPR and gel synthesis can be found in the relevant sections. 
Section 2.1. Materials 
The dextrans used in this work were all purchased from Sigma-Aldrich (11, 17, 43, 64, 500 
and 2000kD) with the exception of the 6kD dextran which was purchased from Fluka 
Biochemika. The D-glucose, L-glucose, maltose, concanavalin A (conA), cytochrome C 
(cytC), adenosine and insulin were all purchased from Sigma-Aldrich. 
 
The following standard reagents were purchased from Sigma-Aldrich: TRIZMA base, 
NaN3, MnCl2.4H2O, Na2HPO4, sodium chloroacetate, ethanolamine and ethylenediamine. 
MgCl2.6H2O, CaCl2.2H2O, NaCl, NaOH and HCl were purchased from Fisher Scientific. 
EDC was purchased from Alfa Aesar and NHS from Lancaster Synthesis.  
Section 2.2. Buffer Solution 
This work is based around using concanavalin A (conA) to bind to glucose moieties on 
dextran molecules. It is known that a conA monomer contains one calcium and one 
manganese ion and that these are needed to ensure the correct conformation of  the 
saccharide binding site [66].  To prevent leakage from the protein these ions were included 
in the buffer solution that was used through the majority of this work. The complete buffer 
solution comprised: 20mM TRIS (TRIZMA base), 150mM sodium chloride and 0.5mM 
calcium chloride, magnesium chloride and manganese chloride, corrected to pH7.4. For 
those solutions not being frozen once prepared, 0.02wt% sodium azide was added to 
prevent microbial growth. The pH correction was performed using hydrochloric acid or 
sodium hydroxide, additional sodium and chlorine ions from the pH correction being 
negligible compared to the overall concentration of sodium chloride. 
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Section 2.3. Carboxymethyl Dextran 
Carboxymethyl dextran (CM-dextran) was produced for use in the surface plasmon 
resonance (SPR) work and for use in the hydrogels. 
 
The carboxymethylation process involves the addition of sodium chloroacetate to a dextran 
solution. The reaction is initiated by raising the pH using sodium hydroxide and by heating 
the solution to 60
o
C. The length of time the reaction is allowed to proceed controls the 
degree of reaction. The reaction is stopped by returning the mixture to pH 7 using 
hydrochloric acid. 
 
Typically: 5g of dextran, dissolved in 75ml of distilled water 
  5g of sodium chloroacetate is added 
  Reaction initiated by 25ml of 8M NaOH 
  Reaction allowed to proceed for 15 minutes at 60
o
C 
  6M HCl added until pH 7 
  Solution added to 300ml absolute ethanol, resulting in precipitation, left to 
   stand overnight 
 Precipitate redissolved in distilled water and exhaustively dialysed against  
  distilled water 
  Dialysed solution freeze-dried for storage 
 
Owing to the rejection characteristics of the dialysis tubing it was decided not to dialyse 
CM-dextran produced from the 6, 11 or 17kD dextrans. Instead the CM-dextran, once 
redissolved after the ethanol precipitation step, was precipitated again with a similar 
quantity of ethanol. This was repeated twice (for a total of three precipitations for each 
sample preparation) and produced a freeze-dryable solution of purity similar to the dialysed 
solutions. 
 
The degree of carboxymethylation was determined by UV spectroscopy. Adenosine, a 
nucleoside with one amine group and no carboxylic acid groups, was bound to the CM-
dextran using EDC and NHS (for chemistry see Section 4.1.1). The adenosine-CM-Dextran 
(ACM-dextran) was dialyzed for one day, with the water being replaced twice, and then 
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lyophilised. The ACM-dextran will have an absorption peak at 260nM corresponding to the 
heterocyclic aromatic ring structure within adenosine. Use of the Beer-Lambert law to 
calibrate the absorption values allowed for quantification of the adenosine and thus of the 
carboxylic acid groups. 
 
Table 2-1 Degree of carboxymethylation by dextran molecular mass 
RMM of Dextran 
Number of glucose 
residues per -COOH 
Number of COOH per 
molecule 
6000 818 <0.1 
11000 433 0.2 
17000 64 1.1 
43000 90 2.9 
64000 695 0.6 
500000 25 121.3 
2000000 57 217.0 
 
Section 2.4. Dextran Branching - NMR 
Dextran molecules are produced as exopolysaccharides by various strains of bacteria. These 
have been shown to have variable rates of branching, depending upon the conditions in 
which the bacteria are grown [2-4]. The calculation of the branching rate was performed 
using 
1
H nuclear magnetic resonance (NMR) spectroscopy. (The raw data traces can be 
found in Appendix 1). 
 
Some atomic nuclei, in the right conditions, can behave like bar magnets. Under an applied 
magnetic field these nuclei can be aligned and excited with a radio wave. Those frequencies 
absorbed by the nuclei are dependent upon the surrounding molecular conditions and the 
energy the nucleus contains. The frequencies absorbed from the radio wave are naturally 
emitted by the nuclei as they ‘spin down’ from the higher state of excitation. These emitted 
radio waves are detected and can be converted into a spectrum specific to the molecule 
being investigated. The frequency of each nucleus is calculated in terms of an internal 
standard (in this case residual HOD arising from incomplete deuteration of the D2O 
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solvent) and the operating frequency of the machine. This gives values in parts per million 
(ppm) of the applied field [88]. 
 
At room temperature, C1 hydrogen absorption was found to partially overlap with the HOD 
peak. The spectra were therefore taken at an elevated temperature as this causes a shift in 
the spectra due to the additional energy of the nuclei. In this case this resulted in the C1 
hydrogen absorption being shifted downfield (to a greater ppm) of the HOD peak - 
facilitating analysis. 
 
 
Figure 2-1 Structure of α-D-glucose molecule. 
It is possible to have α(1-6) bonds (resulting in the loss of the C1 hydroxyl and the H of 
the C6 hydroxyl) of the main chain or α(1-3) bonds (resulting in the loss of the C1 
hydroxyl and the H of the C3 hydroxyl) of the branches. 
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Figure 2-2 
1
H spectra for 17kD Dalton dextran. 
Taken at 55
o
C in a 400MHz Bruker NMR Spectrometer. The peaks between 3.5 and 
4.5ppm correspond to the C2 to C6 hydrogen atoms. The peak at 4.75ppm is the HOD 
(solvent impurity) peak. Peaks from 4.8 to 5.8ppm correspond to the C1 hydrogen 
atoms and these are enlarged in Figure 2-3 for clarity. [89-93]  
 
The spectra shown in Figure 2-2 and Figure 2-3 do not show the hydrogen of the hydroxyl 
groups. This peak is not visible beneath the HOD solvent. The ratio of the magnitudes of 
the remaining peaks can be used to calculate the branching ratio. The total area of the C2 to 
C6 hydrogen peaks compared to the C1 peaks should be 6:1. The ratio of the main chain 
α(1-6) groups to the branch α(1-3) will equal the branching ratio.  
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Figure 2-3 
1
H spectra for 17kD Dalton dextran (Blue) and maltotriose (green) 
taken at 55
o
C in a 400MHz Bruker NMR Spectrometer.  
 
Comparison of the dextran spectrum to maltotriose in Figure 2-3 enables identification of 
the type of branches in the dextran. The maltotriose spectrum, in green, has three peaks in 
the C1 region. The doublets A and C (4.9 and 5.5ppm respectively) correspond to the β and 
α configurations of the reducing end C1 [92]. The third peak, E (between 5.6 and 5.7ppm) 
must therefore be due to the two α(1-4) linkages in maltotriose. This is confirmed by the 
ratio of areas of peaks E : A+C being 2:1. For the dextran spectrum, peaks A and C are the 
same as those of maltotriose. Peaks B and D must therefore correspond to the linkages of 
the main chain and of the branches, respectively. The main chain linkages are known to be 
α(1-6) in dextran whilst the branches can either be α(1-3) or α(1-4), depending on the 
species used for production [9, 92]. The triplet, D, does not appear at the same signal as the 
maltotriose peak, E. Therefore, given that the maltotriose peak is known to be α(1-4), the 
dextran branches from this species must be α(1-3). The ratio of peak D to peak B will give 
the branching ratio of the dextran. 
 
C 
B 
A 
D 
E 
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Table 2-2 Branching ratio by dextran molecular mass 
RMM of Dextran Branching ratio / % 
6000 5.5 
11000 3.0 
17000 3.9 
43000 3.9 
64000 4.8 
500000 4.6 
2000000 4.1 
 
Section 2.5. Dextran Summary 
The branching ratio of the different dextran sizes available fluctuates around the literature 
value of 5%, with no noticeable trend between them. The degree of carboxymethylation 
showed a noticeable difference between the molecular masses. The lower mass dextrans 
have very few groups attached. This may be due to the smaller dextrans naturally forming 
insoluble beads in solution [86, 94]. The beads reduce the amount of dextran available for 
modification from a given dissolved mass. 
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Section 2.6. Hydrogel Production and Casting 
All of the hydrogels were produced using the following recipe: 
 
  1g of dextran, dissolved in 4.2ml of distilled water 
  210mg of EDC and 30mg of NHS, dissolved in 1.5ml of distilled water 
  The two solutions are combined and stirred gently for 10 minutes 
  130mg of conA, dissolved in 3ml of buffer added to solution 
  Mixture poured into mould and placed in fridge to set overnight. 
 
The dextran used was the carboxymethylated version so as to allow covalent cross-linking 
within the gel. The mass of the dextran was always 50% 500kD with the other 50% being 
one of the seven molecular masses available (6, 11, 17, 43, 64, 500 and 2000kD). This is to 
ensure a reasonable level of structure within the hydrogels. The moulds were made from 
acetate sheet. The top and bottom glass plates were covered in Parafilm to prevent adhesion 
to the glass. Ethanol was pipetted between the gel and Parafilm (by peeling back a corner) 
to separate them once the gel had set and was ready for use.  
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Part 1 – Investigation of Concanavalin 
A / Dextran Interaction 
The interaction of unmodified dextran with conA was studied using two techniques: 
isothermal titration calorimetry (ITC) and surface plasmon resonance (SPR). This work was 
carried out in order to investigate the differences, if any, between the various available 
dextran sizes and their interaction with conA.  
 
The ITC experiments were performed in order to identify the type of binding that occurs 
between the polysaccharide and the lectin and to identify any trends between the molecular 
mass of the dextran and the binding equilibria. This was achieved by use of an isothermal 
titration calorimeter. 
 
SPR experiments were performed to investigate the kinetics of the binding between the 
various dextran sizes and conA molecules. This is achieved by use of an SPR machine 
produced by BIAcore®. 
 
These two techniques complemented each other. The ITC work provided data on the 
strength of the binding and the energy released during this process. The SPR results allow 
quantification of the interaction kinetics.  
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Section 3. Isothermal Titration Calorimetry 
ITC (Isothermal Titration Calorimeter) experiments were performed in a MicroCal™ VP-
ITC MicroCalorimeter (MicroCal, LLC. Northampton, MA, 01060-2327, USA) which is 
used to evaluate the association binding constant (K), enthalpic change (∆H) and entropic 
change (∆S) of a reaction or binding interaction (see Section 1.5.1).  
 
Section 3.1. Theory 
Section 3.1.1. Isothermal Titration Calorimetry 
The MicroCal
TM
 ITC comprises two cells, one for the sample and one as a reference. These 
are held within a heated shield which is set to the temperature required by the user. A 
constant reference power is fed to the reference cell, the magnitude of which is dependent 
upon the amount of heat expected to be released by the interaction under investigation (in 
this description, it will always be assumed that the interaction in question is exothermic). 
The temperatures of the two cells are monitored and the difference between the two 
calculated. If the sample cell is of a different temperature to the reference cell, a Peltier 
element supplies or removes energy to equalise the temperature of the two cells. 
 
The titrations are added to the sample cell at a set rate and volume (typically 5µl every 2 
minutes). The energy evolved from the interaction results in the sample cell requiring less 
energy from the Peltier element to achieve the same temperature as the reference cell. 
Hence a trace of the energy input to the cell is produced over time with troughs 
corresponding to the amount of energy produced by the interaction (see Figure 3-1). 
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Figure 3-1 Raw Data of titration of D-glucose into conA. 
Reference power set to 42µJs-1. Thirty one 5µl injections, one injection every 2 
minutes. 
 
Figure 3-1 shows a series of 31 injections of D-glucose into conA. The system, once all the 
solutions are in place, takes approximately 20 minutes to equilibrate at the required 
temperature before the first injection can occur. Due to diffusion caused by the rotating 
syringe (ca. 400rpm) during the equilibration period the first injection is always slightly 
erroneous and MicroCal
TM
 recommend removing it from subsequent analysis [95].  
 
The baseline of the injections (at approximately 39µJ/s in this case) corresponds to the 
amount of energy supplied to the sample cell when there are no injections and is equivalent 
to the reference power supplied to the reference cell (There is a small difference due to 
energy from the stirrer). The injections then show the reduction in energy input due to the 
energy released from the molecular interactions. With each subsequent injection, fewer new 
interactions are formed and so less energy is released and the size of the troughs from the 
reference baseline decrease. The energy released per injection is calculated by integrating 
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the area between the curve and the reference line. The total concentration of dextran and 
conA (bound and unbound) can be calculated from a mass balance over the cell. It should 
be noted that, in order to keep the size of the sample cell constant, each injection pushes the 
equivalent volume of liquid out of the sample cell, resulting in a small reduction in conA 
concentration and a loss of energy due to the interacting species within this volume. 
 
The quantity of conA / dextran complexes were calculated using the derivation detailed in 
Appendix 2. In summary, mass balances were taken across the sample cell for each 
component. These were then related to the experimental data using the enthalpic energy 
change. The binding association constant, K, and the enthalpy change, ∆H, were estimated 
and mathematical models (see Section 3.2.3) used iteratively to find a ‘best fit’, in this case 
a minimised chi squared value, for the data. 
Section 3.1.2. Thermodynamics of the System 
The enthalpic and entropic changes of the reaction are an indication of the reaction’s 
“likelihood of occurring”. The enthalpic change, ∆H, and the association constant, K, are 
obtained from the solving of the equations detailed in Appendix 2. They were used to 
determine the Gibbs free energy, ∆G, from Equation 3-1, and in turn Equation 3-2 was used 
to determine, ∆S: 
Equation 3-1 
Equation 3-2 
 
The Gibbs free energy is a measure of the overall energy change of a reaction. If it has a 
negative value, the reaction can happen spontaneously, though there may be activation 
energies which need to be supplied. If the value is positive the reaction will not proceed 
without external energy input.  
 
KRTG ln−=∆
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S
∆−∆
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Section 3.1.3. Lectin / Saccharide Binding 
In order to analyse the experimental data, the type of binding had to be considered. The ITC 
control package incorporates Origin
TM
, a graphics and data analysis package, to provide a 
non-linear least squares fit to the appropriate binding isotherm equation. The two main 
options are single site and sequential site models. The single site model is based on the 
concept that each ligand and each binding site have the same chance of combining, 
irrespective of the amount of binding that has already occurred. This is the model described 
in detail in Appendix 2.1. 
 
The sequential binding model is based on the concept that once one ligand has bound, a 
second binding to the same conA molecule is either made easier or harder (positive and 
negative cooperativity respectively) [96].  
 
Equation 3-3 
 
 
Figure 3-2 shows two attempts at modelling a dataset. Image A shows a Langmuir type 
binding, image B shows a sequential sites model. C and D are residual plots for A and B 
respectively. 
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Figure 3-2 Plots A and B both represent 31 5µl injections of 11kD dextran into 
0.1mM conA. 
The line of best fit in figure A shows a Langmuir type binding, figure B shows a 
sequential sites model. Plots C and D are the residual errors (C applies to A, D applies 
to B) (1µCal = 4.184µJ).  
 
It is clear from Figure 3-2 that a single site model is not ideal. The line of best fit in A 
(Langmuir) shows systematic deviation from the data, as confirmed in the residual plot, C. 
In B, where a sequential binding model was used, the corresponding residual plot, D, shows 
a more random residual distribution. 
 
A 
D C 
B 
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Section 3.1.4. Sequential Sites Mathematical Model 
ConA is a tetrameric protein. It is possible, therefore, to have up to four stages of sequential 
binding, with each subsequent attachment releasing a different quantity of energy and 
having a different binding strength. It was decided to produce each of the four models, 
whereby the maximum degree of binding is either [MX], [MXX], [MXXX] or [MXXXX].  
 
The modelling of the four sequential site models was done based on the principle that Adair 
postulated in 1925 [96] when examining Haemoglobin. When the first dextran branch binds 
to a free conA molecule, statistically there are four possible binding sites, for the second 
there will only be three available. Similarly, when a conA tetramer is fully bound there are 
four possible dextran branches to lose and so on. Therefore the equilibrium equations 
should be written thus: 
 
 
Equation 3-4 
 
 
 
  
The K values are the apparent, overall, association constants, the KI values are the intrinsic 
association constants. The numerator and denominator of the KI values are the statistical 
attachment and detachment chances respectively. In order to consider whether or not there 
is cooperativity, the intrinsic association constants must be considered as they are the 
fundamental constants.[96-98]  
 
The modelling of the one site model resulted in a quadratic equation which could be simply 
solved. The sequential site systems, if solved in a similar manner result in cubic, or higher, 
equations. Though possible to solve analytically, they can be complex and may result in 
non-real roots. Therefore they were solved numerically (see Appendix 2.2). 
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Section 3.1.5. Parameter ‘c’ 
Wiseman et al. [99], in their initial description of isothermal titration calorimetry defined a 
parameter, c, as a function of the association constant of the reaction and the concentration 
of the analyte in the sample cell:  
Equation 3-5 
Ideally the c value should be between 5 and 100. This will give a sensible energy signature 
without inducing macromolecular problems. 
 
The stoichiometric coefficient, ns, is unity when the concentration of conA ([M TOT]) is 
measured in terms of monomer units rather than tetramers. Work by Santori [100] and 
Zhang [101] has shown K for glucose to be of the order 10
2
 – 10
3
 M
-1
. Visual observations 
of conA solutions showed that a concentration of 0.1mM was the highest feasible given that 
viscosity effects will begin to affect the ‘well-mixed’ status of the system. This gives, at 
most, a c value of 0.1, constrained by the weak binding constant and high molecular mass 
of the dextran. 
 
Section 3.2. Experimental Conditions and Data Analysis 
Section 3.2.1. Experimental Conditions  
All experiments with the ITC were performed in the buffer detailed in Section 2.2 and at 
37
o
C. This meant the experiments were at physiological temperature and pH. The solutions 
were found to be more stable, particularly the conA solution, if they were frozen after being 
made and only thawed prior to use each day. In all experiments 31 injections of 5µl were 
injected at 2min intervals. The first injection, due to diffusion during the temperature 
equilibration period prior to the experimental run, is always smaller than expected and is 
thus removed from the subsequent analysis [95]. The concentration of conA in the cell, as 
stated in Section 3.1.5, was kept at 0.1mM, this being the highest usable concentration 
without viscosity effects. The dextrans were used at as high a concentration as possible 
without making the solution unduly viscous. The dextrans used were of 6, 11, 17, 43, 64, 
500 and 2000kD molecular mass.  
 
[ ]TOTs MKnc =
 Page 36 
The dextran solutions used were initially planned to have the same binding concentration 
irrespective of molecular mass, assuming 5% branching. This was, however, not feasible as 
the larger mass dextrans produce highly viscous solutions at relatively high concentrations 
(see Section 5.2 for more detail). Therefore an initial solution was made at the desired 
concentration and its viscosity visually observed. An estimate was then made as to the 
reduction in concentration required to produce a freely flowing solution. The final 
concentrations used are detailed in Table 3-3. 
 
To eliminate thermal changes due to dilution effects, background runs were performed. 
This involved injecting the same dextran solutions as used in the standard tests into buffer 
devoid of conA. This shows the energy signature of the dilution effects of the buffer, which 
can then be subtracted from the standard run to give the energy signature that is solely due 
to the binding interactions. 
Section 3.2.2. Model Accuracy and Error Calculation 
The accuracy of a binding model is calculated as a χ2 value. This is a summation of the 
square of the error between the model and data, divided by the number of degrees of 
freedom: 
Equation 3-6 
 
The number of degrees of freedom is found by subtracting the number of parameters, p, 
from the number of data points, np. This is to identify the statistical quality of the model. In 
pure mathematical terms, if the number of parameters is increased the model will fit the 
data set more accurately. However, each parameter introduced must be meaningful in terms 
of the biology of the system. This can be monitored statistically using Equation 3-6. As the 
number of parameters is increased, the denominator decreases in size. Hence, if the 
reduction in the error (numerator) due to an additional parameter is not significant it will 
not offset the reduction in the magnitude of the denominator and χ2 will not be reduced. 
This equation will be used to compare the different models as well as to identify the values 
of the parameters within a given model. 
)(
)(
2
2
pn
dataModel
p −
−
= ∑χ
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Section 3.2.3. Model Selection 
The analysis of the dextrans must be performed using one of the four models detailed in 
Section 3.1.4. In order to do this, one set of data was selected and analysed using each of 
the models and their error (χ2) compared. Each of the models was written in the software 
package Scientist® (Version 2.0), a computer program from MicroMath® for mathematical 
modelling of non-linear and implicit equations. (see Appendix 3 for coding). The program 
was split into two halves. The first calculated the various concentrations and the energy 
release for an injection, i, using the equations listed in Section 3.1.4. The second half 
performed the same calculations, but for the injection i+1. The energy values were then 
calculated. The whole system was performed for each injection systematically and the 
parameters estimated with each iteration.  
 
Each model was run in two modes. The first allowed each of the intrinsic association 
constants and enthalpy values to be different for each binding site (cooperativity), the 
second prevented them from varying relative to each other (no cooperativity). An additional 
model was also written whereby the conA was viewed as a monomer, but as if there were 
two populations of dextran, with differing binding strengths. This would show if there was 
a notable difference between branches of different lengths. Each of these models was run 
using a data set of 500kD dextran.  
 
Table 3-1 Comparison of data analysis models based on size of error 
  KI, ∆H equal KI, ∆H different 
ConA Units 1 2 3 4 2 3 4 
2x Dextran 
Number of parameters 2 2 2 2 4 6 8 4 
χ2 3.200 3.400 3.619 5.421 0.491 0.609 0.615 3.200 
 
From Table 3-1 it can be seen that the best is the two site model with cooperativity. The 
models with no cooperativity get progressively worse as the number of conA units 
considered increases. The model with two sets of dextran branches provides no 
improvement on the one site model. The two, three and four site cooperative models are 
significantly better than the non-cooperative models and the two site is the best of these. 
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Section 3.2.4. Model Instability 
The modelling process was found to produce variable results depending upon the initial 
estimates entered into Scientist®. Table 3-2 below shows three separate pairs of binding 
constants and enthalpy values for a 500kD dextran data set (the same as used in Section 
3.2.3). 
Table 3-2 Variability of binding parameters depending upon initial estimates 
1 2 3 
 
Estimate Fit Estimate Fit Estimate Fit 
KI1 / M
-1
 1000 8630 1000 2500 10000 2410 
∆H1 / kJmol-1 -10000 -23.2 -10000 -19.8 -10000 -20.3 
KI2 / M
-1
 10 456 100 132 10 13.1 
∆H2 / kJmol-1 -10000 682 -10000 -93.5 -10000 -837 
χ2 0.516 0.491 0.517 
 
The primary binding site parameters are of the same order of magnitude for each fitted set. 
The secondary site parameters vary over orders of magnitude without greatly affecting the 
error. This weaker dependence on the secondary site is due to the respective energy releases 
of the two binding sites. Of the total energy produced during this titration 31% was 
generated by the secondary binding, hence a larger difference in the K and ∆H values does 
not have as large a bearing on the fitting process.   
 
Figure 3-3 and Figure 3-4 show the number of complexes formed and the respective energy 
release of injecting 500kD dextran into conA. The number of secondary complexes, [MXX], 
being formed is significantly less than the primary complex, [MX], but the amount of 
energy released per mole is greater resulting in the small number of secondary complexes 
having a significant effect on the binding fit.  
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Figure 3-3 Moles of primary and secondary complex formed by 30 injections of 
0.15mM 500kD dextran with 0.1M conA. 
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Figure 3-4 Energy release of primary and secondary complex formation by 30 
injections of  0.15mM 500kD dextran into 0.1M conA. 
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Section 3.3. Results and Discussion 
Each of the dextran sizes, D-glucose, maltose and maltotriose were run in duplicate and the 
data modelled in Scientist® using the two site binding model described previously to obtain 
the binding parameters. The modelling for glucose, maltose and maltotriose was performed 
using the monomeric concentration of conA as there are no size constraints associated with 
tese small molecules. Data shown is for the ‘best’ two experimental runs. Several of the 
dextrans required five or six repeats to achieve two similar sets of data. This is due to the 
energy release of this type of interaction being low (see Section 3.1.5). (The raw data 
graphs can be found in Appendix 4). 
 
Table 3-3 Branching Concentrations from ITC experiments 
Dextran MW / kD Branch Ratio / % Concentration / mM 
Branch ends 
concentration / mM 
Glucose – rep1 - 134.03 - 
Glucose – rep2 - 134.03 - 
Maltose – rep1 - 68.14 - 
Maltose – rep2 - 70.36 - 
Maltotriose – rep1 - 68.25 - 
Maltotriose – rep2 - 69.16 - 
6 – rep1 5.5 11.89 36.1 
6 – rep2 5.5 11.89 36.1 
11 – rep1 3.0 11.42 34.7 
11 – rep2 3.0 11.48 34.9 
17 – rep1 3.9 9.18 46.7 
17 – rep2 3.9 9.70 49.5 
43 – rep1 3.9 3.00 34.1 
43 – rep2 3.9 3.00 34.1 
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Table 3-3 cont. 
Dextran MW / kD Branch Ratio / % Concentration / mM 
Branch ends 
concentration / mM 
64 – rep1 4.8 1.44 28.7 
64 – rep2 4.8 1.44 28.7 
500 – rep1 4.6 0.15 21.4 
500 – rep2 4.6 0.15 21.4 
2000 – rep1 4.1 0.04 20.3 
2000 – rep2 4.1 0.04 20.3 
 
 
Table 3-4 Binding Parameters from ITC experiments 
Dextran MW / 
kD 
KI1 / M
-1
 
∆H1 / 
kJmol
-1
 
KI2 / M
-1
 
∆H2 / 
kJmol
-1
 
[MXX] 
energy 
release / % 
Glucose – rep1 159 -10.2 - - - 
Glucose – rep2 189 -8.31 - - - 
Maltose – rep1 1380 -8.60 - - - 
Maltose – rep2 1500 -9.02 - - - 
Maltotriose – rep1 568 -18.4 - - - 
Maltotriose – rep2 569 -32.9 - - - 
6 – rep1 1190 -34.1 109 -155 38.2 
6 – rep2 1470 -27.3 225 -73.1 44.8 
11 – rep1 683 -82.0 14.5 -1320 9.9 
11 – rep2 740 -79.9 35.1 -427 7.7 
17 – rep1 376 -128 2.07 -17700 15.1 
17 – rep2 307 -218 1.02 -29000 8.2 
43 – rep1 714 -27.5 200 -106 49.0 
43 – rep2 556 -111 125 -417 31.1 
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Table 3-4 cont. 
Dextran MW / 
kD 
KI1 / M
-1
 
∆H1 / 
kJmol
-1
 
KI2 / M
-1
 
∆H2 / 
kJmol
-1
 
[MXX] 
energy 
release / % 
64 – rep1 1710 -28.6 676 -53.3 37.3 
64 – rep2 1600 -30.2 6.93 -2160 16.0 
500 – rep1 2500 -19.8 132 -93.4 30.8 
500 – rep2 1940 -17.3 198 -51.1 31.7 
2000 – rep1 2700 -25.6 6.15 -333 2.1 
2000 – rep2 2910 -34.5 0.35 -54100 12.5 
 
0
500
1000
1500
2000
2500
3000
3500
100 1000 10000 100000 1000000 10000000
Dextran Molecular Mass / Daltons
A
s
s
o
c
ia
ti
o
n
 C
o
n
s
ta
n
t 
/ 
M
-1
Monomeric Model
Tetrameric Model
 
Figure 3-5 Intrinsic association constant of primary binding of glucose, maltose (a 
glucose dimer), maltotriose (a glucose trimer) and various dextrans with conA. 
Data is mean of two replicates, error bars are +/- 1 standard deviation. Dextran data 
modelled using tetrameric conA concentration. Non dextran data modelled using 
monomeric concentration of conA.  
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Figure 3-6 Enthalpy change of primary binding of glucose, maltose (a glucose 
dimer), maltotriose (a glucose trimer) and various dextrans with conA. 
Data is mean of two replicates, error bars are +/- 1 standard deviation. Dextran data 
modelled using tetrameric conA concentration. Non dextran data modelled using 
monomeric concentration of conA. 
 
The association constant of the primary binding site, Figure 3-5, has a general correlation of 
increasing binding strength with increasing molecular mass. The amount of energy released 
by these complexes does not follow a similar correlation, Figure 3-6. The data for the 
secondary binding site, Table 3-4, is a lot more variable both between replicates and 
between molecular masses. The energy released by the secondary binding sites ranges from 
~10% for 11kD dextran to ~40% for the 6 and 43kD dextrans. The lower this figure, the 
harder it is for the fitting process to accurately predict the values. The greater strength of 
association for maltose, compared to glucose, follows the knowledge of how lectins bind to 
saccharides (see Section 1.3) but this does not follow through for maltotriose.  
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Mangold et al. [102] have performed similar tests on monomeric and dimeric conA using 
ITC.  Titrations of various dendrimers with terminal mannose groups have shown that the 
association constant of binding increases as the number of terminal groups increases. The 
modelling performed in their work did not include sequential binding for the dimeric conA. 
The crystallographic work performed by Reeke et al. [67] produced an image of the 
structure of conA. 
 
Figure 3-7 Structure of a conA tetramer, consisting of two pairs of dimers on top of 
each other. 
Ca, Mn and S represent the calcium ion, manganese ion and substrate binding sites 
respectively. Each sub-unit is approximately 4x4x4 nm. 
The size of each monomer is approximately 4x4x4 nm. Figure 3-7 shows that a conA 
tetramer exists as two planes of substrate binding sites. Units I and II have approximately 
5nm between their binding sites with III and IV in a similar position on the opposite face of 
the tetramer. The hydrodynamic radius of dextran has been shown to be between 1.5 and 
30nm for dextrans up to 2000kD [103, 104]. It is therefore unlikely that more than two 
dextran molecules can bind to a conA simultaneously due to the physical constraints. This 
is supported by the sequential site analysis which showed the three and four site models to 
be inappropriate and the glucose, maltose and maltotriose data which allowed full 
tetrameric binding. The weak strength of the secondary bind compared to the primary can 
also be explained by the size restrictions.  
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Section 3.4. Conclusion 
The interaction between conA and dextran has been thermodynamically investigated. It has 
been shown that a weak prediction of the primary association constant can be made from 
the size of the dextran molecule. No prediction of the enthalpic change of binding is 
possible.  
 
Lectin binding sites are shallow compared to those of enzymes and antibodies [105], with 
binding being enhanced by secondary effects of the molecule “lying” across the surface of 
the protein, reflecting the biological role of oligosaccharide recognition. As the length of 
the dextran chain increases the amount of additional binding should increase, making the 
binding stronger. 
 
There is a suggestion that the secondary binding is weaker than the primary binding, 
implying negative cooperativity. This is likely to be due to physical constraints, similar to 
those that prevent tertiary and quaternary binding, rather than changes in chemical 
conformation. It is therefore possible to state that, should this work be continued to test 
non-toxic proteins with dextran, that the number of monomers bound together is not the 
important factor - the relative position and distance between the saccharide binding sites is 
the essential characteristic. 
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Section 3.5. Nomenclature 
c   Wiseman feasibility parameter 
∆G   Gibbs free energy change (Jmol-1) 
∆H   Enthalpic change (Jmol-1) 
K   Apparent association constant (M
-1
) 
KI   Intrinsic association constant (M
-1
) 
ka   Association rate (M
-1
s
-1
) 
kd   Dissociation rate (s
-1
)
 
[M]   Concentration of free lectin (conA) (M) 
[MX]   Concentration of conA/dextran complex (M) 
[MXX]   Concentration of conA/dextran/dextran complex (M) 
[MTOT]   Total conA sites, bound and unbound (M) 
ns   Stoichiometric coefficient 
np   Number of data points 
p   Number of parameters 
Qi   Total energy released (J) 
dQi   Energy change over one injection (J) 
R   Universal gas constant = 8.31 Jmol
-1
K
-1
 
∆S   Entropic change (Jmol-1K-1) 
t   Time (s) 
T    Temperature (K)  
VC   Volume of sample cell (L) 
Vinj   Volume of injection i (L) 
[X]   Free dextran binding ligands at injection, i (M) 
[XTOT]   Total dextran ligands, bound and unbound (M) 
χ2   Size of error  
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Section 4. Surface Plasmon Resonance 
The SPR (Surface Plasmon Resonance) experiments were performed using a BIAcore® X, 
(BIAcore AB, S-754 50 Uppsala, Sweden), which can be used to evaluate the kinetics 
(association and dissociation rates of binding) of the dextran / conA binding. 
Section 4.1. Theory 
Section 4.1.1. Surface Plasmon Resonance 
SPR experiments are conducted in a system where the receptor is bound to a surface such 
that the rate of association and dissociation can be found when the ligand passed through 
the system in solution is bound. The standard technique, when using CM5 sensor chips, 
involves covalent binding of ligand via an amine group. 
 
The surface of the chip is coated in dextran with carboxylic acid moieties. These are 
activated by a set regimen involving ethyl-(3-3-dimethylaminopropyl) carbodiimide 
hydrochloride (EDC) and N-hydroxysuccinimide (NHS). This produces a surface capable 
of binding amine groups (see Figure 4-1).  
 
 
Figure 4-1 Depiction of the standard amine binding process 
The material desired to be bound is then passed over the surface (typically for 7 minutes at 
5µLmin-1). If more than one amine group is present on the injectant then a heterogeneous 
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surface will be produced because there is no way of controlling the molecular orientation 
within the cell. The binding process is concluded by passing ethanolamine through the 
system. This blocks any remaining active groups from the EDC/NHS phase which haven’t 
bound with amine groups. 
 
SPR works on the principle that some metals, particularly gold and silver, are capable of 
propagating plasmons along their surface. A plasmon, a quasiparticle, is caused by a photon 
of light at a specific wavelength striking a free electron on the surface of the metal. At the 
correct incidence angle the plasmon will propagate along the surface rather than being 
reflected to the photodiode array. The refractive index of the metal film affects the 
occurrence of surface plasmons and it is this refractive index which is affected by the 
presence of material bound to the opposite side of the metal layer (see Figure 4-2).  
 
 
Figure 4-2 Schematic of SPR technology: L: light source, D: photodiode array, 
P: prism, S: sensor surface, F: flow cell. 
The two dark lines in the reflected beam projected on to the detector symbolise the 
light intensity drop following the resonance phenomenon at time = t1 and t2. The line 
projected at t1 corresponds to the situation before binding of antigens to the 
antibodies on the surface and t2 is the position of resonance after binding. 
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Section 4.1.2. Kinetic Experiments 
The kinetic parameters of an interaction, the association and dissociation rates, can be 
found experimentally using SPR. Kinetic experiments were performed by passing a ligand 
solution across the activated chip for a given length of time, then followed by buffer 
without ligand at the same rate. This allows association and then dissociation to occur. The 
data is recorded and analysed. To obtain kinetic data it is recommended to pass solutions of 
increasing concentration of ligand through the cell. This will give a set of data as illustrated 
in Figure 4-3. The use of several concentrations is to ensure that the data analysis is not 
hindered by localised effects. It is possible for too high concentrations to have mass transfer 
limitations or bulk refractive index problems and for too low concentrations to produce data 
at the level of the noise of the detection system; if the kinetic model can produce a good fit 
for all the concentrations used it is more likely to be accurate. 
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Figure 4-3 Injections of ConA over 2000kD Dextran. Concentration of conA 
(1.1µM, 2.5µM, 4.3µM, 6.8µM and 10.2µM) increasing in direction of arrow. 
At t = 180s flow returned to just buffer with no conA. 
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The injected sample should be preceded by an air gap (as recommended by BIAcore). This 
prevents effects similar to that seen in the 6.8µM injection in Figure 4-3. At the end of the 
association phase the response begins to decrease, rather than continuing towards the 
equilibrium state. This is because the injected fluid has diffused into the previous samples 
still present in the sample loop. The air gap provides a physical barrier against diffusion, 
maintaining the injection concentration throughout the course of the association phase. 
Section 4.1.3. Analysis 
The analysis of the SPR data is based around the type of interaction it is believed is 
occurring. There are several binding models built into the BIAcore evaluation software of 
which the following three are most applicable. 
 
Langmuir type binding assumes a simple 1:1 ratio of binding sites to ligands. The 
association and dissociation rates are calculated iteratively from an estimation of the total 
binding sites available on the sensor chip surface and the concentrations known to have 
been passed through the system. A least squares fit can be performed, similar to Section 
3.2.2 (but only incorporating the size of the error, not the number of parameters or data 
points) to calculate the accuracy of the rates. Details of the equations are in Appendix 5. 
 
At physiological pH conA is a tetramer. Therefore assuming a Langmuir type binding is 
likely to be an inappropriate model. The next option is a bivalent model which assumes that 
the binding of a second dextran ligand to a conA tetramer has different association and 
dissociation rates than the primary bind. The modelling process is similar to that of the 
Langmuir binding, but with two sets of association and dissociation rates. The difference 
between the first and second bind to a conA molecule could have a positive or a negative 
effect. There may be conformational changes caused by the first binding which facilitate 
the other binding sites, or there could be problems caused by the dextran orientation of the 
conA when it is bound to the sensor chip surface. 
 
The third type of model assumes a heterogeneous ligand population. This is based on the 
fact that the dextran is not a homogenous material. It is possible that branches or different 
lengths will bind to conA with different strengths. Therefore this binding model assumes 
that there are two populations of dextran which in total account for all of the binding. 
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Section 4.1.3.1. Additional Effects 
There are two additional effects which can alter the response detected by the BIAcoreX. 
The first is mass transfer, MT. It is possible, due to the potentially large and tangled bulk of 
dextran on the surface of the sensor chip that there is a diffusion limitation on the dextran 
before all the terminal groups can reach the conA binding sites.  
 
The second potential effect is that of bulk refractive index, Ri. The solution passing over the 
sensor surface during the association phase contains a significant amount of material, which 
could potentially enhance the response of the system. This effect can be incorporated as a 
simple multiple of the injectant concentration. 
 
Section 4.2. Experimental Conditions 
Section 4.2.1. Experimental Conditions  
Throughout the experiments the buffer detailed in Section 2.2 was used, except during the 
surface preparation when the standard amine coupling technique was followed. Flowrates 
were set to 20µlmin-1 throughout. The time allowed for association was 180s with a 150s 
dissociation phase. Rejuvenation of the sensor chip surface (removal of remaining dextran) 
was performed using a 1M phosphoric acid solution, as recommended by Mann et al. [106]. 
The BIAcore approved technique of adding air gaps to the injectant to isolate from previous 
solutions was followed at all times.  
Section 4.2.2. Binding ConA or Dextran to the Sensor Chip Surface 
The technique recommended by BIAcore involves binding at a pH below the pK value of 
the protein, for conA, this is pH4.5. However this means that the ConA will be binding 
when in its dimeric form, not the tetrameric form that was used in the ITC or to make the 
hydrogels. Two other problems were also found with binding the conA to the surface of the 
SPR chip. The orientation of the binding was not known, and so it is likely that many of the 
binding sites were inaccessible to the large dextran molecules. The second problem was 
related to an issue raised by Hubble [107, 108], who suggested that when there is 
multivalency, the dissociation rate is based on the statistical probability of all bonds 
dissociating at the same time. Assuming 5% branching, the number of branches varies from 
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3 on a 6kD molecule to over 600 for the 2000kD dextran. The sensorgrams produced with 
conA bound to the SPR suggested that this was indeed a problem; the dextran, once bound, 
was very difficult to remove. 
 
Preparing the surface with conA not being productive, it was decided to bind the dextran to 
the surface of the SPR chip. This was achieved by using the carboxymethylated dextran 
that was to be used in the hydrogel production (see Section 2.3). The binding protocol 
described in Section 4.1.1 was then followed, but with diaminoethane bound to the 
EDC/NHS prepared surface. Once the ethanolamine had been passed through the system 
the carboxymethylated dextran (CM-dextran), dissolved in an EDC/NHS solution, was then 
passed through until sufficient was believed to be bound to the surface. It was not known 
where the carboxymethyl groups were positioned on the dextran molecule and it was likely 
that some of them, once bound to the sensor surface, would prevent some branch terminals 
from binding to conA. However, as the same protocol was used to cross-link the hydrogels, 
this would provide a more accurate representation of the binding occurring within a 
hydrogel. Once bound it was possible to pass conA through in solution at pH 7.4 (thus 
tetrameric) with the maximum bound points of a molecule in solution being 4 rather than 
the much larger figures possible with the larger dextran molecules. 
Section 4.3. Data Analysis and Results 
A set of kinetic experiments were performed for the 43, 500 and 2000kD dextrans. Data 
was also obtained for the ‘blank’ sensor surface as this was made from CM-dextran and 
would in theory also be able to bind to conA. (The raw data can be found in Appendix 7.2). 
The resulting data was then condensed down into a set of five injections of varying 
concentration. An example section of data from the 2000kD dextran activated surface can 
be seen in Figure 4-4. The supplied BIAcore software is incapable of fixing the ratio of the 
species of binding sites for heterogeneous sites; a factor which logic suggests should be 
constant for a given dextran surface. Therefore this binding would have to be evaluated in 
Scientist®. For consistency, it was decided that all the data should be evaluated in the same 
computer package, thus the BIAcore software was not used for data analysis. 
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Figure 4-4 Graph showing the first 2000 seconds of the data using the 2000kD 
dextran activated surface. 
This section of data contains five injections, starts of which indicated by the arrows. 
The first, third and fifth injections are of conA, the second and fourth are cleaning 
injections of phosphoric acid. 
Section 4.3.1. Binding Type Analysis 
The binding analysis involved finding the correct model to describe the data. There were 
two parts to this – the primary half involved finding the appropriate model based on the 
molecular nature of the materials such as whether the conA was capable of all four of its 
binding sites being used. The second half incorporated the bulk refractive index and mass 
transfer terms. The material being injected over the surface of the sensor chip can cause 
response effects even if there is no binding. This is known as the bulk refractive index term 
and is represented by a constant value during the association phase, linked to the 
concentration of the injectant. The mass transfer affect requires the calculation of the 
concentration on the surface of the chip, rather than in the bulk stream. This is done as a 
mass transfer coefficient multiplied by the concentration difference. 
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Figure 4-5 to Figure 4-8, below, show the attempted data analysis of a 10.2µM conA 
solution over a 2000kD dextran activated sensor surface, the four remaining injections (at 
1.1µM, 2.5µM, 4.3µM and 6.8µM) are not shown for clarity, though all were analysed 
together to ensure that the estimated parameters are applicable for all data. Figure 4-5 
shows all the attempts using a Langmuir binding. It is clear that this is not an appropriate 
model, and it is not enhanced by the addition of mass transfer or bulk refractive index 
functions, though the equilibrium state at the end of the association phase is more accurate 
with a refractive index term. In both the case of pure Langmuir and Langmuir with a 
refractive index term, the mass transfer term produces no discernible benefit. 
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Figure 4-5 Graph representing data analysis of an injection of 10.2µM conA 
(monomer concentration) over a 2000kD dextran activated surface. 
Injection is stopped at 180s to allow dissociation to be recorded. The data recorded is 
shown as the experimental data line. Type of binding is Langmuir throughout (see 
Appendix 5.1) with inclusion of a bulk refractive index term (Ri) and / or a mass 
transfer term (MT). (Pink and green lines are superimposed on top of each other due 
to lack of influence of the MT term) 
 
Figure 4-6 shows that a bivalent model for the binding of conA to dextran is not 
appropriate either, again without any great benefit from either the refractive index or the 
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mass transfer term. In the case of both the Langmuir and bivalent models the refractive 
index term aids the model in reaching the equilibrium state at the end of the association 
phase. However neither model is showing suitably rapid association or dissociation at the 
beginning of each phase. The fact that very rapid association occurs underlines the reason 
for the mass transfer term being ineffectual. Mass transfer effects will no longer be 
considered, whereas refractive index effects will be permanently employed. 
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Figure 4-6 Graph representing data analysis of an injection of 10.2nM conA 
(monomer concentration) over a 2000kD dextran activated surface. 
Injection is stopped at 180s to allow dissociation to be recorded. The data recorded is 
shown as the experimental data line. Type of binding is Bivalent throughout (see 
Appendix 5.2) with inclusion of a bulk refractive index term (Ri) and / or a mass 
transfer term (MT). 
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The heterogeneous model, with refractive index, (see Figure 4-7) is far superior to both the 
Langmuir and bivalent models. This model entails there being more than one population of 
sites bound to the surface of the sensor chip. In particular the latter half of the association 
phase and the dissociation phase are not well approximated in the other models. This model 
is further improved, in Figure 4-8, by applying a bivalent binding to each of the two 
populations of binding sites, though this additional improvement in the error calculation 
may be due to the large increase in the number of parameters (see Table 4-1). 
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Figure 4-7 Graph representing a heterogeneous model, with refractive index, for 
all the concentrations of conA. 
(1.1µM, 2.5µM, 4.3µM, 6.8µM and 10.2µM – arrow indicates increasing 
concentration). Blue lines represent the experimental data, pink lines represent the 
heterogeneous model. 
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Figure 4-8 Graph representing a bivalent heterogeneous model, with refractive 
index, for all the concentrations of conA. 
(1.1µM, 2.5µM, 4.3µM, 6.8µM and 10.2µM – arrow indicates increasing 
concentration). Blue lines represent the experimental data, pink lines represent the 
heterogeneous model. 
 
Table 4-1 Number of parameters in the various models used for data analysis 
Model Number of parameters with RI factor 
Langmuir 3 4 
Bivalent 5 6 
Heterogeneous 6 7 
Heterogeneous / Bivalent 10 11 
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Section 4.3.2. Binding Type Summary and Discussion 
In Section 4.3.1 it was shown that a simple Langmuir or bivalent binding model is not an 
appropriate approximation of the interaction between conA and bound dextran. Addition of 
a refractive index term, suggesting that the conA in solution is also affecting the SPR 
response, showed improvement in the analysis. A mass transfer limited model was ruled 
out due to the rapid association at the start of the interaction, something which would not 
occur to this extent if there was a mass transfer limitation. 
 
The heterogeneous sites model, where it is suggested that the bound dextran is not uniform, 
from the perspective of the conA, is far superior to the simpler models and again is 
improved with a refractive index term but unchanged by a mass transfer term. This is 
conceivable as it has been shown by Sidebotham [109] that chain length and dextran 
molecular size can affect the binding. Such a variable material being bound to a fixed 
surface would result in some binding sites being more favourable and thus the association 
and dissociation rates varying. The addition of bivalent binding to the heterogeneous model 
shows that there may be other factors altering the binding of the conA, particularly as it is a 
tetramer. 
 
The analysed response for the 10.2µM injection across the 2000kD dextran activated chip 
has been deconstructed in Figure 4-9 to its five components, that of the primary and 
secondary bindings for two populations of dextran ligands and the refractive index 
contribution. 
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Figure 4-9 Graph of response components that comprise the total seen response of 
an injection of 10.2µM conA over 2000kD dextran. 
Model is Heterogeneous with bivalency and bulk refractive index term. 
 
The deconvoluted data in Figure 4-9 describes how the binding is being modelled. The first 
population of dextran ligands (creating complex [MX1] and [MXX1] - dark blue and green 
respectively) show that there is a rapid binding up to an equilibrium state after 50s and that 
this is a dynamic equilibrium. Once the free conA is removed from solution, at 180s, the 
concentration rapidly decreases. Conversely, the second dextran ligand population (creating 
complex [MX2] and [MXX2] – light blue and purple respectively) takes a long time to build 
up and does not readily dissociate once the free conA has been removed. The secondary 
binding to create [MXX2] virtually doesn’t exist. The interactions seen with an active layer 
of 43kD, 500kD and the blank sensor chip behaved in a similar manner (see Appendix 7.1). 
 
This can be clarified thus; there is a standard interaction between conA and dextran which 
rapidly reaches equilibrium in the presence of excess conA, and which then rapidly 
dissociates in the absence of an excess of conA. This interaction may contain negative 
cooperativity towards a second bond to the same conA molecule. There is a second binding 
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process, here viewed as a second population of dextran sites, which does not readily 
dissociate until the phosphoric acid cleaning solution is passed through the system.  
Section 4.3.3. Results 
The bivalent heterogeneous model has been used to analyse data produced from injecting 
varying concentrations of conA across a blank sensor surface and across sensor surfaces 
activated with 43kD, 500kD and 2000kD dextran. 
 
Table 4-2 contains the parameter values from the data analysis and Table 4-3 contains the 
calculated association constants (Subscripts 1,2,3 and 4 correspond to [MX1], [MXX1], 
[MX2] and [MXX2] respectively). 
 
Table 4-2 Table of parameters fitted to experimental data using Scientist® 
 Blank 43kD 500kD 2000kD 
RMax 2.4 x10
3
 1.4 x10
3
 1.3 x10
3
 1.1 x10
3
 
ka1 / M
-1
s
-1
 6.7 x10
3
 11.4 x10
3
 8.4 x10
3
 9.2 x10
3
 
kd1/ s
-1
 3.8 x10
-2
 3.3 x10
-2
 4.5  x10
-2
 32.9 x10
-2
 
ka2/ M
-1
s
-1
 4.1 x10
-4
 16.9 x10
-4
 36.1 x10
-4
 0.7 x10
-4
 
kd2/ s
-1
 4.0 x10
-2
 16.4 x10
-2
 40.6 x10
-2
 1.7 x10
-2
 
ka3/ M
-1
s
-1
 3.9 x10
2
 3.5 x10
2
 3.4 x10
2
 4.6 x10
2
 
kd3 / s
-1
 2.7 x10
-33
 3.3 x10
-18
 2.7 x10
-33
 1.8 x10
-3
 
ka4/ M
-1
s
-1
 4.0 x10
-47
 2.7 x10
-1
 3.8 x10
-2
 3.4 x10
-2
 
kd4 / s
-1
 5.3 x10
-18
    18.4      18.5      14.3 
Y     0.79    0.66      0.72      0.73 
Ri 3.4  x10
7
 2.4 x10
7
 1.9 x10
7
 2.3 x10
7
 
 
Table 4-3 Calculated values of association constants from the experimental data 
 Blank 43kD 500kD 2000kD 
Ka1 / M
-1
 1.8x10
5 
3.4x10
5 
1.9x10
5 
0.3x10
5 
Ka2 / M
-1
 10.2x10
-3 
10.3 x10
-3
 8. 9 x10
-3
 4.5 x10
-3
 
Ka3 / M
-1
 1.4x10
35
 1.1x10
20
 1.2 x10
35
 2.5 x10
5
 
Ka4 / M
-1
 7.5E-30 14.7 x10
-3
 2.0 x10
-3
 2.4 x10
-3
 
 
The primary observation concerns the rate of dissociation of the complexes. Figure 4-10 
shows the highest concentration injection for each dextran type, normalised so that the 
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maximum response value is set to 1. The association phase is dependent upon the 
concentration of the injected conA (not constant across the range of dextrans) and is also 
dependent upon the amount of material bound during the activation stage, something which 
is not controllable. The dissociation phase, however, is purely dependent upon the 
dissociation rates. The shorter dextran molecules have lower dissociation rates, resulting in 
the conA binding to them more strongly.  
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Figure 4-10 Graph showing normalised injection data for the blank sensor surface 
and that activated by 43, 500 and 2000kD dextran 
 
The maximum response, RMax (see Table 4-2), is greatest for the unmodified surface of the 
sensor chips. This implies that the CM-dextran applied to the surface is not as accessible to 
binding. 
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Section 4.4. Conclusions 
This investigation into the rates of association and dissociation of the interaction between 
conA and dextran has shown some potentially interesting facts. Primarily that, as with the 
thermodynamic data from Section 3.3, there is a difference in the binding characteristics 
depending upon the size of the dextran chain. However, the data for the primary binding 
site shows that the association constant decreases as the molecular mass of dextran 
increases – this is contrary to the ITC data. This difference could be caused by the dextran 
being immobile on the sensor chip, resulting in the larger dextran molecules being harder to 
access than the smaller molecules. There is strong evidence to suggest that some of the 
interactions are very hard to dislodge without the introduction of phosphoric acid. This 
could result in hydrogels maintaining structural strength in the presence of glucose, as some 
bonds will not dislodge, or could result in a maximum swelling ratio.  
 
Further work was not performed due to the expense of the sensor chips when compared 
with the likelihood of improved data. 
Section 4.5. Nomenclature 
Ka   Association constant (M
-1
) 
ka   Association rate (M
-1
s
-1
) 
kd   Dissociation rate (s
-1
)
 
[M]i   Concentration of free lectin (conA) (M) 
[MX]i   Concentration of conA/dextran complex (M) 
[MXX]i   Concentration of conA/dextran/dextran complex (M) 
R    Response (RU) 
Rt    Total response (RU) 
Rmax    Max. dextran binding capacity (RU) 
Ri    Refractive index effect (RU M
-1
) 
t   Time (s) 
[X]i   Free dextran binding ligands at injection, i (M) 
[X]TOT   Total dextran ligands, bound and unbound (M) 
χ2   Size of error  
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Part 1 - Conclusions 
The results from the ITC work have shown that, though conA exists as a tetramer at 
physiological pH, it is only possible for two separate dextran molecules to bind. This has 
been confirmed by a study of the relative sizes of the molecules and the arrangement of the 
binding sites. It has also shown that there is a general trend of increasing binding strength 
with increasing molecular mass, though this is not universal. 
 
The ITC and SPR work have not provided comparable data. This was due to the SPR not 
being effective in measuring the association and dissociation rate of conA / dextran 
binding. This was due to the multivalent nature of the components. 
 
The combination of these two sections allows the conclusion that the larger dextrans will be 
more suited to the hydrogels. The increased binding strength, combined with the higher 
achievable number of carboxylic acid groups result in stronger hydrogels being produced 
from the larger dextran molecules. 
 
 Page 64 
Part 2 - Production and Evaluation of 
Dextran / Concanavalin A Hydrogels 
The second part of this work investigated the characteristics of the hydrogels produced with 
dextran and conA. Three techniques were used to characterise the gelling process itself and 
the response of the hydrogels to glucose. 
 
The first section details the rheological work performed on the gelation process. This 
entailed mixing the hydrogel and allowing it to set between the plates of the rheometer. The 
change in the viscosity properties were then measured as the hydrogel set. 
 
The second section investigated the diffusional properties of the hydrogels when placed 
into a flow chamber. Hydrogels were cast in a mould and then placed into a two 
compartment flow cell. Cytochrome C was then used as a tracer to investigate the diffusion 
rates possible though the hydrogels. 
 
The third section details the swelling rate of the hydrogels when cast within a cuvette. A 
large molecular mass dye was used to measure the rate of uptake of water into the hydrogel. 
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Section 5. Rheology 
Rheological experiments were performed in a Bohlin CVOR200 rheometer.  
Section 5.1. Theory 
The Bohlin CVOR200 rheometer was set up with a cone and plate configuration (see 
Section 5.1.1). Approximately 1.5ml of solution was poured onto the bottom, flat, plate. 
The upper plate (4
o
 cone) was then lowered into position. Any excess solution was removed 
from the edge of the cone to ensure no interference from solution not in the measuring 
system. The cone was then rotated in the desired manner and the resulting response was 
measured by the lower plate. 
Section 5.1.1. Cone and Plate Measuring System 
The oscillatory tests were performed in a cone and plate measuring system. This 
configuration has a flat plate as the lower section of the system. The upper section is a cone 
of a low angle. 
 
 
Figure 5-1 Cone and plate measuring system, of radius, r, and angle, α. 
 
The shear rate on the fluid is found by dividing the velocity, v, of the upper plate by the 
thickness, z, of the fluid it is shearing. In this case, assuming that the angle is small (angular 
velocity = ω): 
Equation 5-1 
Equation 5-2 
Equation 5-3 
 
α
ω
α
ω
γ ==
r
r
&
rv ω=
( ) αα rrz ≈= tan
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Therefore the shear rate across the fluid is independent of the radius, greatly simplifying the 
conversion of experimental data into viscometric terms. 
Section 5.1.2. Rheological Solutions 
An ideal Newtonian solution has a constant viscosity when sheared. It is highly unlikely 
that dextran behaves in this way. Many solutions show either pseudoplastic or thixotropic 
behaviour, that is the viscosity decreases with increasing shear rate and time respectively. 
More rare are dilatant and rheopectic solutions whose viscosity increases with shear rate 
and time respectively. Viscoelastic materials are those that show both viscous and elastic 
response to stress, resulting in more complex responses to applied stresses [110-113].  
Section 5.2. Viscosity of Pure Dextran 
Section 5.2.1. Experimental Procedure 
The rheometer was set to use a 20mm 4
o
 cone and plate system. The shear rate was ramped 
from 10s
-1
 to 500s
-1
 and back over the course of 2000 seconds. The steady state viscosity 
found in the low shear rate portion was recorded as the viscosity of the solution. Each 
dextran was tested at 15, 20 and 25wt% in the standard buffer (Section 2.2). The viscosity 
data was recorded on both the upsweep and downsweep of the experiment. 
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Figure 5-2 Viscosity test of 20wt% 43kD dextran 
Shear rate increased linearly from 10 to 500s
-1
 and back over 2000 seconds. Viscosity 
recorded every 5 seconds 
Section 5.2.2. Results and Discussion 
The data shown in Figure 5-2 represents a 20wt% solution of 43kD dextran. It can be seen 
that, after an initial fluctuation, the viscosity is relatively constant prior to a shear rate of 
approximately 250s
-1
. The viscosity then fluctuates unpredictably until the shear decreases 
below the same rate. This was observed for all dextran samples. Further tests performed 
using other fluids and measuring systems within the same rheometer implied that this was 
likely a problem with the machine rather than an actual change in the viscosity of the 
solution. The rheometer is able to directly control either strain rate or stress meaning this 
problem is unlikely to be due to the control system. However, it could be due to the rate of 
rotation not changing smoothly, or due to an uneven mass distribution on the rotating head. 
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Figure 5-3 Viscosity of dextran solutions, shear rate increasing  
Dextran at 15, 20 and 25wt% in standard buffer (Section 2.2) 
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Figure 5-4 Viscosity of dextran solutions, shear rate decreasing 
Dextran at 15, 20 and 25wt% in standard buffer (Section 2.2) 
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The viscosity values show the same overall pattern during both an increasing shear rate 
sweep and a decreasing shear rate sweep. As the molecular mass and the concentration 
increase, the viscosity increases. 
 
The values during the decreasing sweep are generally slightly lower than those of the 
increasing sweep, implying pseudoplastic behaviour, though the effect is only slight. The 
lower molecular mass dextrans show an additional feature. The viscosity on the increasing 
sweep is near constant between 6, 11 and 17 kD dextrans, but at a critical dextran size, the 
viscosity increases much more rapidly. On the decreasing sweep the data fits one trend for 
all dextran sizes, though the low molecular masses do not perfectly fit this trend at the 
lower concentrations. It is known that low molecular mass dextran readily forms beads [86, 
94] and it is likely that the initial viscosities recorded are for a combination of a dextran 
solution and a dextran bead suspension. The high shear rate in the middle of the experiment 
fully dissolves the beads that were present, making the solution more uniform and therefore 
fit the overall trend seen in the remaining data. 
Section 5.2.3. Conclusions 
The dextran solutions produced followed the expected trend of increasing viscosity with 
increasing molecular mass and increasing concentration. Some signs of pseudoplastic 
behaviour were observed, but this was a small factor. The change in viscosity of the lower 
molecular mass dextran implies the initial small beads created in dextran solutions are 
broken apart by the shearing force. 
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Section 5.3. Rheology of Gelation mixture 
Section 5.3.1. Viscoelastic Materials  
Dextran solutions do not exhibit pure Newtonian behaviour. Tests in Section 5.2 showed 
that the viscosity decreased with time during a ramped shear rate experiment. Other tests 
showed that the viscosity was not very stable at constant shear rates. The dextran solutions 
are likely to be viscoelastic in nature as the dextrans have been shown to form solid 
regions, in the form of beads, when in solution [86, 94]. 
 
In order to model the behaviour of dextran solutions they must be viewed as having both 
viscous and elastic properties. These can be defined by the equations for a Newtonian 
solution and by Hooke’s law for a spring: 
Equation 5-4 
Equation 5-5 
It can be seen from these two equations that the shear stress for a solution is proportional to 
the rate at which it is being sheared. For a spring the stress is proportional to the magnitude 
of the strain. 
 
Maxwell [111] developed a model which contained a Hookean spring and a Newtonian 
dashpot in series. 
γησ &=
γσ G=
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Figure 5-5 Depiction of a Maxwell model, incorporating a Hookean spring and a 
Newtonian dashpot in series 
For a finite shear strain applied constantly over time, the spring will respond, giving a 
maximum stress. The dashpot will gradually release that stress through movement of the 
piston in the fluid. Combining Equation 5-4 and Equation 5-5 will enable the description of 
a viscoelastic fluid from the strain applied to it: 
Equation 5-6 
 
However it is still difficult to perform viscometric tests to obtain the values for the spring 
modulus and the viscosity. 
Section 5.3.2. Oscillatory Tests 
The nature of a viscoelastic material means that it cannot simply be sheared at a known rate 
such that viscosity can be calculated from the resulting stress. Oscillatory tests, known as 
dynamic mechanical spectroscopy, have been developed to investigate the combination of 
η
σσ
γ +=
G
&
&
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the elastic and viscous properties [112]. Two specific values are obtained from oscillatory 
tests: that of the complex modulus, |G*|, and the phase difference, δ. The complex modulus 
is the ratio of the peak shear strain applied to a substance and the resulting peak shear 
stress. The phase difference is a measure of the contributions of the two properties. A 
purely viscous solution would have a phase difference of 90
o
 as the stress would be 
proportional to the rate of shear strain. A purely elastic solid would have a phase difference 
of 0
o
 because the stress is directly proportional to the magnitude of the shear strain. 
 
Figure 5-6 Application of an oscillating shear strain and the resulting shear stress 
(from [112]) 
 
Using the Maxwell model as a starting point, it is possible to model oscillatory shear strain 
and stress to obtain values for the complex modulus and the phase difference. (The 
derivation can be found in Appendix 8 and Appendix 10.)  
 
Monitoring of the gelation process under an oscillatory strain shows the gel point and 
fluidity of the final hydrogel. 
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Figure 5-7 Oscillation at 1Hz and 0.5% of a 500kD dextran based gelation  
In Figure 5-7 the phase angle describes the nature of the hydrogel mixture. Initially the 
mixture has a phase angle of over 70
o
, suggesting that the mixture is predominantly fluid. 
As time progresses the creation of covalent bonds between the conA and the carboxylic 
acid groups of the dextran, as well as the reversible interactions with the terminal glucose 
groups, causes the hydrogel to become more solid. At approximately 800s the phase angle 
decreases below 45
o
. It is now more solid than liquid, as confirmed by the elastic modulus 
now having a greater magnitude than the viscous modulus. This is known as the gel point 
[114, 115]. As time progresses the gelation process finishes and the phase angle reaches 
equilibrium. The final value of the phase angle, the time at the gel point and the rate of 
gelation at the gel point are characteristic of the gelation of a given mixture. 
Section 5.3.3. Experimental Procedure 
The gelation process was measured within a cone and plate system. The cone was oscillated 
at a frequency of 1Hz and a strain of 0.5%. The size of the strain was kept small to avoid 
deformation of the hydrogel as it began to set. The hydrogel mixture was produced as 
described in Section 2.6. The mixture was then placed onto the lower plate and the cone 
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lowered into place. Any excess mixture was removed to avoid interference with the 
measurements. The cone was then set to oscillate and the resulting stress measured.  
Section 5.3.4. Results and Discussion 
The dextrans of 50% 43, 64, 500 and 2000kD dextran (with the other 50% always being 
500kD) were allowed to gel within the cone and plate system. The hydrogels made with 6, 
11 and 17kD dextran did not have sufficient initial viscosity for the gelation process to 
begin, this problem being increased due to the mechanical work performed on the mixture 
by the oscillating plate. Due to this they did not produce viable results. 
 
Table 5-1 Rheological Properties of Gelation 
Dextran / kD 
Gel Point 
Time / s 
Gel Point G' 
and G'' / Pa 
Gel Point 
∆δ x102 / o 
Final Phase 
Angle / 
o
 
Final  
G* / Pa 
43 – rep1 980 1.6 2.9 18.2 670 
43 – rep2 620 1.5 4.9 14.2 1410 
43 – rep3 2000 1.3 2.4 17.7 690 
64 – rep1 440 1.7 4.7 19.8 2000 
64 – rep2 300 2.8 8.4 15.9 4150 
64 – rep3 280 2.5 7.5 15.1 4030 
500 – rep1 840 10.7 3.5 24.8 350 
500 – rep2 560 6.9 6.7 17.0 2690 
500 – rep3 440 9.0 7.1 21.0 8000 
2000 – rep1 560 26.0 7.2 17.9 7000 
2000 – rep2 620 37.0 5.5 -* -* 
2000 – rep3 740 21.0 5.9 21.0 2830 
*Experiment ended before steady state was reached 
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Figure 5-8 Time for gel point to be reached for hydrogel mixtures (43, 64, 500 and 
2000kD – average of three replicates, error bars show +/- 1 standard deviation) 
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Figure 5-9 Complex and elastic modulus value at gel point (43, 64, 500 and 2000kD 
– average of three replicates, error bars show +/- 1 standard deviation) 
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Figure 5-10 Rate of change of phase angle at gel point (43, 64, 500 and 2000kD – 
average of three replicates, error bars show +/- 1 standard deviation) 
 
The data taken at the gel point is shown in Figure 5-8 - Figure 5-10. The value of the elastic 
and viscous modulus at the gel point shows a clear trend, similar to that of the viscosity of 
pure dextran solutions (see Section 5.2). The larger dextran molecules will reduce the 
amount of flexibility due to the increased number of interactions per molecule. This in turn 
increases the amount of force required to achieve the same shear, thereby increasing the 
modulus values. 
 
The time for the gel point to be reached is difficult to quantify as there was a finite time to 
mix a solution and pour it onto the lower plate of the rheometer. There was also a delay 
whilst the upper plate is lowered into place and excess material removed. The inherent 
variability in this process is seen in Figure 5-8. The variability is greater for the weaker 
gels. This is unsurprising as the weaker gels have fewer affinity interactions and therefore 
will be more susceptible to the variability of the dextrans. The gel point, from this data, 
could be viewed as always occurring after the same period of time.  
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The rate of change of the phase angle at the gel point is also very variable. Once the gel is 
well mixed and within the rheometer, the conA and dextran will start to interact. The rate of 
the gelation is dependent upon the kinetics of the carboxylic acid group binding to the 
protein and the creation of new affinity interactions. The lack of a trend in this data would 
suggest, again, that the dextrans have an inherent variability in their production. 
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Figure 5-11 Final phase angle of hydrogel (43, 64, 500 and 2000kD – average of 
three replicates, error bars show +/- 1 standard deviation) 
 
The final phase angle of the gels is relatively constant. The phase angle, a measure of the 
fluidity of the gel, is going to be based on the amount of water present within the gel and 
the strengths of the interactions. The amount of water is the same for each mixture and as 
such it is expected that the final phase angle is constant. 
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Figure 5-12 Final complex modulus of hydrogel (43, 64, 500 and 2000kD – average 
of three replicates, error bars show +/- 1 standard deviation) 
The final complex modulus is very variable. This is primarily due to very few of the 
experiments having reached steady state. This is partly due to evaporation of the remaining 
water once gelation has finished. It is also due to the continued breakage and creation of the 
affinity cross-links. 
Section 5.3.5. Conclusions 
The rheology experiments have shown that there is a strong correlation between the 
molecular mass of the dextran and the complex modulus of the gel at the gel point. This 
corresponds to the increase in association constant seen in Section 3 as well as the increase 
in viscosity of pure dextran mixtures seen in Section 5.2. The ratio of the peak stress to 
peak strain of the system will be dependent upon both the inherent viscosity of the 
materials and the new bonds being formed by the gelation process. 
 
The remaining features of the gelation process are either roughly constant, in the case of the 
time to reach the gel point, or show no correlation to the dextran molecular mass. The 
hydrogels produced within the system will not be responding exactly as expected due to the 
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deformation caused by the oscillatory tests. It is likely that the final complex modulus 
would have a similar relationship as the gel point complex modulus, but the hydrogels are 
damaged as they become more solid. 
Section 5.4. Nomenclature 
G   Spring Modulus (Pa) 
v   Velocity (ms
-1
) 
ω   Angular velocity (rads-1) 
r   Radius (m) 
z   Thickness of fluid between plates (m) 
α   Angle of upper plate to the horizontal (o) 
γ   Shear strain 
   Shear strain rate (s-1) 
η   Viscosity (Pas) 
σ   Shear stress (Pa) 
   Shear stress rate (Pas
-1
) 
 
γ&
σ&
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Section 6. Diffusion Rate Experiments 
Diffusion rate experiments were carried out using a Shimadzu UV1601 and an in house 
produced flow chamber. The primary aim of the hydrogels produced in this work was for 
there to be a change in the swelling of the hydrogel in the presence of glucose, thus 
increasing the diffusion rate of a protein through the material. 
Section 6.1. Hydrogel Theory 
The hydrogels are a mixture of conA and CM-dextran. The covalent bonds between the 
carboxylic acid groups and amine groups on the conA molecule provide a base structure 
which is supplemented by the reversible interactions of the terminal glucose groups of the 
dextran and the saccharide binding sites on the conA. A hydrogel, as implied by its name, is 
a highly hydrated system. This results in the hydrogel acting like a concentrated solution 
rather than a solid material within a liquid. Therefore there are strong osmotic forces acting 
on the hydrogel, trying to dilute the system. When some of the reversible interactions are 
stopped by the presence of glucose in solution, there are fewer resistances to the osmotic 
forces, resulting in a swelling of the hydrogel. The swelling of the hydrogel causes the 
inherent mesh size of the system to increase, allowing diffusion of larger molecules and of 
greater diffusion of smaller molecules. 
Section 6.2. Hydrogel Production 
The original technique for casting hydrogels of CM-dextran and conA devised by Zhang 
[101] was found to be difficult to use reliably. It was therefore necessary to perfect the 
production method prior to the experimental work of this section. 
 
The original approach involved casting a mass of gel between two clingfilm coated glass 
plates, the plates being large enough to contain three usable hydrogels. Nylon gauze, to 
increase the strength of the hydrogel, was placed into the hydrogel mixture before the upper 
plate was placed on top. Spacers were used to ensure the desired thickness of hydrogel. In 
order to be able to cast the hydrogels, the final mixture was allowed a period of 30 minutes 
to partially set, thus increasing the viscosity and allowing the mixture to be poured onto the 
glass sheet without it overflowing the sides of the glass plate.  
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Removing one of the glass plates, to enable removal of the cast hydrogel, proved very 
difficult. In order to successfully separate them it was necessary to submerge the plates, 
allowing the hydrogels to hydrate and therefore not adhere as strongly to the clingfilm. 
However this was sometimes still not sufficient. It also resulted in several hydrogels being 
fully hydrated before required, resulting in wastage of protein.  
 
For the mixtures involving the lower molecular mass dextrans the period of time the 
mixture was allowed to partially set increased to several hours. This was deemed 
unworkable, due to the possibility of the mixture setting in the beaker before it was poured. 
The combination of these two problems resulted in the decision to make individual moulds. 
 
The resulting moulds were still problematic due to the clingfilm adhering to the hydrogels. 
Parafilm was therefore tried instead. The more robust nature of the parafilm made 
preparation of the moulds simpler, both physically and visually. The removal of the glass 
plates from the parafilm was much simpler than for clingfilm and a small droplet of ethanol 
between the parafilm and the hydrogel edge resulted in rapid separation - the hydrogel then 
being rinsed in distilled water to remove residual ethanol.  
 
Casting the hydrogel mixtures in the moulds, particularly of hydrogels involving lower 
molecular mass dextran, involved pouring the freshly combined final mixture into the 
mould. These hydrogels were found to not swell as much as the hydrogels cast after the 30 
minute pause. It was assumed that there were some covalent bonds being formed between 
the mixture and the nylon support mesh. The hydrogels were therefore cast without the 
mesh support. Instead, an additional mesh support was placed in the diffusion cell, upon 
which was placed a hydrated hydrogel. 
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Section 6.3. Experimental Conditions and Data Analysis 
Section 6.3.1. In-House Diffusion Chamber 
A diffusion cell was contructed to test the hydrogels. It consisted of two matching halves: 
one to act as the donor chamber, the other to be the receptor chamber (see Figure 6-1). Each 
chamber had baffles so as to aid mixing. The open surface area between the two chambers, 
where the hydrogel would be positioned was 4.6x10
-4
m
2
. On opposite sides of each 
chamber were inlet and outlet holes for connecting the necessary tubing. In the four corners 
are holes that pass through the whole depth to allow the system to be bolted together. 
 
Figure 6-1 Schematic of diffusion cell. 
Side view shows baffled chamber with two connection holes. Plan view shows central 
hollow chamber, with baffles. The surrounding ring is the indented step for placement 
of the membrane. The four corner holes are for bolts to hold the two halves together. 
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Figure 6-2 Photograph of diffusion cell. 
The two halves of the diffusion cell. The additional holes (seen as dark blue marks) 
around the central chamber were for a separate purpose and for these tests have been 
filled with silicon sealant.  
 
Section 6.3.2. Experimental Conditions  
The key characteristic of hydrogel performance is the rate of diffusion of protein. In order 
to find this the hydrogel membrane was placed in a flow cell which had a known volume on 
each side. Through the donor chamber a solution was pumped containing the target 
molecule (e.g. insulin) and, where applicable, the molecule which causes the hydrogel to 
swell or contract (D-glucose). The liquid in the receptor chamber was passed through a UV 
Spectrophotometer, which monitored the protein transmitted from changes in absorption of 
the receiving solution at the appropriate wavelength. 
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Figure 6-3 Schematic of flow cell set-up. 
The receptor chamber / UV half is a closed loop. The donor chamber / solute reservoir 
side has a sufficient excess of solution to ensure constant concentration on the donor 
side. 
 
The solute reservoir and the flow cell were kept in a waterbath at 37
o
C reflecting 
physiological conditions. The standard buffer (see Section 2.2) was also used for this 
reason. The receptor chamber was agitated with a magnetic flea at 180 rpm to prevent a 
stagnant layer of protein from forming beneath the hydrogel. Both pumps operated at 
recycle flow of 10ml min
-1
. 
 
Cytochrome C (cytC) was used as the solute during flow experiments in place of insulin 
due to cost and ease of detection. It is a heme protein of 12kD, making it approximately 
twice the mass of an insulin monomer. Work by Kataoka et al. and Bohidar on cytC and 
insulin has shown that at 37
o
C and pH 7.4 the hydrodynamic radii are 1.7 and 7.5nm 
respectively [116, 117]. The insulin is larger than expected due to aggregation. The liquid 
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phase diffusivities of cytC and insulin are 11.4 and 5.5 x10
-11
m
2
s
-1
 [116-118]. These were 
considered sufficiently similar to justify the use of cytC.  
 
As can be seen in Figure 6-4, cytC has a very vivid red colour allowing for simple detection 
in the UV spectrophotometer. The use of 410nm as the target wavelength, rather than a 
wavelength associated with general protein absorption is that there will be no interference 
from any possible leakage of conA from the hydrogel. 
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Figure 6-4 Absorption spectrum of cytochrome C showing the strong absorbance 
at 410nm. 
 
The absorption of 410nm wavelength radiation is linear with respect to concentration, 
enabling simple conversion of absorption data into terms of concentration of cytC. 
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Figure 6-5 Calibration graph of various concentrations of cytochrome C, enabling 
conversion of spectrometric data from absorbance units to concentration units. 
Hydrogels were produced using the method detailed in Section 2.6. Hydrogels containing 
50% 6, 11 or 64KD dextran were found to not form solid hydrogels. This corresponds to 
the dextrans which were found to have less than one carboxylic acid per molecule (see 
Section 2.3). In the case of the two smallest dextrans there would also be a limited amount 
of affinity cross-linking per molecule which again resulted in a weak hydrogel. 
 
Once cast, gels were allowed to come to room temperature before being removed from the 
mould and placed into the flow cell. Once in the flow cell, buffer was circulated through the 
system to allow full hydration for 30 minutes. In this situation the receptor side piping is 
operated as an open loop so that it can be flushed of any remaining cytC. Once hydrated the 
following procedure was followed: 
 
• Magnetic stirrer was set to agitate the receptor chamber. 
• Flow cell was placed in water bath with cytC reservoir. 
• Receptor side piping was made a closed loop (ensuring minimal air bubbles enter 
the system). 
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• Open ends of donor side piping were placed in reservoir of 0.05gL-1 cytC. 
• Pump and UV data logger were turned on simultaneously. 
• CytC circulated through donor side for 10 minutes. 
• Pump stopped and piping moved to 0.05gL-1 cytC reservoir containing desired 
concentration of glucose. 
• Pump turned on and glucose / cytC mixture allowed to circulate for 10 minutes. 
• Pump stopped, receptor side closed loop opened and both sides flushed with buffer 
for 10 minutes. 
 
Each hydrogel was used until destruction or for one day. The concentration of glucose in 
the second reservoir was raised incrementally over the course of the experiments, with at 
least two replicates being performed at each concentration. 
Section 6.3.3. Data Analysis 
The flow cell experiments produced data such as that shown in Figure 6-6. 
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Figure 6-6 Time course of cytC passage through a 500kD dextran hydrogel. 
Addition of 0.075M Glucose at 10 minutes 
 
The data was first converted into concentration of cytC from the absorption data using the 
calibration curve, Figure 6-5. The gradient of the data is the concentration flux through the 
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hydrogel, in gL
-1
min
-1
. The initial gradient, between 0 and 10 minutes is the rate at which 
cytC passes through the hydrogel without additional swelling effects caused by the 
presence of glucose. There is a lag phase, after the introduction of glucose at 10 minutes, 
before the rate of concentration flux increases. This is due to the finite period of time 
required for the concentration of glucose to reach steady state in the donor chamber and for 
the cytC that has diffused through the hydrogel to reach the UV beam. The perceived tail-
off of the concentration flux, at approximately 19 minutes is due to the rate of diffusion 
through the hydrogel ceasing to be the limiting factor.  
 
Therefore the concentration flux before and after introduction of glucose was taken as the 
gradient between 7 and 10 minutes and between 12 and 15 minutes respectively. For each 
experiment, the ratio of the pre- and post-glucose concentration flux was the quoted figure. 
This compensates for the fact that each hydrogel has a different concentration flux in the 
absence of glucose. 
Section 6.3.4. Swelling Model 
Diffusion through a hydrogel can be modelled by assessing the cross-linked structure and 
calculating the mesh size created by the degree of swelling. Within the conA – CM-dextran 
hydrogels there are covalent cross-links between the carboxymethyl groups and the amine 
groups of the conA and there are affinity cross-links between the terminal glucose groups 
and the conA binding sites. Together these hold the two components together forming the 
hydrogel.  
 
The mixture of conA and CM-dextran, when fully hydrated, acts as a concentrated solution 
and osmotic forces try to force the hydrogel to swell. The combination of the covalent and 
affinity cross-links cause the gel to act as a spring which opposes this force. When the 
competitor, glucose, is introduced the number of affinity cross-links decreases resulting in a 
weaker opposition to the osmotic forces leading to swelling.  
 
Flory-Rehner [119, 120] proposed a theory to explain the relationship between crosslink 
density and swelling in rubber compounds. Peppas and Merrill [121] have modified this 
original equation to produce a relationship which allows the calculation of the swelling 
ratio of hydrogel based materials: 
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Equation 6-1 
 
 
Where:   – Number average molecular mass of the polymer chain between cross-links 
   – Number average molecular mass of the polymer chain 
   – Partial specific volume of the polymer 
 V1  – Molar volume of water 
 χ1  – Flory polymer-solvent interaction parameter 
 v2,s  – Polymer fraction of the gel at equilibrium swelling 
 v2,r  – Polymer fraction of the gel after gel formation 
 
The total number of cross-links was determined by finding the respective number of 
affinity and covalent bonds. The number of covalent bonds was assumed to equal the 
number of carboxymethyl groups measured for the dextran material used (see Section 2.3) 
as it was assumed that each binds to a conA molecule. Affinity cross-links were calculated 
by solving the binding equation. It was assumed that there was only one dextran binding 
per tetramer. Although this is not strictly rigorous, the modelling was greatly simplified. 
Once swelling had been calculated the gel mesh size could be estimated and used to 
determine the gel phase diffusion coefficient of the solute molecule. (see Appendix 12). 
 
The following equation can be used to calculate the mesh size: 
Equation 6-2 
 
Where:  Cn – Flory characteristic ratio 
 Mr – Molecular mass of repeat unit 
 l – Unit length along the polymer backbone 
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The swelling ratio can be found by dividing the polymer fraction of the gel after formation 
by the polymer fraction after swelling. The volume increase due to the swelling will be seen 
as a reduction in the polymer fraction, therefore the swelling ratio will be greater than 1: 
Equation 6-3 
The mesh size can then be used to calculate the rate of diffusion, based on the deviation 
from the liquid phase diffusivity [122, 123]: 
 
Equation 6-4 
 
Where: Dl – Liquid phase diffusivity of the solute 
 r – Hydrodynamic radius of the solute 
 
This diffusivity value can be used to calculate the concentration flux through a hydrogel. 
The amount of protein that diffuses through the membrance can be found using Fick’s first 
law:  
Equation 6-5 
 
Where J is the flux through the hydrogel per unit area per unit time, δG is the swollen 
membrane thickness and CD and CR are the donor and receiving chamber concentrations 
respectively. 
 
A mass balance can then be taken on the receiving side of the flow cell to obtain the 
concentration flux: 
 
Mass at time, t = Mass at time, 0 + Flux through the hydrogel 
 
 
Equation 6-6 
 
Where A is the surface area of the membrane and V is the receiving chamber volume [124]: 
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It can be assumed that the concentration of cytC in the receiving chamber is significantly 
less than the bulk concentration of the donor chamber: 
Equation 6-7 
 
The swelling calculated in Equation 6-3 has a twofold effect on the proceeding calculations. 
The thickness of the hydrogel increases (it is assumed that the cross-sectional area is 
constrained by the flow cell and does not change), thus the path length for diffusion 
increases. It also, however, dilutes the conA and glucose terminal groups within the 
hydrogel, thus reducing the number of affinity cross-links. The modelling must therefore be 
done iteratively to find the values for the swelling and thus the concentration flux (A Power 
Basic model for this can be found in Appendix 13).  
 
Several of the parameters are known from the literature or can be calculated directly from 
the masses used. For the calculation of the swelling: 
Table 6-1 Swelling model parameters for 500kD hydrogel  
Parameter Value Reference 
0.473 (dextran/water) [125] 
Flory interaction parameter 
0.48 (dextran/salt water) [126] 
Partial volume of dextran 0.62 cm
3
g
-1
 - 0.644cm
3
g
-1
 
[125, 127, 
128] 
Polymer fraction of the gel 0.099gg
-1
 Section 2.6 
Number average molecular mass 
between covalent cross-links 
4050gmol
-1
 Section 2.3 
Number average molecular mass of 
polymer chain 
500kD  
Molar volume of water 18cm
3
mol
-1
  
Association constant, conA/dextran 2220M Section 3 
Association constant, conA/glucose 170M Section 3 
Concentration of conA [Mtot] 1.49 x10
-4
 M Section 2.6 
Concentration of terminal glucose 
groups [Xtot] 
3.4 x10
-2
 M Section 2.6 
D
G
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C C
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=
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The calculation of the concentration flux from the swelling ratio of the hydrogel is 
performed using the parameters in Table 6-2. 
Table 6-2 Mesh size, diffusivity and flux calculation parameters for 500kD 
hydrogel  
Parameter Value Reference 
Flory characteristic ratio 1.8 - 10 [124, 129] 
Molecular mass of repeat unit 162gmol
-1
  
Unit length along polymer backbone 0.46nm [129] 
Liquid phase diffusivity of cytC 11.4 x10
-11
m
2
s
-1
 [118] 
Hydrodynamic radius of cytC 1.7nm [117] 
Conc. of solute in donor chamber 0.05gL
-1
  
Thickness of cast hydrogel 0.48mm  
Volume of receiving chamber 4.6 x10
-6 
m
3
  
Surface area of hydrogel 4.6 x10
-4 
m
2
  
 
Initial estimates of the association constants for conA-dextran and conA-glucose were 
taken from the ITC work (see Section 3). However, those values are for reactions in free 
solution, whereas within the hydrogel there will be spatial constraints which might be 
expected to modify these values.  
Section 6.4. Results and Discussion 
Section 6.4.1. Experimental Data 
Hydrogels were produced using mixtures of 50% 500kD CM-dextran with 50% of either 
17, 43, 500 or 2000kD CM-Dextran (see Section 2.6) and used in the flow cell. The data in 
Figure 6-7 to Figure 6-10 represents the average of two or three replicates. 
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Figure 6-7 Diffusion ratio with respect to glucose concentration for 17-500kD 
hydrogels 
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Figure 6-8 Diffusion ratio with respect to glucose concentration for 43-500kD 
hydrogels 
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Figure 6-9 Diffusion ratio with respect to glucose concentration for 500kD 
hydrogels 
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Figure 6-10 Diffusion ratio with respect to glucose concentration for 500-2000kD 
hydrogels 
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The majority of the hydrogels show a general trend of the diffusion ratio increasing with 
increasing glucose concentration. The 500kD hydrogel shows the greatest response to 
glucose concentration whereas the 500-2000kD hydrogel does not respond as much. The 
amount of data available was limited by the difficulty in removing the hydrogels from the 
mould. The 500-2000kD hydrogel was particularly difficult to extract without causing 
irreparable damage. There were a few instances of hydrogels suffering tears in the surface, 
normally by large air bubbles forcing through the surface. However it was possible to push 
the sides of the tears back together and the hydrogel could continue to be used with only a 
slight increase in diffusion rate. This was the cause of the jumps in the data where a low 
glucose concentration has a higher diffusion ratio than later tests with higher 
concentrations, e.g. 43-500kD gel 2. 
Section 6.4.2. Swelling Model 
The swelling model was used to replicate the behaviour of a 500kD hydrogel using the data 
in Table 6-1 and Table 6-2. 
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Figure 6-11 Concentration flux variation with glucose for 500kD hydrogel – Base 
model using data from Table 6-1 and Table 6-2. (Inset displays trend for all glucose 
concentrations) 
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The swelling model, when using the values from literature and direct calculations from this 
work is shown in Figure 6-11. Although this appears to show good variation with glucose 
concentration, the concentration flux variation is over a small scale and is very low. The 
inset graph shows the overall trend, that as the concentration of glucose increases it ceases 
to be the limiting factor. The hydrogels used in this work, at these glucose concentrations, 
are represented by the linear portion of this curve. The data shown in Figure 6-6 has a pre-
glucose concentration flux of 0.45mgL
-1
min
-1
 and a concentration flux of 1.5mgL
-1
min
-1
 
after the introduction of 0.075M glucose. In contrast, the model gives these values as 
4.86x10
-4
 and 4.90x10
-4
 mgL
-1
min
-1
 for no glucose and 0.075M glucose resepectively. The 
data is therefore three orders of magnitude too high, compared to the swelling model: if the 
diffusion rate is assumed to be equal to the liquid phase diffusivity the rate is still only 
7.13x10
-2
mgL
-1
min
-1
.  
 
Of the data used in the swelling model, some of the parameter values are not necessarily 
accurate. Those that are from literature (such as the Flory Interaction parameter) and those 
that are definite calculations from experiments (such as the cytC concentration being 
0.05gL
-1
) will be assumed correct. However the concentrations of binding groups, the 
association constants, the Flory characteristic ratio, the backbone unit length and the 
membrane thickness were not definite values. Therefore a series of tests were performed 
whereby the stated parameter was increased and decreased by 20% to see which had 
noticeable effects upon the concentration flux through the hydrogel. 
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Section 6.4.2.1. Terminal Glucose Group Variation 
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Figure 6-12 Concentration flux variation with glucose for 500kD hydrogel – 
Terminal glucose group variation 
The model has been recalculated in Figure 6-12 with the concentration of terminal glucose 
groups altered. An inverse relationship is seen between concentration flux and terminal 
group concentration. This is expected. The number of groups available to form affinity 
cross-links with conA is likely to be lower than the maximum available due to the spatial 
restrictions caused by the covalent cross-links. However the change in concentration flux is 
minimal compared to the three orders of magnitude difference when compared to the 
experimental results. 
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Section 6.4.2.2. ConA Variation 
0.475
0.480
0.485
0.490
0.495
0.500
0.00 0.02 0.04 0.06 0.08 0.10 0.12 0.14 0.16 0.18 0.20
Glucose Concentration / M
F
lu
x
 /
 µµ µµ
g
L
-1
m
in
-1
[Mtot] - 20%
[Mtot]
[Mtot] + 20%
 
Figure 6-13 Concentration flux variation with glucose for 500kD hydrogel – ConA 
concentration variation 
The concentration of conA in the hydrogel has a similar, though greater, effect on the 
concentration flux as the concentration of terminal glucose groups. A reduction in 
concentration allows greater concentration flux of glucose, but the variation is not sufficient 
to cause an order of magnitude change. 
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Section 6.4.2.3. Covalent Cross-Link Variation 
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Figure 6-14 Concentration flux variation with glucose for 500kD hydrogel – 
Number average molecular mass between covalent cross-links variation 
The average molecular mass between the covalent cross-links has a strong effect on the 
concentration flux through the hydrogel. It is plausible that, though the number of possible 
covalent cross-links per dextran is known, this is a maximum value and the number actually 
formed is lower than this (corresponding to a higher Mp value). This is capable of 
increasing the concentration flux by an order of magnitude, making the model slightly more 
realistic compared to the experimental data. 
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Section 6.4.2.4. Association Constant Variation 
 
Figure 6-15 Concentration flux variation with glucose for 500kD hydrogel – 
ConA/dextran association constant variation 
 
Figure 6-16 Concentration flux variation with glucose for 500kD hydrogel – 
ConA/glucose association constant variation 
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Decreasing the association constant between conA/dextran makes the hydrogel weaker, 
resulting in greater concentration flux. The difference is, however, only slight. The change 
in concentration flux caused by a variation in the conA/glucose association constant, Figure 
6-16, is equally slight. The response is reversed as glucose is a competitor and therefore 
stronger affinity bonds with the conA will reduce the number of bonds available to the 
dextran. 
Section 6.4.2.5. Flory Characteristic Ratio Variation 
The value of the Flory characteristic ratio is not known from the literature. It can be seen 
from Figure 6-17 that over the range of feasible values it does not have a significant effect 
upon the concentration flux. 
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Figure 6-17 Concentration flux variation with glucose for 500kD hydrogel – Flory 
characteristic ratio variation 
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Section 6.4.2.6. Backbone Unit Length Variation 
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Figure 6-18 Concentration flux variation with glucose for 500kD hydrogel – Unit 
length of backbone variation 
The unit length of the backbone, together with the average molecular mass between cross-
links, controls the physical distance between bonds in the hydrogel. This relates directly to 
the mesh size of the hydrogel and therefore its diffusivity. This is shown by the noteworthy 
effect it has on the concentration flux. 
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Section 6.4.2.7. Membrane Thickness Variation 
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Figure 6-19 Concentration flux variation with glucose for 500kD hydrogel – 
Membrane thickness variation 
The membrane thickness has a noticeable effect upon the concentration flux. The 
membrane thickness is the shortest path length available to cytC as it diffuses through the 
hydrogel, therefore it is expected that it would have a strong influence on the concentration 
flux. 
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Section 6.4.2.8. Membrane Surface Area Variation 
The surface area of the membrane was initially calculated based on the open area between 
the two sides of the diffusion cell. However it was observed during experiments that the 
swelling resulted in the hydrogel ‘ballooning’ up into the donor chamber. This was 
approximately to a height of 5mm above the starting position, with the rim of the hydrogel 
not moving due to it being clamped in place. If it is assumed that the swelling is the upper 
portion of a perfect sphere it can be calculated that the surface area will have increased by 
17%.  
 
Section 6.5. Conclusions 
A more robust method has been produced for the casting of dextran / conA hydrogels, 
resulting in simpler production and reduced protein wastage. 
 
The experimental data has shown that glucose responsive hydrogels can be produced from 
a combination of different dextrans and conA. However, it has also shown that the 
hydrogels have a variable degree of response from batch to batch as well as from recipe to 
recipe. 
 
The swelling model has shown that the hydrogels do not respond as the literature data 
would suggest. A sensitivity analysis covering the uncertainty of the model parameters has 
shown that the strength and concentration of the affinity bonds has a weaker effect upon the 
swelling than the thickness of the hydrogel and the number of covalent linkages. Using the 
data from the base model, each molecule of 500kD dextran will have fewer than one 
affinity bond and over 100 covalent cross-links attached. It is therefore unsurprising that 
altering the strength and number of affinity bonds does not greatly influence the total 
number of bonds. The number of covalent bonds actually created between dextran 
molecules is likely to be lower than this maximum. 
 
The thickness of the hydrogel, and thus the minimum path length, is likely to be the main 
cause of error between the swelling model concentration flux and the experimental 
concentration flux. The swelling model assumes that the entire hydrogel is a homogenous 
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phase of uniform thickness and of the calculated mesh size. SEM images of conA/dextran 
hydrogels [1] show that the hydrogel is a honeycomb of conA/dextran with voids of 
approximately 1µm: 
 
 
Figure 6-20 SEM image of conA/dextran hydrogel.Taken from [1]. 
Hydrogel is fully swollen in standard buffer (Section 2.2).10000x Magnification.  
 
Therefore the cytC has to diffuse through very thin phases of hydrogel between voids that 
do not hinder liquid phase diffusion. This results in a very small active thickness. This is 
supported by the observation that torn hydrogels could reseal sufficiently to continue 
producing concentration fluxes of a similar magnitude. Any covalent bonds will be 
permanently broken by the tear, but the affinity cross-links will be able to reform. This 
would only be able to produce very thin sections of hydrogel in the presence of glucose. As 
such the active thickness of the hydrogel must be equally thin for this phenomenon to be 
correct. It is also likely that the cast hydrogel is not of uniform thickness, but will have 
parts that are thinner (including voids) than wanted. It was also observed that whilst the 
edges of the gel were constrained so that it could not swell sideways, the gels did wrinkle 
and balloon once swollen. This would have the potential to increase the surface area of the 
gel by a significant amount. 
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Section 6.6. Nomenclature 
A   Surface area of hydrogel (m
2
) 
Cd   Concentration of cytC, donor side (mgL
-1
) 
Cn   Flory characteristic ratio 
Cr   Concentration of cytC, receiving side (mgL
-1
) 
Dgel   Gel phase diffusivity (m
2
s
-1
) 
Dl   Liquid phase diffusivity of the solute (m
2
s
-1
) 
J   Flux (mgm
-2
min
-1
) 
JC   Concentration flux (mgL
-1
min
-1
) 
l   Unit length along the polymer backbone (m) 
   Number average molecular mass of the polymer chain between 
cross-links (gmol
-1
) 
   Number average molecular mass of the polymer chain (gmol
-1
) 
Mr   Molecular mass of repeat unit (gmol
-1
) 
Q   Swelling ratio 
r   Hydrodynamic radius of the solute (m) 
   Partial specific volume of the polymer 
V   Volume of receiving side (m
3
) 
V1   Molar volume of water (m
3
g
-1
) 
v2,r   Polymer fraction of the gel after gel formation (gg
-1
) 
v2,s   Polymer fraction of the gel at equilibrium swelling (gg
-1
) 
δG   Thickness of hydrogel (m) 
χ1   Flory polymer-solvent interaction parameter 
ξ   Mesh size (m) 
cM
nM
v
 Page 107 
Section 7. Swelling Rate of Hydrogels 
Swelling rate experiments were carried out using a Shimadzu UV1601. The achievable flux 
of a conA/dextran hydrogel will not be usable in a glucose responsive implant if the rate of 
change of flux with the introduction of glucose is too slow.  
Section 7.1. Swelling Rate Theory 
The swelling rate of the hydrogels could not be taken directly from the diffusion cell 
experiments due to the lag between cytC diffusing through the hydrogel and being pumped 
to the flow cuvette in the UV-VIS spectrophotometer. Noomrio et al. developed a simple 
experimental system to find the rate of swelling [130]. A batch of hydrogel material is 
mixed and cast on the inside (non optical) face of a spectrophotometer cuvette. Once this 
has set the opposite face is similarly cast with hydrogel, leaving a gap in between for the 
spectrophotometer beam to pass through the liquid phase and two optical faces of the 
cuvette. A solution of a very high molecular mass dye, in this case 2000kD blue dextran, is 
poured into the gap and the cuvette placed in the spectrophotometer. As the hydrogel swells 
the dye becomes more concentrated as it is too big to diffuse into the hydrogel. The 
corresponding change in absorption can be converted to a change in concentration and thus 
a change in swelling. 
Section 7.1.1. Calculations 
A simple mass balance is required to calculate the swelling ratio. The volume of a blank 
cuvette, Vtot, is known and the volume of added dye solution, Vl, for each experiment was 
recorded. Therefore: 
Equation 7-1 
 
The concentration of the dye initially added is known, therefore the total mass of dye, MD, 
present in the cuvette is easily found. The concentration of dye during the experiment is 
found from a calibration curve and the absorption data from the spectrophotometer.  
G tot lV V V= −
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Therefore the swelling ratio: 
 
 
Equation 7-2 
 
 
 
Section 7.2. Experimental Conditions 
The cuvettes were cast with hydrogel using the standard recipe (Section 2.6). Each side was 
allowed to set overnight before the opposing side was cast. The blue dextran was dissolved 
in buffer (Section 2.2) at a concentration of 0.18mgml
-1
 at room temperature. It was not 
possible to heat the spectrophotometer chamber to 37
o
C, so the experiments occurred at 
room temperature (~20
o
C). The volume of liquid required was found by pippetting buffer 
into the space between the hydrogel. This was used to zero the spectrophotometer before 
being poured out and replaced with an equal volume of blue dextran solution. The cuvette 
was placed in the spectrophotometer and the experiment allowed to proceed for five hours. 
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Section 7.3. Results and Discussion 
The swelling rate experiment was performed for each hydrogel mixture (6, 11, 17, 43, 64, 
500 and 2000kD) with glucose concentrations of 0, 25 and 50mM. 
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Figure 7-1 Swelling rate with respect to dextran molecular mass. 
The swelling rate in the absence of glucose is consistently greater than the swelling rates in 
the presence of glucose (The data for 25mM is too scattered to justify a trendline). This is 
surprising as the glucose should facilitate the swelling process. The reason for this is that 
the hydrogels were not hydrated before the experiments were performed. Therefore osmotic 
forces created by the presence of the glucose will be acting to prevent water from entering 
the hydrogel.  
 
Osmotic pressure is calculated using the van’t Hoff equation [131]: 
Equation 7-3 
 
Where C is the concentration of the solute in gm
-3
, R is the universal gas constant, T is the 
absolute temperature and M is the molecular mass of the solute. 
 
M
CRT
=Π
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It can be seen from this equation that the smaller molecular mass components have a 
greater effect upon the osmotic pressure than larger molecules. Using the data in Section 
6.3.4, the osmotic pressures of the system have been calculated, Table 7-1. It is clear that 
the osmotic pressure of the glucose dominates the system, therefore restricting the 
hydration of the hydrogel. 
 
Table 7-1 Osmotic Pressures of cuvette swelling experiments, 500kD hydrogel  
Ingredient Osmotic Pressure / Pa 
Dextran in hydrogel ~500 
ConA in hydrogel ~400 
Blue Dextran (0.18mgml
-1
) ~1 
Glucose (25mM) ~6x10
4
 
 
Swelling rates for the 25mM glucose hydrogels shows no clear pattern, however the 50mM 
glucose shows a clear trend of decreasing swelling rate with increasing molecular mass. 
This is likely to be due to the corresponding increase in association constant that was found 
in Section 3. 
Section 7.4. Conclusions 
The swelling rate experiments shown are actually showing the rate of hydration of the 
hydrogel. The data shows that hydrogels do not hydrate effectively in the presence of 
glucose. This is due to the high osmotic pressure generated within the solution phase of the 
cuvette experiments. Future tests would be more effective if the hydrogel layers were pre-
hydrated in buffer for a fixed period of time. The buffer solution would then be carefully 
pipetted out before the introduction of glucose in blue dextran solution. It is also possible 
that the layers of hydrogel were too thick. This would cause additional mass transfer 
problems for the hydration of the hydrogels. Once fully hydrated, the glucose is a 
sufficiently small molecule to mean it would diffuse rapidly through the water in the 
hydrogel.  
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Section 7.5. Nomenclature 
C Concentration of solute / gm
-3
 
D Concentration of dye / gml
-1
 
M Molecular mass of solute / gmol
-1 
MD Mass of dye / g 
R Universal gas constant = 8.314 JK
-1
mol
-1
 
SR Swelling Ratio 
T Absolute temperature / K 
Vg Volume of gel / ml 
Vl Volume of liquid / ml 
Vtot Total volume / ml 
Π Osmotic pressure / Pa 
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Part 2 - Conclusions 
The rheological tests have shown that increasing both the molecular mass and the 
concentration of the dextran increases the viscosity of the solution. The oscillatory 
rheological tests have shown that the hydrogels follow the same pattern as the dextran 
solutions, that is that the greater the length of the dextran chain, the greater the complex 
viscosity. 
 
The conA / dextran hydrogels produced have been shown to swell in the presence of 
glucose, increasing the diffusion rate of protein. There isn’t an apparent link between 
diffusion rate through the gels and the complex viscosity of the hydrogels. This is due to 
the non-reproducible nature of the hydrogels. The heterogeneity of the dextran material 
resulted in it not being possible to produce a hydrogel using a given recipe and be able to 
predict what the diffusion rate would be for a given glucose concentration. 
 
The swelling rate experiments showed that hydration of the hydrogels is decreased by the 
osmotic pressure of the glucose in the solution. 
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Part 3 – Overall Conclusions and 
Future Work 
Section 8. Overall Conclusions 
Dextran and conA have been used to produce hydrogels which swell in the presence of 
glucose. The strength of the association between conA and dextran has been shown to have 
a slight increasing trend as the molecular mass is increased. For these hydrogels to be 
viable for human implantation, the swelling of the hydrogel must be triggered in the 
physiological range of glucose concentrations, approximately 5mM. The diffusion cell 
experiments performed at 10mM glucose showed minimal swelling, whereas those at 
25mM and 50mM showed greater swelling. Therefore it can be said that these hydrogels 
will not successfully swell in physiological conditions. This is confirmed by considering 
the dissociation constants of the dextran / conA complexes (the dissociation constant is 
equal to the reciprocal of the association constants quoted in Section 3). The dissociation 
constant of 17kD dextran is the highest at approximately 3mM, the lowest is that of 
2000kD dextran at approximately 0.4mM. For glucose to competitively bind to the conA 
the dextran must have a dissociation constant roughly equal or higher than the glucose 
concentration. Therefore this confirms that glucose at physiological concentrations cannot 
outcompete the larger molecular mass dextrans. This is, however, dependent upon the 
components within the hydrogel binding with the same strength as they do when in free 
solution. 
 
The smaller dextran samples did not produce fully set hydrogels. This made them unusable 
for these experiments. The beading effect had a twofold effect. Firstly, the number of 
branch end groups accessible to a conA molecule is decreased due to some of the dextran 
molecules being encapsulated within other dextran material. The smaller dextran molecules 
also had fewer carboxylic acid groups for the same reason. The quantities of the EDC and 
NHS within the gelation mixture give an approximate 1:1 ratio of binder to carboxylic acid 
group for the 500kD dextran. Those dextrans with fewer carboxylic groups will therefore 
not combine with all of the binding groups available in the initial 10 minute mixing stage. 
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When the conA is added to this mixture, some of the unused binding groups will react with 
carboxylic acid groups present on the protein, potentially resulting in clumps of protein. If 
this is the case, the spatial constraint of having protein tetramers bound together will result 
in fewer possible affinity cross-links, thereby weakening the hydrogel. 
 
The physical robustness of the hydrogels, when measured as the complex viscosity, also 
showed an increase with increasing molecular mass of the dextran. This effect, as well as 
being caused by the degree of carboxymethylation, was caused by the greater viscosity of 
the high molecular mass dextrans. 
 
The heterogeneous nature of the dextran material, caused by the uncontrolled batch 
production, resulted in unpredictable responses of the hydrogels. Kim et al. [82] showed 
that not controlling the batch conditions of dextran production would result in variable 
molecular mass and branching ratio. Both of these factors effect the binding strength of the 
affinity interaction and thus control of these factors would result in greater homogeneity.  
 
The diffusion rate through the hydrogel was found to be several orders of magnitude 
higher, within the fluctuations, than the predicted value from Flory-Rehner model 
calculations. It is likely that this was caused by the hydrogel having large voids which 
greatly reduced the active thickness of the hydrogel. There is also a suggestion that the 
hydrogel structure stretched with time. The ITC tests showed that the majority of conA 
tetramers only have one dextran group capable of attaching due to the spatial constraints 
with occasional secondary attachments. This is particularly true once covalent attachment 
of the conA to the dextran has occurred. Therefore, once free glucose had disrupted this 
affinity linkage and the hydrogel swelled, it was unlikely that the conA would rebind to the 
same terminal group. This resulted in the hydrogel stretching within the flow cell, 
increasing the surface area for diffusion. However, due to the voids previously discussed, 
the active thickness of the hydrogel did not greatly change, as evidenced by the zero free 
glucose diffusion rate being relatively stable for a given hydrogel. 
 
This thesis has shown that the multivalency of the conA is not advantageous in the manner 
expected. For a protein to be effective in this type of system it must have the following 
characteristics. Firstly it must bind to glucose with a dissociation constant of approximately 
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5mM, so that the physiological glucose concentration will have an effect upon swelling. 
Secondly, the protein must be of sufficient size to enable an affinity cross-link to form 
when there is already a covalent attachment to the protein. Therefore, though it is unlikely 
that more than one dextran terminal group will form an affinity cross-link to a single conA 
tetramer, the presence of four saccharide binding sites increases the probability that one 
will not be spatially effected by the covalently bound dextran present. 
 
This work has shown that, though working hydrogels can be produced from these 
ingredients, the repeatability is not high. It has also been shown that high multivalency of 
the binding protein used is not essential. A monomeric protein could be used with covalent 
cross-linking and would have the same number of affinity cross-links as a seemingly more 
multivalent protein, due to the spatial restrictions. A spatial study of the protein and ligand 
is as important as a study of the thermodynamics of the system. 
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Section 9. Future Work Plans 
This research has revealed several opportunities for further work. 
 
The carboxymethylation process has been found to not attach the same number of 
carboxylic acid groups to each mass range of dextran and for the smaller dextran molecules 
almost none were attached. For the dextrans where significant amounts were attached, the 
time allowed for carboxymethylation could be altered to give the same for each sample. For 
those dextrans that had very little carboxymethylation (primarily the smaller dextrans) it is 
possible that this is caused by very small beads of dextran forming - the precursors to those 
found by Stenekes et al. and Mellors et al. [86, 94]. Stenekes found that heating the beads 
to 100
o
C for 60 minutes resulted in the breakdown of the structures, returning the dextran to 
solution. It should therefore be possible to achieve carboxymethylation of these dextrans by 
performing one of two options. Either pre-heating the dextran solution to 100
o
C for 60 
minutes, then cooling the solution to 60
o
C and proceeding with the standard 
carboxymethylation protocol. Alternatively the whole carboxymethylation process could be 
performed at 100
o
C. Once dextrans of similar degrees of carboxymethylation have been 
produced the diffusion cell experiments could be repeated to see if the smaller dextrans, 
with more appropriate dissociation constant values, are viable. 
 
The beading effect of the smaller molecular mass dextrans is, itself, promising. Colleagues 
have shown the beads to be very stable, once formed, and have also shown it is possible to 
both incorporate proteins within the structure and to create the beads within a glass fibre 
membrane [94, 132]. The formation of responsive hydrogels within a glass fibre membrane 
removes the problem of mechanical weakness. The creation of storable dextran beads could 
be of use for drug delivery.  
 
The ITC work showed a trend of increasing association constant with increasing molecular 
mass. The CM-dextrans were assumed to cross-link to the conA in the same manner. 
Additional experiments should be performed on the CM-dextrans to test this assumption. 
The smaller molecular mass dextrans should also be retested after being heated to melt the 
beads. The ITC data shown assumed all branch ends were available for binding, this would 
not have been the case if small beads had formed. 
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The mechanical strength of the hydrogels was a problem when placing them into the 
diffusion cell and would prove problematic in any future uses of this technique. Tests could 
be carried out whereby the gelation is performed with some fibres of carboxymethyl 
cellulose added to the dextran mixture. These will not enter solution, but the carboxylic 
acid groups should still be available for some cross-linking. These fibres may then provide 
structural support without restricting the swelling of the hydrogel. 
 
For the larger molecular mass dextrans, the heterogeneity caused problems in 
reproducibility. Work in the literature has shown that it is possible to produce dextrans with 
a reliable size and branching ratio if the growth conditions are controlled. This could be an 
avenue for generating reproducible dextrans and therefore reproducible hydrogels. 
 
This thesis has shown that the conA tetramer is effective at producing glucose responsive 
membranes, but has also shown that a multivalent protein is perhaps not essential. 
Therefore a study of available glucose binding proteins should be performed to identify any 
other proteins that may be effective. Multivalency of the protein provides a higher 
probability of an active site being available after covalent cross-linking, but mono- or 
divalent proteins should not be dismissed. Smaller monomeric proteins could be just as 
effective. 
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Appendix 1. NMR Traces 
This appendix contains the NMR traces of glucose, maltose and the seven dextran samples. 
3.03.54.04.55.05.56.0
1
H / ppm
R
e
s
p
o
n
s
e
 /
 a
rb
 
1
H NMR trace of glucose 
3.03.54.04.55.05.56.0
1
H / ppm
R
e
s
p
o
n
s
e
 /
 a
rb
 
1
H NMR trace of maltotriose 
 
 Page 127 
3.03.54.04.55.05.56.0
1
H / ppm
R
e
s
p
o
n
s
e
 /
 a
rb
 
1
H NMR trace of 6kD dextran 
 
3.03.54.04.55.05.56.0
1
H / ppm
R
e
s
p
o
n
s
e
 /
 a
rb
 
1
H NMR trace of 11kD dextran 
 Page 128 
3.03.54.04.55.05.56.0
1
H / ppm
R
e
s
p
o
n
s
e
 /
 a
rb
 
1
H NMR trace of 17kD dextran 
 
3.03.54.04.55.05.56.0
1
H / ppm
R
e
s
p
o
n
s
e
 /
 a
rb
 
1
 Page 129 
3.03.54.04.55.05.56.0
1
H / ppm
R
e
s
p
o
n
s
e
 /
 a
rb
 
1
H NMR trace of 64kD dextran 
 
3.03.54.04.55.05.56.0
1
H / ppm
R
e
s
p
o
n
s
e
 /
 a
rb
 
1
H NMR trace of 500kD dextran 
 Page 130 
3.03.54.04.55.05.56.0
1
H / ppm
R
e
s
p
o
n
s
e
 /
 a
rb
 
1
H NMR trace of 2000kD dextran 
 
 
 Page 131 
Appendix 2. Isothermal Titration Calorimetry Binding Theory 
This appendix contains the derivation of the equations necessary to model data from the 
ITC. 
Appendix 2.1. One Site Model 
The rate equation for a single site interaction of the lectin, [M], and the ligand, [X], (conA 
and dextran respectively) can be described as:  
 
Equation A2-1 
 
At equilibrium, the association and dissociation rates of the conA/dextran complex are 
equal to each other and can be rearranged in terms of the association constant: 
 
Equation A2-2 
 
Equation A2-3 
 
Equation A2-1 is equivalent to the mass balance for the conA/dextran complex during an 
injection. The mass balance for the total conA and total dextran during an injection can 
similarly be written: 
 
Equation A2-4 
 
Equation A2-5 
 
Equation A2-4 and Equation A2-5 can be simplified to give the total conA and dextran 
after the completion of the injection. This is done by assuming that the material lost during 
the injection is equivalent to the average, before (subscript 0) and after (subscript 1) the 
injection, of the concentrations: 
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Equation A2-6 
 
This can be rearranged to: 
Equation A2-7 
 
And 
Equation A2-8 
This can be rearranged to: 
Equation A2-9 
 
Equation A2-3 can be rewritten in terms of the individual mass balances of conA and 
dextran: 
Equation A2-10 
Equation A2-11 
Equation A2-12 
 
This can be rearranged for [MX], giving a quadratic equation, and solved for the physically 
meaningful root: 
Equation A2-13 
Where: 
 
 
Equation A2-13 can therefore be solved using Equation A2-7 and Equation A2-9. The 
energy released for a calculated quantity of [MX] can then be found: 
 
Equation A2-14 
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The energy released by an individual injection can be calculated as the difference between 
the energy for the amount of [MX] before the injection and the amount of [MX] after the 
injection. As with previous calculations, a term must be included for what occurs outside of 
the sample cell: 
Equation A2-15 
 
The preceding set of equations can be entered into a spreadsheet or mathematical package 
and fitted against an experimental data set by estimating values for the parameters K and 
∆H.  
 
Appendix 2.2. Two Site Model 
When considering conA as more than a monomer, the mass balances must be rewritten. For 
a dimer: 
 
Equation A2-16 
 
The following four equations enable calculation of the free conA and dextran and the two 
complexes: 
 
 
 
Equation A2-17 
 
 
 
 
The amount of energy released is calculated: 
Equation A2-18 
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Equation A2-17 and Equation A2-16 must be solved numerically, estimating the two 
association constants and two enthalpy changes. The system is completed by using 
Equation A2-15 in the same manner as the single site model. 
 
Nomenclature: 
∆G   Gibbs free energy change (Jmol-1) 
∆H   Enthalpic change (Jmol-1) 
K   Apparent association constant (M
-1
) 
KI   Intrinsic association constant (M
-1
) 
ka   Association rate (M
-1
s
-1
) 
kd   Dissociation rate (s
-1
)
 
[M]   Concentration of free lectin (conA) (M) 
[MX]   Concentration of conA/dextran complex (M) 
[MXX]   Concentration of conA/dextran/dextran complex (M) 
[MTOT]   Total conA sites, bound and unbound (M) 
Qi   Total energy released (J) 
dQi   Energy change over one injection (J) 
R   Universal gas constant = 8.31 Jmol
-1
K
-1
 
∆S   Entropic change (Jmol-1K-1) 
t   Time (s) 
T    Temperature (K)  
VC   Volume of sample cell (L) 
Vinj   Volume of injection i (L) 
[X]   Free dextran binding ligands at injection, i (M) 
[XTOT]   Total dextran ligands, bound and unbound (M) 
 
 Page 135 
Appendix 3. Isothermal Titration Calorimetry Models 
This appendix contains the programs for the ITC experiments which were entered into 
Scientist® in order to model the data.  
 
Appendix 3.1. One Site Model 
 
// ITC 1 site model 
// Iterative solution 
// n = number of injections 
// bf = branch factor - number of branches per molecule 
// occ = ligand molecular concentration in syringe 
// cc = ligand branch end concentration in syringe 
// mtoi = initial concentration of macromolecule in the cell  
// mto = concentration of macromolecule in the cell after first injection 
// fvi = volume of first injection 
// vi = volume of second and subsequent injections 
// vc = cell volume 
// mt = total macromolecule, [m]tot 
// me = free macromolecule, [m] 
// xt = total ligand, [x]tot 
// xe = free ligand, [x] 
// mx11 = total complex, [mx] 
// Q = total energy release 
// dq = energy release for given injection 
 
IndVars: n 
DepVars: dq 
 
Params: vi,fvi,vc,mtoi,K1,dh1,bf,occ 
 
// Effect of first injection, fvi, receptor concentration in the cell prior to recorded injections 
 
mto=mtoi*((2*vc-fvi)/(2*vc+fvi)) 
cc=occ*bf 
 
//Energy released from all injections up to the previous injection 
// Add volume of initial injection to volume added up to previous injection 
 
dv1=fvi+(n-1)*vi 
mt1=mtoi*((2*vc-dv1)/(2*vc+dv1)) 
xt1=(2*dv1*cc)/(2*vc+dv1) 
 
me1=mt1/(1+K1*xe1) 
xe1=xt1/(1+K1*me1) 
mx11=K1*me1*xe1 
 
Q1=(mx11*dh1)*vc 
 
//Energy released from all injections including the current injection 
// Add volume of initial injection to volume added up to current injection 
 
dv2=fvi+n*vi 
mt2=mtoi*((2*vc-dv2)/(2*vc+dv2)) 
xt2=(2*dv2*cc)/(2*vc+dv2) 
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me2=mt2/(1+K1*xe2) 
xe2=xt2/(1+K1*me2) 
mx21=K1*me2*xe2 
 
Q2=(mx21*dh1)*vo 
 
 
//Heat evolved from current injection 
 
dq=(Q2+(vi/vo)*((Q2+Q1)/2)-Q1)*1000000 
 
// Molar ratio of titrant to macromolecule 
y=xt2/mt2 
 
*** 
0<xe1<xt1 
0<me1<mt1 
0<xe2<xt2 
0<me2<mt2 
 
Appendix 3.2. Two Site Model with Constant K and ∆H values 
 
// ITC 2 site model with constant K and dH values 
// Iterative solution 
// n = number of injections 
// bf = branch factor - number of branches per molecule 
// occ = ligand molecular concentration in syringe 
// cc = ligand branch end concentration in syringe 
// mtoi = initial concentration of macromolecule in the cell  
// mto = concentration of macromolecule in the cell after first injection 
// fvi = volume of first injection 
// vi = volume of second and subsequent injections 
// vc = cell volume 
// mt = total macromolecule, [m]tot 
// me = free macromolecule, [m] 
// xt = total ligand, [x]tot 
// xe = free ligand, [x] 
// mx11 = total one site complex, [mx] 
// mx12 = total two site complex, [mxx] 
// Q = total energy release 
// dq = energy release for given injection 
 
// K values are intrinsic association constants 
 
IndVars: n 
DepVars: dq 
 
Params: vi,fvi,vc,mtoi,K1,dh1,bf,occ 
 
// Effect of first injection, fvi, receptor concentration in the cell prior to recorded injections 
 
mto=mtoi*((2*vc-fvi)/(2*vc+fvi)) 
cc=occ*bf 
 
//Energy released from all injections up to the previous injection 
// Add volume of initial injection to volume added up to previous injection 
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dv1=fvi+(n-1)*vi 
mt1=mtoi*((2*vc-dv1)/(2*vc+dv1)) 
xt1=(2*dv1*cc)/(2*vc+dv1) 
 
me1=mt1/(1+2*K1*xe1+K1^2*xe1^2) 
xe1=xt1/(1+2*K1*me1+2*K1^2*me1*xe1) 
mx11=2*K1*me1*xe1 
mx12=K1^2*me1*xe1^2 
 
Q1=(mx11*dh1+mx12*(dh1*2))*vc 
 
//Energy released from all injections including the current injection 
// Add volume of initial injection to volume added up to current injection 
 
dv2=fvi+n*vi 
mt2=mtoi*((2*vc-dv2)/(2*vc+dv2)) 
xt2=(2*dv2*cc)/(2*vc+dv2) 
 
me2=mt2/(1+2*K1*xe2+K1^2*xe2^2) 
xe2=xt2/(1+2*K1*me2+2*K1^2*me2*xe2) 
mx21=2*K1*me2*xe2 
mx22=K1^2*me2*xe2^2 
 
Q2=(mx21*dh1+mx22*(dh1*2))*vc 
 
//Heat evolved from current injection 
 
dq=(Q2+(vi/vc)*((Q2+Q1)/2)-Q1)*1000000 
 
// Molar ratio of titrant to macromolecule 
y=xt2/mt2 
 
*** 
0<xe1<xt1 
0<me1<mt1 
0<xe2<xt2 
0<me2<mt2 
 
Appendix 3.3. Two Site Model with Variable K and ∆H Values 
 
// ITC 2 site model with variable K and dH values 
// Iterative solution 
// n = number of injections 
// bf = branch factor - number of branches per molecule 
// occ = ligand molecular concentration in syringe 
// cc = ligand branch end concentration in syringe 
// mtoi = initial concentration of macromolecule in the cell  
// mto = concentration of macromolecule in the cell after first injection 
// fvi = volume of first injection 
// vi = volume of second and subsequent injections 
// vc = cell volume 
// mt = total macromolecule, [m]tot 
// me = free macromolecule, [m] 
// xt = total ligand, [x]tot 
// xe = free ligand, [x] 
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// mx11 = total one site complex, [mx] 
// mx12 = total two site complex, [mxx] 
// Q = total energy release 
// dq = energy release for given injection 
 
// K values are intrinsic association constants 
 
IndVars: n 
DepVars: dq 
 
Params: vi,fvi,vc,mtoi,K1,K2,dh1,dh2,bf,occ 
 
// Effect of first injection, fvi, receptor concentration in the cell prior to recorded injections 
 
mto=mtoi*((2*vc-fvi)/(2*vc+fvi)) 
cc=occ*bf 
 
//Energy released from all injections up to the previous injection 
// Add volume of initial injection to volume added up to previous injection 
 
dv1=fvi+(n-1)*vi 
mt1=mtoi*((2*vc-dv1)/(2*vc+dv1)) 
xt1=(2*dv1*cc)/(2*vc+dv1) 
 
me1=mt1/(1+2*K1*xe1+K1*K2*xe1^2) 
xe1=xt1/(1+2*K1*me1+2*K1*K2*me1*xe1) 
mx11=2*K1*me1*xe1 
mx12=K1*K2*me1*xe1^2 
 
Q1=(mx11*dh1+mx12*(dh1+dh2))*vc 
 
//Energy released from all injections including the current injection 
// Add volume of initial injection to volume added up to current injection 
 
dv2=fvi+n*vi 
mt2=mtoi*((2*vc-dv2)/(2*vc+dv2)) 
xt2=(2*dv2*cc)/(2*vc+dv2) 
 
me2=mt2/(1+2*K1*xe2+K1*K2*xe2^2) 
xe2=xt2/(1+2*K1*me2+2*K1*K2*me2*xe2) 
mx21=2*K1*me2*xe2 
mx22=K1*K2*me2*xe2^2 
 
Q2=(mx21*dh1+mx22*(dh1+dh2))*vc 
 
//Heat evolved from current injection 
 
dq=(Q2+(vi/vc)*((Q2+Q1)/2)-Q1)*1000000 
 
// Molar ratio of titrant to macromolecule 
y=xt2/mt2 
 
*** 
0<xe1<xt1 
0<me1<mt1 
0<xe2<xt2 
0<me2<mt2 
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Appendix 3.4. Three Site Model with Constant K and ∆H Values 
 
// ITC 3 site model with constant K and dH values 
// Iterative solution 
// n = number of injections 
// bf = branch factor - number of branches per molecule 
// occ = ligand molecular concentration in syringe 
// cc = ligand branch end concentration in syringe 
// mtoi = initial concentration of macromolecule in the cell  
// mto = concentration of macromolecule in the cell after first injection 
// fvi = volume of first injection 
// vi = volume of second and subsequent injections 
// vc = cell volume 
// mt = total macromolecule, [m]tot 
// me = free macromolecule, [m] 
// xt = total ligand, [x]tot 
// xe = free ligand, [x] 
// mx11 = total one site complex, [mx] 
// mx12 = total two site complex, [mxx] 
// mx13 = total three site complex, [mxxx] 
// Q = total energy release 
// dq = energy release for given injection 
 
// K values are intrinsic association constants 
 
IndVars: n 
DepVars: dq 
 
Params: vi,fvi,vc,mtoi,K1,dh1,bf,occ 
 
// Effect of first injection, fvi, receptor concentration in the cell prior to recorded injections 
 
mto=mtoi*((2*vc-fvi)/(2*vc+fvi)) 
cc=occ*bf 
 
// Energy released from all injections up to the previous injection 
// Add volume of initial injection to volume added up to previous injection 
 
dv1=fvi+(n-1)*vi 
mt1=mtoi*((2*vc-dv1)/(2*vc+dv1)) 
xt1=(2*dv1*cc)/(2*vc+dv1) 
 
me1=mt1/(1+3*K1*xe1+3*K1^2*xe1^2+K1^3*xe1^3) 
xe1=xt1/(1+3*K1*me1+3*K1^2*me1*xe1+K1^3*me1*xe1^2) 
mx11=3*K1*me1*xe1 
mx12=3*K1^2*me1*xe1^2 
mx13=K1^3*me1*xe1^3 
 
Q1=(mx11*dh1+mx12*(dh1*2)+mx13*(dh1*3))*vc 
 
// Energy released from all injections including the current injection 
// Add volume of initial injection to volume added up to current injection 
 
dv2=fvi+n*vi 
mt2=mtoi*((2*vc-dv2)/(2*vc+dv2)) 
xt2=(2*dv2*cc)/(2*vc+dv2) 
 
me2=mt2/(1+3*K1*xe2+3*K1^2*xe2^2+K1^3*xe2^3) 
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xe2=xt2/(1+3*K1*me2+3*K1^2*me2*xe2+K1^3*me2*xe2^2) 
mx21=3*K1*me2*xe2 
mx22=3*K1^2*me2*xe2^2 
mx23=K1^3*me2*xe2^3 
 
Q2=(mx21*dh1+mx22*(dh1*2)+mx23*(dh1*3))*vc 
 
// Heat evolved from current injection 
 
dq=(Q2+(vi/vc)*((Q2+Q1)/2)-Q1)*1000000 
 
// Molar ratio of titrant to macromolecule 
y=xt2/mt2 
 
*** 
0<xe1<xt1 
0<me1<mt1 
0<xe2<xt2 
0<me2<mt2 
 
Appendix 3.5. Three Site Model with Variable K and ∆H Values 
 
// ITC 3 site model with variable K and dH values 
// Iterative solution 
// n = number of injections 
// bf = branch factor - number of branches per molecule 
// occ = ligand molecular concentration in syringe 
// cc = ligand branch end concentration in syringe 
// mtoi = initial concentration of macromolecule in the cell  
// mto = concentration of macromolecule in the cell after first injection 
// fvi = volume of first injection 
// vi = volume of second and subsequent injections 
// vc = cell volume 
// mt = total macromolecule, [m]tot 
// me = free macromolecule, [m] 
// xt = total ligand, [x]tot 
// xe = free ligand, [x] 
// mx11 = total one site complex, [mx] 
// mx12 = total two site complex, [mxx] 
// mx13 = total three site complex, [mxxx] 
// Q = total energy release 
// dq = energy release for given injection 
 
// K values are intrinsic association constants 
 
IndVars: n 
DepVars: dq 
 
Params: vi,fvi,vc,mtoi,K1,K2,K3,dh1,dh2,dh3,bf,occ 
 
// Effect of first injection, fvi, receptor concentration in the cell prior to recorded injections 
 
mto=mtoi*((2*vc-fvi)/(2*vc+fvi)) 
cc=occ*bf 
 
// Energy released from all injections up to the previous injection 
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// Add volume of initial injection to volume added up to previous injection 
 
dv1=fvi+(n-1)*vi 
mt1=mtoi*((2*vc-dv1)/(2*vc+dv1)) 
xt1=(2*dv1*cc)/(2*vc+dv1) 
 
me1=mt1/(1+3*K1*xe1+3*K1*K2*xe1^2+K1*K2*K3*xe1^3) 
xe1=xt1/(1+3*K1*me1+3*K1*K2*me1*xe1+K1*K2*K3*me1*xe1^2) 
mx11=3*K1*me1*xe1 
mx12=3*K1*K2*me1*xe1^2 
mx13=K1*K2*K3*me1*xe1^3 
 
Q1=(mx11*dh1+mx12*(dh1+dh2)+mx13*(dh1+dh2+dh3))*vc 
 
// Energy released from all injections including the current injection 
// Add volume of initial injection to volume added up to current injection 
 
dv2=fvi+n*vi 
mt2=mtoi*((2*vc-dv2)/(2*vc+dv2)) 
xt2=(2*dv2*cc)/(2*vc+dv2) 
 
me2=mt2/(1+3*K1*xe2+3*K1*K2*xe2^2+K1*K2*K3*xe2^3) 
xe2=xt2/(1+3*K1*me2+3*K1*K2*me2*xe2+K1*K2*K3*me2*xe2^2) 
mx21=3*K1*me2*xe2 
mx22=3*K1*K2*me2*xe2^2 
mx23=K1*K2*K3*me2*xe2^3 
 
Q2=(mx21*dh1+mx22*(dh1+dh2)+mx23*(dh1+dh2+dh3))*vc 
 
// Heat evolved from current injection 
 
dq=(Q2+(vi/vc)*((Q2+Q1)/2)-Q1)*1000000 
 
// Molar ratio of titrant to macromolecule 
y=xt2/mt2 
 
*** 
0<xe1<xt1 
0<me1<mt1 
0<xe2<xt2 
0<me2<mt2 
 
Appendix 3.6. Four Site Model with Constant K and ∆H Values 
 
// ITC 4 site model with variable K and dH values 
// Iterative solution 
// n = number of injections 
// bf = branch factor - number of branches per molecule 
// occ = ligand molecular concentration in syringe 
// cc = ligand branch end concentration in syringe 
// mtoi = initial concentration of macromolecule in the cell  
// mto = concentration of macromolecule in the cell after first injection 
// fvi = volume of first injection 
// vi = volume of second and subsequent injections 
// vc = cell volume 
// mt = total macromolecule, [m]tot 
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// me = free macromolecule, [m] 
// xt = total ligand, [x]tot 
// xe = free ligand, [x] 
// mx11 = total one site complex, [mx] 
// mx12 = total two site complex, [mxx] 
// mx13 = total three site complex, [mxxx] 
// mx14 = total four site complex, [mxxxx] 
// Q = total energy release 
// dq = energy release for given injection 
 
// K values are intrinsic association constants 
 
IndVars: n 
DepVars: dq 
 
Params: vi,fvi,vc,mtoi,K1,dh1,bf,occ 
 
// Effect of first injection, fvi, receptor concentration in the cell prior to recorded injections 
 
mto=mtoi*((2*vc-fvi)/(2*vc+fvi)) 
cc=occ*bf 
 
// Energy released from all injections up to the previous injection 
// Add volume of initial injection to volume added up to previous injection 
 
dv1=fvi+(n-1)*vi 
mt1=mtoi*((2*vc-dv1)/(2*vc+dv1)) 
xt1=(2*dv1*cc)/(2*vc+dv1) 
 
me1=mt1/(1+4*K1*xe1+6*K1^2*xe1^2+4*K1^3*xe1^3+K1^4*xe1^4) 
xe1=xt1/(1+4*K1*me1+12*K1^2*me1*xe1+12*K1^3*me1*xe1^2+4*K1^4*xe1^4) 
mx11=4*K1*me1*xe1 
mx12=6*K1^2*me1*xe1^2 
mx13=4*K1^3*me1*xe1^3 
mx14=K1^4*me1*xe1^4 
 
Q1=(mx11*dh1+mx12*(dh1*2)+mx13*(dh1*3)+mx14*(dh1*4))*vc 
 
// Energy released from all injections including the current injection 
// Add volume of initial injection to volume added up to current injection 
 
dv2=fvi+n*vi 
mt2=mtoi*((2*vc-dv2)/(2*vc+dv2)) 
xt2=(2*dv2*cc)/(2*vc+dv2) 
 
me2=mt2/(1+4*K1*xe2+6*K1^2*xe2^2+4*K1^3*xe2^3+K1^4*xe2^4) 
xe2=xt2/(1+4*K1*me2+12*K1^2*me2*xe2+12*K1^3*me2*xe2^2+4*K1^4*xe1^4) 
mx21=4*K1*me2*xe2 
mx22=6*K1^2*me2*xe2^2 
mx23=4*K1^3*me2*xe2^3 
mx24=K1^4*me2*xe2^4 
 
Q2=(mx21*dh1+mx22*(dh1*2)+mx23*(dh1*3)+mx24*(dh1*4))*vc 
 
// Heat evolved from current injection 
 
dq=(Q2+(vi/vc)*((Q2+Q1)/2)-Q1)*1000000 
 
// Molar ratio of titrant to macromolecule 
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y=xt2/mt2 
 
*** 
0<xe1<xt1 
0<me1<mt1 
0<xe2<xt2 
0<me2<mt2 
 
Appendix 3.7. Four Site Model with Variable K and ∆H Values 
 
// ITC 4 site model with variable K and dH values 
// Iterative solution 
// n = number of injections 
// bf = branch factor - number of branches per molecule 
// occ = ligand molecular concentration in syringe 
// cc = ligand branch end concentration in syringe 
// mtoi = initial concentration of macromolecule in the cell  
// mto = concentration of macromolecule in the cell after first injection 
// fvi = volume of first injection 
// vi = volume of second and subsequent injections 
// vc = cell volume 
// mt = total macromolecule, [m]tot 
// me = free macromolecule, [m] 
// xt = total ligand, [x]tot 
// xe = free ligand, [x] 
// mx11 = total one site complex, [mx] 
// mx12 = total two site complex, [mxx] 
// mx13 = total three site complex, [mxxx] 
// mx14 = total four site complex, [mxxxx] 
// Q = total energy release 
// dq = energy release for given injection 
 
// K values are intrinsic association constants 
 
IndVars: n 
DepVars: dq 
 
Params: vi,fvi,vc,mtoi,K1,K2,K3,K4,dh1,dh2,dh3,dh4,bf,occ 
 
// Effect of first injection, fvi, receptor concentration in the cell prior to recorded injections 
 
mto=mtoi*((2*vc-fvi)/(2*vc+fvi)) 
cc=occ*bf 
 
// Energy released from all injections up to the previous injection 
// Add volume of initial injection to volume added up to previous injection 
 
dv1=fvi+(n-1)*vi 
mt1=mtoi*((2*vc-dv1)/(2*vc+dv1)) 
xt1=(2*dv1*cc)/(2*vc+dv1) 
 
me1=mt1/(1+4*K1*xe1+6*K1*K2*xe1^2+4*K1*K2*K3*xe1^3+K1*K2*K3*K4*xe1^4) 
xe1=xt1/(1+4*K1*me1+12*K1*K2*me1*xe1+12*K1*K2*K3*me1*xe1^2+4*K1*K2*K3*K4*xe1^4) 
mx11=4*K1*me1*xe1 
mx12=6*K1*K2*me1*xe1^2 
mx13=4*K1*K2*K3*me1*xe1^3 
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mx14=K1*K2*K3*K4*me1*xe1^4 
 
Q1=(mx11*dh1+mx12*(dh1+dh2)+mx13*(dh1+dh2+dh3)+mx14*(dh1+dh2+dh3+dh4))*vc 
 
// Energy released from all injections including the current injection 
// Add volume of initial injection to volume added up to current injection 
 
dv2=fvi+n*vi 
mt2=mtoi*((2*vc-dv2)/(2*vc+dv2)) 
xt2=(2*dv2*cc)/(2*vc+dv2) 
 
me2=mt2/(1+4*K1*xe2+6*K1*K2*xe2^2+4*K1*K2*K3*xe2^3+K1*K2*K3*K4*xe2^4) 
xe2=xt2/(1+4*K1*me2+12*K1*K2*me2*xe2+12*K1*K2*K3*me2*xe2^2+4*K1*K2*K3*K4*xe1^4) 
mx21=4*K1*me2*xe2 
mx22=6*K1*K2*me2*xe2^2 
mx23=4*K1*K2*K3*me2*xe2^3 
mx24=K1*K2*K3*K4*me2*xe2^4 
 
Q2=(mx21*dh1+mx22*(dh1+dh2)+mx23*(dh1+dh2+dh3)+mx24*(dh1+dh2+dh3+dh4))*vc 
 
// Heat evolved from current injection 
 
dq=(Q2+(vi/vc)*((Q2+Q1)/2)-Q1)*1000000 
 
// Molar ratio of titrant to macromolecule 
y=xt2/mt2 
 
*** 
0<xe1<xt1 
0<me1<mt1 
0<xe2<xt2 
0<me2<mt2 
 
Appendix 3.8. One Site Model with Two Populations of Dextran 
 
// ITC 1 site model with two populations of dextran 
// Iterative solution 
// n = number of injections 
// bf = branch factor - number of branches per molecule 
// occ = molecular concentration 
// cc = concentration of branch ends in syringe 
// mtoi = initial concentration of macromolecule in the cell  
// mto = concentration of macromolecule in the cell after first injection 
// fvi = volume of first injection 
// vi = injection volume 
// vc = cell volume 
// mt = total macromolecule [m]t 
// me = free macromolecule [m] 
// xat = total dextran, length a [xa]t 
// xae = free dextran, length a [xa] 
// xbt = total dextran, length b [xb]t 
// xbe = free dextran, length b [xb] 
// xratio = xat/(xat+xbt) 
// mxa = [mxa] 
// mxb = [mxb] 
// Q = total energy release 
// dq = energy release for given injection 
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IndVars: n 
DepVars:dq 
 
// K values are intrinsic 
 
Params: vi,fvi,vo,mtoi,Ka,Kb,dha,dhb,bf,occ,xratio 
 
// Effect of first injection, fvi, on receptor concentration in the cell prior to recorded injections 
 
mto=mtoi*((2*vc-fvi)/(2*vc+fvi)) 
cc=occ*bf 
 
//Energy released from all injections up to the previous injection 
 
dv1=fvi+(n-1)*vi 
mt1=mtoi*((2*vc-dv1)/(2*vc+dv1)) 
xt1=(2*dv1*cc)/(2*vc+dv1) 
 
me1=mt1/(1+Ka*xae1+Kb*xbe1) 
xae1=(xt1*xratio)/(1+Ka*me1) 
xbe1=(xt1*(1-xratio))/(1+Kb*me1) 
mxa1=Ka*me1*xae1 
mxb1=Kb*me1*xbe1 
 
Q1=(mxa1*dha+mxb1*dhb)*vc 
 
//Energy released from all injections including the current injection 
// Add volume of initial injection to volume added up to current injection 
 
dv2=fvi+n*vi 
mt2=mtoi*((2*vc-dv2)/(2*vc+dv2)) 
xt2=(2*dv2*cc)/(2*vc+dv2) 
 
me2=mt2/(1+Ka*xae2+Kb*xbe2) 
xae2=(xt2*xratio)/(1+Ka*me2) 
xbe2=(xt2*(1-xratio))/(1+Kb*me2) 
mxa2=Ka*me2*xae2 
mxb2=Kb*me2*xbe2 
 
Q2=(mxa2*dha+mxb2*dhb)*vc 
 
//Heat evolved from current injection 
 
dq=(Q2+(vi/vc)*((Q2+Q1)/2)-Q1)*1000000 
 
// Molar ratio of titrant to macromolecule 
y=xt2/mt2 
 
*** 
0<xae1<xt1 
0<xbe1<xt1 
0<me1<mt1 
0<xae2<xt2 
0<xbe2<xt2 
0<me2<mt2 
*** 
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Appendix 4. Isothermal Titration Calorimetry Raw Data 
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ITC Raw Data, Maltotriose 
-1.5
-1.0
-0.5
0.0
-10 0 10 20 30 40 50 60 70
Time (min)
µ
ca
l/
se
c
0 50 100 150 200 250 300
-0.16
-0.14
-0.12
-0.10
-0.08
-0.06
-0.04
Molar Ratio
k
c
a
l/m
o
le
 o
f 
in
je
c
ta
n
t
 
ITC Raw Data, 6kD dextran 
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ITC Raw Data, 11kD dextran 
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ITC Raw Data, 17kD dextran 
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ITC Raw Data, 43kD dextran 
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ITC Raw Data, 64kD dextran 
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ITC Raw Data, 500kD dextran 
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ITC Raw Data, 2000kD dextran 
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Appendix 5. Surface Plasmon Resonance Binding Theory 
This appendix contains the derivation of the equations necessary to model data from the 
SPR. 
Appendix 5.1. Langmuir Model 
The analysis of the SPR data is based around the type of interaction it is believed is 
occurring. The most simple of which is a Langmuir binding: 
 
Equation A5-19 
 
Equation A5-20 
 
Equation A5-21 
 
Equation A5-21 is substituted into Equation A5-20 as it is not possible to calculate the 
concentration of unbound dextran ligands. The total concentration, of bound and unbound 
dextran, is estimated as part of the data analysis (an explanation of why dextran, rather than 
conA, is bound to the sensor chip surface can be found in Section 4.2.2). Equation A5-20, 
once [X] has been replaced, can be rewritten in terms of the SPR signal: 
 
Equation A5-22 
 
During the association phase the whole of Equation A5-22 is active. During dissociation 
the concentration of lectin, C, is negligible and so Equation A5-22 becomes: 
 
Equation A5-23 
 
Once the data is loaded into the software that is supplied by BIAcore, a least squares fit can 
be performed using Equation A5-22 (least squares fit is similar to Section 3.2.2, but without 
the denominator). 
 
][][][ MXXM =+
][]][[
][
MXkXMk
dt
MXd
da −=
][][][ MXXX TOT −=
[ ]( ) RkRRMk
dt
dR
da −−= max
Rk
dt
dR
d−=
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Appendix 5.2. Bivalent Model 
The bivalent model assumes that the binding of a second dextran ligand to a conA tetramer 
has different association and dissociation rates than the primary bind: 
 
Equation A5-24 
 
Equation A5-25 
 
Both of these equations are then fitted with an extended form of Equation A5-19, taking 
into account the additional removal and production of [MX] in the second binding 
(Equation A5-27). The unbound dextran term is now substituted using : 
 
Equation A5-26 
 
Equation A5-27 
 
The difference between the first and second bind to a conA molecule could have a positive 
or a negative effect. There may be conformational changes caused by the first binding 
which facilitate the other binding sites, or there could be problems caused by the dextran 
molecules once the conA is no longer free-floating in solution. 
 
Appendix 5.3. Heterogeneous Ligand Population Model 
This binding model assumes that there are two populations of [X], which in total account 
for all of the binding: 
 
Equation A5-28 
 
Equation A5-29 
 
][]][[
][
1111
1 MXkXMk
dt
MXd
da −=
][][][ MXXXMX =+
][]][[
][
22 MXXkXMXk
dt
MXXd
da −=
][][][][ MXXMXXX TOT −−=
( )][]][[][]][[][ 2[211 MXXkXMXkMXkXMk
dt
MXd
dada −−−=
][][][ 11 MXXM =+
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Equation A5-30 
 
Equation A5-31 
 
In this case the total of bound and unbound dextran ligands is divided into two populations, 
both of which must be estimated in the analysis. This is done most simply by setting a fixed 
ratio, Y, and then estimating the total, Equation A5-29 and Equation A5-31 can therefore be 
rewritten in terms of the SPR signal: 
 
Equation A5-32 
 
Equation A5-33 
 
Appendix 5.4. Additional Effects 
Langmuir binding, with mass transfer effect, MT: 
 
 Equation A5-34 
 
[Ms] is then used in the proceeding equations rather than [M]. Similar equations can be 
written for the bivalent binding and heterogeneous binding analyses. 
 
Bulk refractive index (RI) effect, incorporated as a simple multiple of the conA 
concentration: 
 
Equation A5-35 
 
 
 
 
][]][[
][
2222
2 MXkXMk
dt
MXd
da −=
( ) ( )][]][[][][][ MXkXMkMMk
dt
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dsast
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Nomenclature: 
Ka   Association constant (M
-1
) 
ka   Association rate (M
-1
s
-1
) 
kd   Dissociation rate (s
-1
)
 
[M]i   Concentration of free lectin (conA) (M) 
[MX]i   Concentration of conA/dextran complex (M) 
[MXX]i   Concentration of conA/dextran/dextran complex (M) 
R    Response (RU) 
Rt    Total response (RU) 
Rmax    Max. dextran binding capacity (RU) 
Ri    Refractive index effect (RU M
-1
) 
t   Time (s) 
[X]i   Free dextran binding ligands at injection, i (M) 
[X]TOT   Total dextran ligands, bound and unbound (M) 
χ2   Size of error  
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Appendix 6. Surface Plasmon Resonance Models 
This appendix contains the programs for the SPR experiments which were entered into 
Scientist® in order to model the data.  
 
Appendix 6.1. Langmuir Model 
// SPR Langmuir model 
// Iterative solution 
// T = Time 
// c1 – c5 = concentration of injections 1 – 5 
// rt1 – rt5 = response, at time t of injections 1 -5 
// rm = maximum response of activated surface 
// r11 – r51 = response of injection 1 to 5 from complex [MX] 
// ka1 = association rate 
// kd1 = dissociation rate 
// ri = refractive index factor 
 
IndVars: T,c1,c2,c3,c4,c5 
DepVars: rt1,rt2,rt3,rt4,rt5 
Params: rm,ka1,kd1,ri 
 
r11'=ka1*c1*(rm-r11)-kd1*r11 
rt1=r11+c1*ri 
 
r21'=ka1*c2*(rm-r21)-kd1*r21 
rt2=r21+c2*ri 
 
r31'=ka1*c3*(rm-r31)-kd1*r31 
rt3=r31+c3*ri 
 
r41'=ka1*c4*(rm-r41)-kd1*r41 
rt4=r41+c4*ri 
 
r51'=ka1*c5*(rm-r51)-kd1*r51 
rt5=r51+c5*ri 
 
// Initial conditions 
t=0 
 
r11=0 
r21=0 
r31=0 
r41=0 
r51=0 
 
*** 
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Appendix 6.2. Langmuir Model with Mass Transfer 
// SPR Langmuir model with mass transfer 
// Iterative solution 
// T = Time 
// c1 – c5 = concentration of injections 1 – 5 
// cs1 – cs5 = concentration at activated surface 
// rt1 – rt5 = response, at time t of injections 1 -5 
// rm = maximum response of activated surface 
// r11 – r51 = response of injection 1 to 5 from complex [MX] 
// ka1 = association rate 
// kd1 = dissociation rate 
// ri = refractive index factor 
// kt = mass transfer coefficient 
 
IndVars: T,c1,c2,c3,c4,c5 
DepVars: rt1,rt2,rt3,rt4,rt5 
Params: rm,ka1,kd1,ri,kt 
 
cs1'=kt*(c1-cs1)-(ka1*cs1*(rm-r11)-kd1*r11) 
r11'=ka1*cs1*(rm-r11)-kd1*r11 
rt1=r11+c1*ri 
 
cs2'=kt*(c2-cs2)-(ka1*cs2*(rm-r21)-kd1*r21) 
r21'=ka1*cs2*(rm-r21)-kd1*r21 
rt2=r21+c2*ri 
 
cs3'=kt*(c3-cs3)-(ka1*cs3*(rm-r31)-kd1*r31) 
r31'=ka1*cs3*(rm-r31)-kd1*r31 
rt3=r31+c3*ri 
 
cs4'=kt*(c4-cs4)-(ka1*cs4*(rm-r41)-kd1*r41) 
r41'=ka1*cs4*(rm-r41)-kd1*r41 
rt4=r41+c4*ri 
 
cs5'=kt*(c5-cs5)-(ka1*cs5*(rm-r51)-kd1*r51) 
r51'=ka1*cs5*(rm-r51)-kd1*r51 
rt5=r51+c5*ri 
 
// Initial conditions 
t=0 
 
cs1=0 cs2=0 cs3=0 cs4=0 cs5=0 
r11=0 r21=0 r31=0 r41=0 r51=0 
 
*** 
 
Appendix 6.3. Bivalent Model 
// SPR Bivalent model 
// Iterative solution 
// T = Time 
// c1 – c5 = concentration of injections 1 – 5 
// rt1 – rt5 = response, at time t of injections 1 -5 
// rm = maximum response of activated surface 
// r11 – r51 = response of injection 1 to 5 from complex [MX] 
// r12 – r52 = response of injection 1 to 5 from complex [MXX] 
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// ka1, ka2 = association rate of [MX] and [MXX] 
// kd1, kd2 = dissociation rate of [MX] and [MXX] 
// ri = refractive index factor 
 
IndVars: T,c1,c2,c3,c4,c5 
DepVars: rt1,rt2,rt3,rt4,rt5 
Params: rm,ka1,ka2,kd1,kd2,ri 
 
r11'=2*ka1*c1*(rm-r11-2*r12)-kd1*r11-(ka2*r11*(rm-r11-2*r12)-2*kd2*r12) 
r12'=ka2*r11*(rm-r11-2*r12)-2*kd2*r12 
rt1=r11+r12+c1*ri 
 
r21'=2*ka1*c2*(rm-r21-2*r22)-kd1*r21-(ka2*r21*(rm-r21-2*r22)-2*kd2*r22) 
r22'=ka2*r21*(rm-r21-2*r22)-2*kd2*r22 
rt2=r21+r22+c2*ri 
 
r31'=2*ka1*c3*(rm-r31-2*r32)-kd1*r31-(ka2*r31*(rm-r31-2*r32)-2*kd2*r32) 
r32'=ka2*r31*(rm-r31-2*r32)-2*kd2*r32 
rt3=r31+r32+c3*ri 
 
r41'=2*ka1*c4*(rm-r41-2*r42)-kd1*r41-(ka2*r41*(rm-r41-2*r42)-2*kd2*r42) 
r42'=ka2*r41*(rm-r41-2*r42)-2*kd2*r42 
rt4=r41+r42+c4*ri 
 
r51'=2*ka1*c5*(rm-r51-2*r52)-kd1*r51-(ka2*r51*(rm-r51-2*r52)-2*kd2*r52) 
r52'=ka2*r51*(rm-r51-2*r52)-2*kd2*r52 
rt5=r51+r52+c5*ri 
 
// Initial conditions 
t=0 
 
r11=0 r12=0 r21=0 r22=0 r31=0 r32=0 r41=0 r42=0 r51=0 r52=0  
 
*** 
 
Appendix 6.4. Heterogeneous Model 
// SPR Heterogeneous model 
// Iterative solution 
// T = Time 
// c1 – c5 = concentration of injections 1 – 5 
// rt1 – rt5 = response, at time t of injections 1 -5 
// rm = maximum response of activated surface 
// r11 – r51 = response of injection 1 to 5 from complex [MX1] 
// r13 – r53 = response of injection 1 to 5 from complex [MX2] 
// ka1, ka3 = association rate of [MX1] and [MX2] 
// kd1, kd3 = dissociation rate of [MX1] and [MX2] 
// ri = refractive index factor 
// y = ratio of [MX1] to [MX2] 
IndVars: T,c1,c2,c3,c4,c5 
DepVars: rt1,rt2,rt3,rt4,rt5 
Params: rm,ka1,ka3,kd1,kd3,y,ri 
 
r11'=ka1*c1*(y*rm-r11)-kd1*r11 
r13'=ka3*c1*((1-y)*rm-r13)-kd3*r13 
rt1=r11+r13+c1*ri 
r21'=ka1*c2*(y*rm-r21)-kd1*r21 
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r23'=ka3*c2*((1-y)*rm-r23)-kd3*r23 
rt2=r21+r23+c2*ri 
 
r31'=ka1*c3*(y*rm-r31)-kd1*r31 
r33'=ka3*c3*((1-y)*rm-r33)-kd3*r33 
rt3=r31+r33+c3*ri 
 
r41'=ka1*c4*(y*rm-r41)-kd1*r41 
r43'=ka3*c4*((1-y)*rm-r43)-kd3*r43 
rt4=r41+r43+c4*ri 
 
r51'=ka1*c5*(y*rm-r51)-kd1*r51 
r53'=ka3*c5*((1-y)*rm-r53)-kd3*r53 
rt5=r51+r53+c5*ri 
 
// Initial conditions 
t=0 
 
r11=0 r13=0 r21=0 r23=0 r31=0 r33=0 r41=0 r43=0 r51=00 r53=0 
 
*** 
 
Appendix 6.5. Heterogeneous Bivalent Model 
// SPR Heterogeneous bivalent model 
// Iterative solution 
// T = Time 
// c1 – c5 = concentration of injections 1 – 5 
// rt1 – rt5 = response, at time t of injections 1 -5 
// rm = maximum response of activated surface 
// r11 – r51 = response of injection 1 to 5 from complex [MX1] 
// r12 – r52 = response of injection 1 to 5 from complex [MXX1] 
// r13 – r53 = response of injection 1 to 5 from complex [MX2] 
// r14 – r54 = response of injection 1 to 5 from complex [MXX2] 
// ka1 – ka4 = association rate of [MX1], [MXX1], [MX2] and [MXX2] 
// kd1 – kd4 = dissociation rate of [MX1], [MXX1], [MX2] and [MXX2] 
// ri = refractive index factor 
// y = ratio of [MX1] to [MX2] 
IndVars: t,c1,c2,c3,c4,c5 
DepVars: rt1,rt2,rt3,rt4,rt5 
Params: rm,ka1,ka2,kd1,kd2,ka3,kd3,ka4,kd4,y,ri 
 
r11'=2*ka1*c1*(rm*y-r11-2*r12)-kd1*r11-(ka2*r11*(rm*y-r11-2*r12)-2*kd2*r12) 
r12'=ka2*r11*(rm*y-r11-2*r12)-2*kd2*r12 
r13'=2*ka3*c1*(rm*(1-y)-r13-2*r14)-kd3*r13-(ka4*r13*(rm*(1-y)-r13-2*r14)-2*kd4*r14) 
r14'=ka4*r13*(rm*(1-y)-r13-2*r14)-2*kd4*r14 
rt1=r11+r12+r13+r14+c1*ri 
 
r21'=2*ka1*c2*(rm*y-r21-2*r22)-kd1*r21-(ka2*r21*(rm*y-r21-2*r22)-2*kd2*r22) 
r22'=ka2*r21*(rm*y-r21-2*r22)-2*kd2*r22 
r23'=2*ka3*c2*(rm*(1-y)-r23-2*r24)-kd3*r23-(ka4*r23*(rm*(1-y)-r23-2*r24)-2*kd4*r24) 
r24'=ka4*r23*(rm*(1-y)-r23-2*r24)-2*kd4*r24 
rt2=r21+r22+r23+r24+c2*ri 
 
r31'=2*ka1*c3*(rm*y-r31-2*r32)-kd1*r31-(ka2*r31*(rm*y-r31-2*r32)-2*kd2*r32) 
r32'=ka2*r31*(rm*y-r31-2*r32)-2*kd2*r32 
r33'=2*ka3*c3*(rm*(1-y)-r33-2*r34)-kd3*r33-(ka4*r33*(rm*(1-y)-r33-2*r34)-2*kd4*r34) 
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r34'=ka4*r33*(rm*(1-y)-r33-2*r34)-2*kd4*r34 
rt3=r31+r32+r33+r34+c3*ri 
 
r41'=2*ka1*c4*(rm*y-r41-2*r42)-kd1*r41-(ka2*r41*(rm*y-r41-2*r42)-2*kd2*r42) 
r42'=ka2*r41*(rm*y-r41-2*r42)-2*kd2*r42 
r43'=2*ka3*c4*(rm*(1-y)-r43-2*r44)-kd3*r43-(ka4*r43*(rm*(1-y)-r43-2*r44)-2*kd4*r44) 
r44'=ka4*r43*(rm*(1-y)-r43-2*r44)-2*kd4*r44 
rt4=r41+r42+r43+r44+c4*ri 
 
r51'=2*ka1*c5*(rm*y-r51-2*r52)-kd1*r51-(ka2*r51*(rm*y-r51-2*r52)-2*kd2*r52) 
r52'=ka2*r51*(rm*y-r51-2*r52)-2*kd2*r52 
r53'=2*ka3*c5*(rm*(1-y)-r53-2*r54)-kd3*r53-(ka4*r53*(rm*(1-y)-r53-2*r54)-2*kd4*r54) 
r54'=ka4*r53*(rm*(1-y)-r53-2*r54)-2*kd4*r54 
rt5=r51+r52+r53+r54+c5*ri 
 
// Initial conditions 
t=0 
 
r11=0 r12=0 r13=0 r14=0 r21=0 r22=0 r23=0 r24=0 r31=0 r32=0 r33=0 
r34=0 r41=0 r42=0 r43=0 r44=0 r51=0 r52=0 r53=0 r54=0 
 
*** 
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Appendix 7. Surface Plasmon Resonance Data 
Appendix 7.1. Deconvoluted SPR data 
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Graph of response components that comprise the total seen response of an injection of 
10.2µM conA over a blank sensor surface. 
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Graph of response components that comprise the total seen response of an injection of 
10.2µM conA over 43kD dextran. 
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Graph of response components that comprise the total seen response of an injection of 
10.2µM conA over 500kD dextran. 
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Appendix 7.2. SPR Raw Data 
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Appendix 8. Rheology - Maxwell Model for Viscoelasticity 
This appendix contains the derivation of the Maxwell model for a viscoelastic material 
[133]. 
 
Given the equations for a Newtonian solution and by Hooke’s law for a spring: 
Equation A8-36 
Equation A8-37 
It can be seen from these two equations that the shear stress for a solution is proportional to 
the rate at which it is being sheared. For a spring the stress is proportional to the magnitude 
of the strain. 
 
Maxwell [111] developed a model which contained a Hookean spring and a Newtonian 
dashpot in series. 
 
For a finite shear strain applied constantly over time, the spring will respond, giving a 
maximum stress. The dashpot will gradually release that stress through movement of the 
piston in the fluid. The release of the stress can be viewed as a first-order rate process: 
Equation A8-38 
γησ &=
γσ G=
σ
σ
k
dt
d
−=
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Integrating Equation A8-38 gives: 
Equation A8-39 
Rearranging and replacing the rate constant with a time constant, τm: 
Equation A8-40 
 
The decay time constant controls the rate at which a stress is released and can be viewed as 
the ratio of the viscosity and the shear modulus: 
Equation A8-41 
 
Therefore it can be seen that a solution with a relatively strong viscous component would 
take a long time to release the stress. Conversely, a solution with a relatively high elastic 
component would more rapidly. 
 
The relaxation function, G(t), can be calculated by dividing Equation A8-40 by the applied 
strain, γ: 
 
 
Equation A8-42 
 
 
To mathematically describe the Maxwell model the rate of strain of the two parts must be 
added together (taking the first derivative of Equation A8-37): 
Equation A8-43 
 
The Maxwell model, Equation A8-43, along with the decay time constant can be used to 
analyse the viscometric tests which were carried out. 
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Nomenclature: 
G   Spring Modulus (Pa) 
t   Time (s) 
γ   Shear strain 
   Shear strain rate (s-1) 
η   Viscosity (Pas) 
σ   Shear stress (Pa) 
   Shear stress rate (Pas
-1
) 
τm   Time constant = η/G (s) 
 
γ&
σ&
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Appendix 9. Mathematics of an Oscillator 
Given a mass on a spring [134]: 
 
 
Assuming Newton’s second law of motion and that the forces acting on the mass are 
gravity and the spring: 
Equation A9-44 
At equilibrium, there is no acceleration (where y0 = y(t) at equilibrium): 
 
 
 
 
 
 
 
 
This final equation is a non-forcing LDE and as such will have a solution of the form: 
 
Taking the natural frequency, ωn, to be the square root of the ratio of the spring constant 
and the mass and realising that the second derivative must be negative: 
 
 
 
Therefore: 
 
( ) ( )( ) mgltyktymF +−−== &&
( )
( ) ( )
( ) ( )( )
( ) ( )( ) ( ) ( )
( ) ( )tx
m
k
tx
tkxlykltxyktxm
mgltxyktxm
txyty
mglyk
−=
−=−+−+−=
+−+−=
+=
=−
&&
&&
&&
00
0
0
0
( ) taetx λ=
n
n
i
m
k
ωλ
ω
=∴
=
( ) ntiaetx ω=
 Page 170 
This can be viewed as Euler’s formula: 
Equation A9-45 
 
It can be shown that a is the amplitude of the oscillator. 
 
Nomenclature: 
a = amplitude of the wave 
F = force (N) 
g = gravitational force = 9.81ms
-2 
i = imaginary number = -1
0.5 
k = the spring constant of the spring (Nm
-1
) 
l  = length of unstretched spring (m) 
m = the mass (kg) 
t = time (s) 
x(t) = displacement from equilibrium position (m) 
y(t) = displacement from baseline (m) 
λ  = LDE factor (s-1) 
ωn = natural frequency (s-1) 
 
 
 
 
 
 
( ) ( ) ( )( )titaaetx ti ωωω sincos +==
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Appendix 10. Oscillatory Rheology 
This appendix contains the derivation of the oscillatory rheological tests, based on a 
Maxwell model [110-112, 114, 135]. 
 
Given an oscillatory applied strain: 
 
 
It can be shown that an oscillator has the formula (see Appendix 9): 
Equation A10-46 
Where A is the amplitude of the oscillation and ω is the frequency. For this system this 
gives a shear strain and shear stress: 
Equation A10-47 
Equation A10-48 
 
To use the Maxwell model (Equation A8-43), the rate of shear strain and shear stress must 
be known: 
Equation A10-49 
( ) ( ) ( )( )tisintcosAAetx ti ωωω +==
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Equation A10-50 
Therefore: 
Equation A10-51 
 
Rearranging and using the decay time constant, Equation A8-41: 
Equation A10-52 
 
Further rearrangement and use of the complex modulus gives: 
 
 
Equation A10-53 
 
Multiplying through by the complex conjugate of the denominator (1-iωτm) gives: 
Equation A10-54 
 
The real part of this complex number is known as the storage modulus, G', and the 
imaginary part is the loss modulus, G". These two terms can also be calculated directly 
from the data achieved during oscillation experiments, the phase difference and the 
complex modulus: 
 
 
 
 
Equation A10-55 
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The likelihood of a viscoelastic solution being described by a single combination of a 
spring and a dashpot is highly unlikely. The total stress on a system can be viewed as a 
summation of the shear strains applied multiplied by the resulting relaxation moduli: 
 
Equation A10-56 
 
This can be expressed as an integral, thus enabling calculation of the total stress for a given 
strain history: 
Equation A10-57 
 
This is the Boltzmann Superposition Principle. 
 
For an oscillating shear strain of frequency ω and being applied as a sine wave, the shear 
strain rate is: 
Equation A10-58 
 
Applying this to Equation A10-57 gives: 
Equation A10-59 
 
Changing the integral limits by assuming s = t – ti and using trigonometry  
 
Equation A10-60 
 
The shear strain was applied as a sine wave. Therefore the term preceded by γ0sin(ωt) is in 
phase with this shear strain and the term preceded by γ0cos(ωt) is out of phase. As 
discussed previously, the elastic modulus is the in phase term and the loss modulus is the 
out of phase term. 
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Therefore, it can be written that: 
Equation A10-61 
The phase difference, δ, can be used to describe the shear stress based on the applied shear 
strain: 
Equation A10-62 
Using the same trigonometry as for Equation A10-60: 
 
Equation A10-63 
 
Equating Equation A10-61 and Equation A10-63 gives: 
 
Equation A10-64 
Equation A10-65 
 
Nomenclature: 
G   Spring Modulus (Pa) 
G*   Complex modulus (Pa) 
G’   Storage modulus (Pa) 
G’’   Loss modulus (Pa) 
t   Time (s) 
γ*   Complex shear strain 
γ0   Peak shear strain 
   Shear strain rate (s-1) 
δ   Phase angle (ο) 
η   Viscosity (Pas) 
σ*   Complex shear stress (Pa) 
σ0   Peak shear stress (Pa) 
τm   Time constant = η/G (s) 
ω   Frequency of oscillation (Hz) 
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Appendix 11. Complex Number Theory 
Complex numbers are written in the form: 
z = x + iy 
where i = (-1)
0.5
,
 
x is the real part of the number (x = Re z) and y the Imaginary part (y = Im 
z). 
 
Complex numbers can be represented on an Argand diagram, where the two real numbers, x 
and y, can be used as Cartesian coordinates. 
 
 
Where: 
 
 
 
 
 
The modulus of a complex number, |z|, can be found using Pythagoras’ theorem and the 
angle, θ, by simple trigonometry. It is possible, therefore, to represent a complex number 
as: 
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If these coordinates are plotted on an Argand diagram for –pi < θ < pi a circle would be 
drawn. This can be used to describe an oscillator, such as that used in Section 5 of this work 
[110, 135]. The result is easier to manage, mathematically, when Euler’s formula is used: 
 
 
Nomenclature: 
i   Imaginary number = -1
0.5
 
r   Modulus of complex number 
z   Complex number 
θ   Argument of complex number 
θθθ sincos irrrez i +==
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Appendix 12. Swelling Model for a Hydrogel 
This appendix contains the derivation of the hydrogel swelling model [124]. 
 
Peppas and Merrill adapted the work of Flory and Rehner to develop an equation for the 
swelling of a polymer network [119, 120, 136, 137]: 
 
 
Equation A12-66 
 
 
Where:   – Number average molecular mass of the polymer chain between cross-links 
   – Number average molecular mass of the polymer chain 
   – Partial specific volume of the polymer = 0.62 [127] 
 V1  – Molar volume of water 
 χ1  – Flory polymer-solvent interaction parameter = 0.473 [127] 
 v2,s  – Polymer fraction of the gel at equilibrium swelling 
 v2,r  – Polymer fraction of the gel after gel formation 
 
The swelling ratio can be found: 
Equation A12-67 
 
The number of covalent cross-links can be equated to the number of carboxymethyl groups 
attached to a given dextran molecule (see Section 2.3). The number of affinity cross-links is 
dependent upon the association constant of the interaction (where [MC] is the concentration 
of cona – glucose interactions): 
 
Equation A12-68 
 
Equation A12-69 
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In order to calculate [MX] Equation A12-69 must be rearranged in terms of the cona-
glucose complex and substituted into Equation A12-68. This results in a quadratic equation: 
 
Equation A12-70 
 
Calculation of [MX] allows the number average molecular mass between affinity crosslinks 
to be calculated: 
Equation A12-71 
 
Where [P] is the concentration of the polymer in the gel. 
 
The concentrations of the components is governed by the degree of swelling, therefore 
calculation of the swelling from Equation A12-66 must be done iteratively with Equation 
A12-70. The swollen polymer fraction can be used to calculate the mesh size of the gel 
[138]: 
Equation A12-72 
 
Where:  Cn - Flory characteristic ratio 
 Mr - Molecular mass of repeat unit 
 l - Unit length along the polymer backbone 
 
The mesh size can be used to calculate the rate of diffusion, based on the deviation from the 
liquid phase diffusivity [122, 123]: 
 
Equation A12-73 
 
Where: Dl – Liquid phase diffusivity of the solute 
 r – hydrodynamic radius of the solute 
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This diffusivity value can be used to calculate the concentration flux through the a hydrogel 
of known swollen membrane thickness, δG, and receiving chamber volume, V [124]: 
 
Equation A12-74 
 
Where CD and CR are the donor and receiving chamber concentrations respectively. 
 
Modelling of the rate of diffusion of a solute through a hydrogel can be achieved using 
Equation A12-66 to Equation A12-74. 
 
Nomenclature: 
A   Surface area of hydrogel (m
2
) 
Cd   Concentration of cytC, donor side (mgL
-1
) 
Cn   Flory characteristic ratio 
Cr   Concentration of cytC, receiving side (mgL
-1
) 
Dgel   Gel phase diffusivity (m
2
s
-1
) 
Dl   Liquid phase diffusivity of the solute (m
2
s
-1
) 
J   Flux (mgL
-1
min
-1
) 
l   Unit length along the polymer backbone (m) 
   Number average molecular mass of the polymer chain between 
cross-links (gmol
-1
) 
   Number average molecular mass of the polymer chain (gmol
-1
) 
Mr   Molecular mass of repeat unit (gmol
-1
) 
Q   Swelling ratio 
r   Hydrodynamic radius of the solute (m) 
   Partial specific volume of the polymer 
V   Volume of receiving side (m
3
) 
V1   Molar volume of water (m
3
g
-1
) 
v2,r   Polymer fraction of the gel after gel formation (gg
-1
) 
v2,s   Polymer fraction of the gel at equilibrium swelling (gg
-1
) 
χ1   Flory polymer-solvent interaction parameter 
ξ   Mesh size (m) 
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Appendix 13. Power Basic Model of Hydrogel Swelling 
This appendix contains the Power Basic model for hydrogel swelling. 
 
    ' Affinity membrane model 
 
    ' J. Hubble, June 2005   -   I. Benzeval, September 2008 
 
        DEFDBL a-z 
        FUNCTION PBMAIN() 
        CLS 
        DIM a(20) 
 
    'Data section 
 
    'Ligand receptor properties 
        a(1)=1.49e-4    '[Mtot] Concentration of ConA in gel (M) 
        a(2)=0.034      '[Xtot] Concentration of terminal glucose groups in gel (M) 
        a(3)=4.5e-4     'Kd     Dissociation constant, ConA-Dextran (M) 
        a(4)=5.9e-3     'Kc     Dissociation constant, ConA-Glucose (M) 
        a(5)=4050       'mp     Average MM between covalent cross-links (g/mol) 
 
    'Polymer properties 
        a(6)=500000     'mn     Dextran mol mass (g/mol) 
        a(7)=162        'mr     Molecular mass of repeat unit (glucose) (g/mol) 
        a(8)=0.62       'vb     Partial specific volume of dextran (cm^3/g) 
        a(9)=18         'v1     Molar volume of water (cm^3/g) 
        a(10)=0.099     'vr     Dextran fraction of gel after formation (g/g) 
        a(11)=0.473     'xi     Flory solvent polymer interaction constant (-) 
        a(12)=5         'cn     Flory characteristic ratio (-) 
        a(13)=4.6e-10   'l      Unit length along the polymer back bone (m) 
        a(14)=a(10)*1000/a(6)  'pc Dextran concentration (M) 
 
    'Solute properties 
        a(15)=11.4e-11  'diff   Liquid phase diffusivity of CytC (m^2/s) 
        a(16)=3.8e-9    'r      Radius of CytC (m) 
 
    'Transport properties 
        a(17)=4.8e-4    'mt     Membrane thickness (m) 
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        a(18)=4.6e-4    'area   Membrane area (m^2) 
        a(19)=4.6e-6    'vol    Volume of receiving chamber (m^3) 
        a(20)=50        'sol    Solute concentration (mg/L) 
 
       'Data output routine 
       f$="test2.txt" 
       OPEN f$ FOR OUTPUT AS #2 
 
         cfin=0.2       'Maximum glucose concentration 
         cs=.01 
            FOR c=0 TO cfin  STEP cs 
                CALL crosslink(c,a(),j,na,np,diffg,namax) 
                PRINT c,j,na,np,diffg,namax 
                PRINT #2,c,j,na,np,diffg,namax 
            NEXT i1 
       CLOSE #2 
 
       print"Error sum =";es 
 
1111        END FUNCTION 
 
SUB crosslink(c,a(),j,na,np,diffg,namax) 
 
        namax=a(1)/a(14)     'Maximum number of affinity cross-links in absence of glucose 
        rlo=(a(3)+a(1)+a(2)-SQR(a(3)^2+2*a(3)*a(1)+2*a(3)*a(2)+a(1)^2-2*a(1)*a(2)+a(2)^2))/2   '[MX] 
no competitor. 
        yo=rlo/a(1)          'Fraction of [Mtot] to [MX] 
        np=(a(6)/a(5))       'Number of covalent cross-links per polymer chain 
        nao=namax*yo         'Number of affinity cross-links in absence of competitor 
        mco=a(6)/(nao+np)    'Molecular mass between ALL cross-links 
 
            CALL bisect(a(),mco,cx)  'Find root 
 
        vso=cx 
        vsp=0                'set initial vs value to zero for convergence test 
        lt=a(2)              'reset concentrations for next competitor value 
        rt=a(1) 
 
1000    aa=a(3)*a(4)+a(3)*c+rt*a(4)+a(4)*lt 
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        bb=a(3)^2*a(4)^2+2*a(3)^2*a(4)*c+2*a(3)*a(4)^2*rt+2*a(3)*a(4)^2*lt+a(3)^2*c^2 
        cc=2*a(3)*c*rt*a(4)+2*a(3)*c*a(4)*lt+rt^2*a(4)^2-2*a(4)^2*rt*lt+a(4)^2*lt^2 
        dd=SQR(bb+cc) 
        rl=(aa-dd)/(2*a(4))  '[MX] with competitor 
        y=rl/rt              'Ratio of new [MX] to previous [MX] 
 
        na=namax*y           'Number of affinity cross-links in presence of glucose 
        bonds=na+np          'Total number of cross-links, covalent + affinity 
        mc=a(6)/bonds        'Molecular mass between all cross-links 
 
            IF bonds < 2 THEN 
                     PRINT "Dissolution - bonds per chain =",bonds   'Insufficient bonds to form a gel 
                GOTO 111 
            END IF 
 
                CALL bisect(a(),mc,cx) 'Find root 
        vs=cx 
        sr=vso/vs        'Swelling ratio - computed with reference to the swollen gel with no glucose 
 
        'Recompute concentrations after swelling 
 
        lt=a(2)/sr 
        rt=a(1)/sr 
 
        'Check for convergence of swelling calculations 
 
            IF ABS((vs-vsp)/vsp)>=1e-4 THEN 
                vsp=vs 
                GOTO 1000 
            END IF 
 
        'mesh - Hydrogel mesh size 
 
        mesh=vs^(-.33)*(a(12)*mc/a(7))^0.5*a(13) 
        'q - Volume degree of swelling - computed with reference to the formation volume 
        q=a(10)/vs 
        'diffg - Gel diffusivity 
        diffg=a(15)*(1-a(16)/mesh)*EXP(-1/(q-1)) 
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            IF diffg <= 0 THEN 
                diffg=0 
            END IF 
 
        'j - Flux 
 
        j=60*((a(18)*diffg)/(a(17)*sr*a(19)))*a(20) 
 
 
111     END SUB 
 
'Bisection root finding routine 
        SUB bisect(a(),mco,cx) 
 
        x1 = a(10)        'Set maximum possible value of vso=vr 
        x2 = 1e-8         'Set minimum possible value of vs0 = a fraction above 0 
 
            CALL func(a(),x2,mco,fmid) 
            CALL func(a(),x1,mco,f) 
 
            IF f * fmid >= 0 THEN 
                PRINT "Root not bracketed",fmid,f 
            GOTO 200 
            END IF 
 
            IF f < 0 THEN   'Orients search 
                cx = x1 
                dx = x2 - x1 
            ELSE 
            cx = x2 
            dx = x1 - x2 
            END IF 
 
        'Bisection loop 
 
        acc = .000001 * (x1 + x2) / 2 
            FOR ii = 1 TO 500 
                dx = .5 * dx 
                xmid = cx + dx 
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                    CALL func(a(),xmid,mco,xr) 
            IF xr <= 0 THEN 
                cx = xmid 
            END IF 
            IF ABS(dx) < acc THEN GOTO 200 
            NEXT ii 
        PRINT "too many bisections" 
 
200     END SUB 
 
'______________________________________________ 
 
    SUB func (a(),vso,mco,x) 
 
        x=2/a(6)-(a(8)/a(9))*(LOG(1-vso)+vso+a(11)*vso^2)/(a(10)*((vso/a(10))^(1/3)-0.5*(vso/a(10))))-
1/mco 
 
    END SUB 
 
'____________________________________ 
 
 
